WO2004089955A1 - Pyrimido compounds - Google Patents

Pyrimido compounds Download PDF

Info

Publication number
WO2004089955A1
WO2004089955A1 PCT/EP2004/003447 EP2004003447W WO2004089955A1 WO 2004089955 A1 WO2004089955 A1 WO 2004089955A1 EP 2004003447 W EP2004003447 W EP 2004003447W WO 2004089955 A1 WO2004089955 A1 WO 2004089955A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidin
phenyl
methoxy
dihydro
pyrimido
Prior art date
Application number
PCT/EP2004/003447
Other languages
French (fr)
Inventor
Yi Chen
Apostolos Dermatakis
Jin-Jun Liu
Kin-Chun Luk
Christophe Michoud
Pamela Loreen Rossman
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Priority to AU2004228155A priority Critical patent/AU2004228155A1/en
Priority to CA002521124A priority patent/CA2521124A1/en
Priority to MXPA05010765A priority patent/MXPA05010765A/en
Priority to JP2006504944A priority patent/JP2006522756A/en
Priority to BRPI0409366-6A priority patent/BRPI0409366A/en
Priority to EP04725039A priority patent/EP1615928A1/en
Publication of WO2004089955A1 publication Critical patent/WO2004089955A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms

Definitions

  • the present invention is directed to novel pyrimido compounds of formula
  • R 1 is selected from the group consisting of -H,
  • n 0, 1, 2, or 3
  • heterocycle, alkyl, cycloalkyl, alkenyl, and alkynyl groups are each independently, optionally substituted by up to 3 groups selected from
  • R 2 and R 3 are independently selected from the group consisting of -H, -OR 9 , -halogen, -COR 10 , -CO 2 R 10 ⁇
  • n 0, 1, 2, or 3
  • the heterocycle, alkyl, cycloalkyl, alkenyl, and alkynyl groups are each independently, optionally substituted by up to 3 groups selected from -OR 9 , -halogen, -COR 10 , and ⁇ CO 2 R 10 ;
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from the group consisting of -H,
  • R 9 is selected from the group consisting of -H, -COR 10 , lower alkyl that optionally may be substituted by hydroxy or alkoxy, cycloalkyl that optionally may be substituted by hydroxy, alkoxy, and lower alkyl, and heterocycle that optionally may be substituted by hydroxy, alkoxy or lower alkyl;
  • R 10 and R 11 are each independently selected from the group consisting of -H, lower alkyl that optionally may be substituted by hydroxy or alkoxy, cycloalkyl that optionally may be substituted by hydroxy, alkoxy or lower alkyl, and heterocycle that optionally may be substituted by hydroxy, alkoxy or lower alkyl;
  • R 12 is selected from the group consisting of -H, lower alkyl and -COR 13 ;
  • R 13 is selected from the group consisting of -H and lower alkyl
  • Protein kinases are a class of proteins (enzymes) that regulate a variety of cellular functions. This is accomplished by the phosphorylation of specific amino acids on protein substrates resulting in conformational alteration of the substrate protein. The conformational change modulates the activity of the substrate or its ability to interact with other binding partners.
  • the enzyme activity of the protein kinase refers to the rate at which the kinase adds phosphate groups to a substrate. It can be measured, for example, by determining the amount of a substrate that is converted to a product as a function of time. Phosphorylation of a substrate occurs at the active- site of a protein kinase.
  • Tyrosine kinases are a subset of protein kinases that catalyze the transfer of the terminal phosphate of adenosine triphosphate (ATP) to tyrosine residues on protein substrates. These kinases play an important part in the propagation of growth factor signal transduction that leads to cellular proliferation, differentiation and migration.
  • ATP adenosine triphosphate
  • fibroblast growth factor FGF
  • NEGF vascular endothelial growth factor
  • FGF fibroblast growth factor
  • NEGF vascular endothelial growth factor
  • NEGF vascular endothelial growth factor
  • KDR kinase insert domain-containing receptor
  • inhibitors of the receptors FGFR and KDR that interfere with the growth signal transduction, and thus slow down or prevent angiogenesis are useful agents in the prevention and treatment of solid tumors. See Klohs W.E. et. al., Current Opinion in Biotechnology 1999, 10, p.544.
  • small molecule inhibitors of protein kinase catalytic activity typically block the phosphorylation of substrates by tightly interacting with the protein kinase ATP binding site (or "active site”).
  • active site protein kinase ATP binding site
  • WO99/61444 (Warner-Lambert) discloses bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines of formula
  • Cdkl cyclin dependent kinases
  • Cdk2 cyclin dependent kinases
  • Cdk4 growth factor receptor tyrosine kinase enzymes
  • PDGFR growth factor receptor tyrosine kinase enzymes
  • FGFR growth factor receptor tyrosine kinase enzymes
  • WO 01/29041 Al and WO 01/29042 disclose alkylamino substituted bicyclic nitrogen heterocycles of formula
  • WO 01/64679 Al discloses l,5-disubstituted-3,4-dihydro- lH-pyrimido[4,5-D]pyrimidin-2-one compounds of formula
  • the present invention relates to novel pyrimido compounds capable of selectively inhibiting the activity of KDR and FGFR. These compounds are useful in the treatment or control of cancer, in particular the treatment or control of solid tumors.
  • the present invention also relates to pharmaceutical compositions comprising a therapeuticaUy effective amount of one or more compounds of formula I, and/or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
  • the present invention further relates to a method for treating or controlling solid tumors, in particular treatment or control of breast, lung, colon and prostate tumors, most particularly breast or colon tumors, by administering to a human patient in need of such therapy an effective amount of a compound of formula I and/ or a pharmaceutically acceptable salt thereof.
  • the present invention is further directed to a process of preparing compounds of formula I and to novel intermediate compounds useful in the preparation of compounds of formula I.
  • Alkyl denotes a straight-chain or branched saturated aliphatic hydrocarbon having 1 to 10, preferably 1 to 6, and more preferably 1 to 4 carbon atoms. Alkyl groups having 1 to 6 carbon atoms are also referred to herein as "lower alkyl.” Typical lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, 2 -butyl, pentyl and hexyl. As used herein the sample designation . alkyl means alkyl having from 1 to 4 carbon atoms.
  • Alkenyl denotes a straight-chain or branched aliphatic hydrocarbon having 2 to
  • Alkynyl denotes a straight-chain or branched aliphatic hydrocarbon having 2 to 10, preferably 2 to 6, carbon atoms and at least one carbon-carbon triple bond, for example ethynyl, and 2-butynyl.
  • Alkoxy means an alkyl radical that is attached to the remainder of the molecule by oxygen (-OR), e.g. methoxy, ethoxy.
  • Cycloalkyl means a non-aromatic, partially or completely saturated cyclic aliphatic hydrocarbon group containing 3 to 10 atoms, preferably 3 to 6 atoms. Examples of cycloalkyl groups include cyclopropyl, cyclopentyl and cyclohexyl.
  • Effective amount or therapeuticicaUy effective amount means an amount of at least one compound for formula I, or a pharmaceuticaUy acceptable salt thereof, that significantly inhibits proliferation of tumor ceUs, including human tumor ceU lines.
  • Halogen means fluorine, chlorine, bromine or iodine, preferably chlorine or fluorine.
  • Hetero atom means an atom selected from N, O and S, preferably N. If the hetero atom is N, it can be present as -NH- or -N-lower alkyl-. If the hetero atom is S, it can be present as S, SO or SO 2 .
  • Heterocycle or “heterocyclyl” means a 3- to 10-membered saturated or partiaUy unsaturated non-aromatic monovalent cyclic radical having from one to 4 hetero atoms selected from nitrogen, oxygen or sulfur or a combination thereof.
  • preferred heterocycles are piperidine, piperazine, pyrrolidine, and morpholine.
  • IC 5 o refers to the concentration of a particular compound according to the invention required to inhibit 50% of a specific measured activity. IC 50 can be measured, inter alia, as is described in Examples 41 and 42, infra.
  • “Pharmaceutically acceptable salt” refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
  • Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like.
  • Sample base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethylammonium hydroxide.
  • the chemical modification of a pharmaceutical compound (i.e. drug) into a salt is a technique weU known to pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. See, e.g., H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 196 and 1456-1457.
  • “PharmaceuticaUy acceptable,” such as pharmaceuticaUy acceptable carrier, excipient, etc. means pharmacologicaUy acceptable and substantiaUy non-toxic to the subject to which the particular compound is administered.
  • substituted as in substituted alkyl, means that the substitution can occur at one or more positions and, unless otherwise indicated, that the substituents at each substitution site are independently selected from the specified options.
  • the invention relates to compounds of formula
  • R 1 is selected from the group consisting of
  • n 0, 1, 2, or 3
  • the heterocycle, alkyl, cycloalkyl, alkenyl, and alkynyl groups are each independently, optionaUy substituted by up to 3 groups selected from
  • R 2 and R 3 are independently selected from the group consisting of -H, -OR 9 , -halogen,
  • n 0, 1, 2, or 3
  • the heterocycle, alkyl, cycloalkyl, alkenyl and alkynyl groups are each independently, optionaUy substituted by up to 3 groups selected from -OR 9 , -halogen, -COR 10 , and -CO 2 R 10 ;
  • R 4 , R 5 , R 6 , R 7 and R are each independently selected from the group consisting of -H,
  • optionaUy may be substituted by hydroxy or alkoxy, -OR 12 , -halogen,
  • R 9 is selected from the group consisting of -H, -COR 10 , lower alkyl that optionaUy may be substituted by hydroxy or alkoxy, cycloalkyl that optionally may be substituted by hydroxy, alkoxy, and lower alkyl, and heterocycle that optionaUy may be substituted by hydroxy, alkoxy or lower alkyl;
  • R 10 and R 11 are each independently selected from the group consisting of -H, lower alkyl that optionaUy may be substituted by hydroxy or alkoxy, cycloalkyl that optionally may be substituted by hydroxy, alkoxy or lower alkyl, and heterocycle that optionaUy may be substituted by hydroxy, alkoxy or lower alkyl;
  • R 12 is selected from the group consisting of -H, lower alkyl and -COR 13 ;
  • R 13 is selected from the group consisting of -H and lower alkyl
  • R 1 is selected from cycloalkyl, cycloalkyl substituted by -OH, heterocycle, lower alkyl, and lower alkyl substituted by -OH.
  • R 2 is -H or - OCH 3 .
  • R 3 is -H, F or -
  • R 2 and R 3 are both -H.
  • R 4 , R 5 and R 7 are -H.
  • R 6 is selected from OR 12 , preferably -OCH 3 , lower alkyl, preferably methyl, or halogen, preferably F.
  • R 8 is -H or -F.
  • R 9 , R 10 and R 11 are independently selected from -H, lower alkyl, or lower alkyl substituted by hydroxy, most preferably -H.
  • R 12 and R 13 are independently selected from -H and lower alkyl, most preferably -H.
  • the invention relates to compounds of formula I wherein
  • R 1 is selected from -H, . -lower alkyl substituted b -OH, COR 10 , -CN, -CQNH 2 , -(CH 2 ) n -heterocycle,
  • R 2 is H or -OCH 3 ;
  • R 3 is H, F or -OCH 3 ;
  • R 4 , R 5 and R 7 are H
  • R 6 is -OCH 3 or lower alkyl
  • R 8 is H or F, preferably H
  • R 10 is lower alkyl substituted by alkoxy
  • n 0 or 1, preferably 0.
  • the compounds of the invention are selective for FGF and KDR kinases. These compounds are useful in the treatment or control of cancer, in particular the treatment or control of solid tumors, specificaUy breast, lung, colon and prostate tumors. These compounds are highly permeable to ceU membranes and thus possess advantageous bioavailabUity profiles such as improved oral bioavailabUity.
  • the present invention relates to pharmaceutical compositions comprising at least one compound of formula I, and/or a pharmaceutically acceptable salt thereof, and a pharmaceuticauy acceptable carrier or excipient.
  • compositions can be administered oraUy, for example in the form of tablets, coated tablets, dragees, hard or soft gelatin capsules, solutions, emulsions or suspensions. They can also be administered rectally, for example, in the form of suppositories, or parenteraUy, for example, in the form of injection solutions.
  • compositions of the present invention comprising compounds of formula I, and/or the pharmaceutically acceptable salts thereof, maybe manufactured in a manner that is known in the art, e.g. by means of conventional mixing, encapsulating, dissolving, granulating, emulsifying, entrapping, dragee-making, or lyophUizing processes.
  • These pharmaceutical preparations can be formulated with therapeuticaUy inert, inorganic or organic carriers. Lactose, corn starch or derivatives thereof, talc, steric acid or its salts can be used as such carriers for tablets, coated tablets, dragees and hard gelatin capsules.
  • Suitable carriers for soft gelatin capsules include vegetable oils, waxes and fats.
  • Suitable carriers for the manufacture of solutions and syrups are water, polyols, saccharose, invert sugar and glucose.
  • Suitable carriers for injection are water, alcohols, polyols, glycerine, vegetable oUs, phospholipids and surfactants.
  • Suitable carriers for suppositories are natural or hardened oUs, waxes, fats and semi-liquid polyols.
  • the pharmaceutical preparations can also contain preserving agents, solubUizing agents, stabUizing agents, wetting agents, emulsifying agents, sweetening agents, coloring agents, flavoring agents, salts for varying the osmotic pressure, buffers, coating agents or antioxidants. They can also contain other therapeuticaUy valuable substances, including additional active ingredients other than those of formula I, in particular other oncological agents.
  • the present invention is directed to the use of a compound of formula I for treating cancer, in particular breast, colon, lung or prostate cancer, by administering to a human patient in need of such therapy an effective amount of a compound of formula I and/or its salt.
  • the compounds of the present invention are useful in the treatment or control of ceU proliferative disorders, in particular oncological disorders.
  • These compounds and formulations containing said compounds are particularly useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors.
  • the present invention is further directed to a method for treating such solid tumors by administering to a patient in need of such therapy an effective amount of a compound of formula I and/or a pharmaceuticaUy acceptable salt thereof.
  • a therapeuticaUy effective amount of a compound in accordance with this invention means an amount of compound that is effective to prevent, aUeviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeuticaUy effective amount is within the skill in the art.
  • the therapeuticaUy effective amount or dosage of a compound according to this invention can vary within wide limits and may be determined in a manner known in the art. Such dosage wiU be adjusted to the individual requirements in each particular case including the specific compound(s) being administered, the route of administration, the condition being treated, as weU as the patient being treated.
  • the daUy dosage can be administered as a single dose or in divided doses, or for parenteral administration, it may be given as continuous infusion.
  • the present invention is directed to a process for the preparation of a compound of formula I, which process comprises
  • the present invention is also directed to the following novel intermediates useful in trip svnthpsis of compounds of formula I: 4-[3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5- d]pyrimidin-l-yl] -piperidine- 1 -carboxylic acid tert-butyl ester (Example 2a),
  • compounds of formula I can be synthesized as foUows.
  • compound 6 ma be obtained from compound 4 as foUows:
  • the foUowing examples Ulustrate preferred methods for synthesizing the compounds and formulations of the present invention.
  • reaction mixture was then partitioned between ethyl acetate and brine.
  • the organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that was purified by chromatography with a sUica gel column using a 0 - 60% ethyl acetate in hexanes gradient.
  • the intermediate that was obtained from this purification was dissolved in anUine (2 mL) (Aldrich), a catalytic amount of 4-(dimethylamino)pyridine (Aldrich) was added and the mixture was then heated at 100 °C.
  • IC 50 (KDR) 0.025 ⁇ M
  • IC 50 (FGFR) 0.049 ⁇ M.
  • reaction mixture was aUowed to slowly warm to room temperature and stirred for 4 hours before it was partitioned between ethyl acetate and brine.
  • the organic layer was then coUected, dried over sodium sulfate, filtered, concentrated and the residue was purified by chromatography on a sUica gel column with 0 - 60% ethyl acetate in hexanes.
  • the product from this purification was then dissolved in aniline (2 mL) (Aldrich) and the resulting solution was heated at 80 °C for a period of 12 hours.
  • reaction mixture was partitioned between ethyl acetate and 1 N aqueous sodium hydroxide and the pH of the aqueous layer was adjusted to 12 by adding solid sodium hydroxide. The organic layer was then washed with water, dried over sodium sulfate, filtered and concentrated to the crude product.
  • IC 50 (KDR) 0.107 ⁇ M
  • IC 50 (FGFR) 0.158 ⁇ M.
  • reaction mixture was then partitioned between ethyl acetate and brine and the organic layer was coUected, dried over sodium sulfate, filtered and concentrated and the residue was purified on a sUica gel column with a 0 - 50% ethyl acetate in hexanes gradient.
  • the intermediate from this purification was dissolved in aniline (3 mL) (Aldrich), a catalytic amount of 4-(dimethylamino)pyridine (Aldrich) was added and the resulting solution stirred at 100 °C for 17 hours.
  • ICso (KDR) 0.075 ⁇ M
  • IC 50 (FGFR) 0.226 ⁇ M.
  • reaction mixture was aUowed to warm up slowly to room temperature, stirred overnight and then partitioned between ethyl acetate and brine.
  • the ethyl acetate layer was coUected, dried over sodium sulfate, filtered, concentrated and the residue was purified by chromatography with a sUica gel column using a 0 - 70% ethyl acetate in hexanes gradient.
  • the intermediate obtained from this purification was dissolved in anUine (2 mL) (Aldrich). A catalytic amount of 4-(dimethylamino)pyridine was added and the resulting solution stirred at 110 °C for 11 hours.
  • (+)-ds-tert-Butyl-dimethyl-(6-oxa-bicyclo[3.1.0]hex-3-yloxy)-sUane (2.15 g, 9.99 mmol) (prepared according to the procedure of Hendrie, S. K., Leonard, J. Tetrahedron, 1987, 43 (14), 3289-3294) was dissolved in ethanol (70 mL). To this solution was added 10% Pd/C (500 mg) (Aldrich) and the mixture was hydrogenated under 1 atmosphere of hydrogen for 24 hours and at 50 psi for another 24 hours. Another portion of 10% Pd/C (500 mg) was added and the mixture was hydrogenated again at 55 psi for 24 hours.
  • the reaction mixture was aUowed to slowly warm up to room temperature, stirred for 5.5 hours and then partitioned between ethyl acetate and water.
  • the organic layer was coUected, dried over sodium sulfate, filtered, concentrated and the residue was purified by chromatography on a sUica gel column with a 0 - 40% ethyl acetate in hexanes gradient.
  • the intermediate obtained from this purification was dissolved in anUine (2 mL) (Aldrich), a catalytic amount of 4-(dimethylamino) pyridine (Aldrich) was added and the resulting solution was stirred for 7 hours at 80 °C.
  • the mixture was then cooled and purified by sUica gel column chromatography using a 0 - 40% ethyl acetate in hexanes gradient.
  • the product from this purification was dissolved in acetonitrUe (3 mL), 5% aqueous hydrofluoric acid (50 ⁇ L) was added and the mixture was stirred for 21 hours.
  • the reaction mixture was then concentrated to a smaU volume and purified by sUica gel column chromatography using a 0 - 100% tetrahydrofuran in hexanes gradient to afford the product.
  • reaction mixture was aUowed to slowly warm up to room temperature, stirred for 48 hours and then partitioned between ethyl acetate and water.
  • the organic layer was coUected, dried over sodium sulfate, filtered and concentrated and the residue was purified by sUica gel column chromatography using a 0 - 30% ethyl acetate in hexanes gradient.
  • the intermediate that was obtained from this purification was dissolved in aniline (2 mL) (Aldrich).
  • a catalytic amount of 4-(dimetbyl- amino)pyridine (Aldrich) was added and the resulting solution was stirred for 8 hours at 80 °C.
  • reaction mixture was then cooled and purified by silica gel column chromatography using a 0 - 100% ethyl acetate in hexanes gradient to give ( ⁇ )-3-ds-(tert- butyl-dimethyl-sUanyloxy)-cyclopentyl-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one as a white solid. (Yield 100 mg, 16%).
  • (+)-3-ds-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl-3-(4- methoxy-phenyl) -7-phenylamino-3 ,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (100 mg, 0.18 mmol) (from Example lOd supra) in acetonitrile (3 mL) was added a 5% aqueous hydrofluoric acid solution (110 ⁇ L, 0.275 mmol).
  • Triethylamine (1 mL) (Aldrich) was added and the solution was cooled to 0 °C. FoUowed a dropwise addition of 20% phosgene in toluene solution (1.3 mL, 2.71 mmol) (Fluka) and stirring at 0 °C for 1.5 hours. The mixture was then partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that was purified by chromatography on a silica gel column with a 0 - 40% ethyl acetate in hexanes gradient.
  • IC 50 (KDR) 0.091 ⁇ M
  • IC 50 (FGFR) 0.257 ⁇ M.
  • reaction mixture was aUowed to slowly warm up to room temperature stirred overnight and then partitioned between ethyl acetate and water.
  • the organic layer was coUected, dried over sodium sulfate, filtered, concentrated and the resulting residue was purified by chromatography on a sUica gel column using a 0 - 70% ethyl acetate in hexanes gradient.
  • the intermediate obtained from that purification was then dissolved in anUine (2 mL) (Aldrich), a catalytic amount of aniline hydrochloride (Aldrich) was added and the solution was stirred at 85 °C for 8 hours.
  • the mixture was then cooled and purified by sUica gel column chromatography with a 0 - 70% ethyl acetate in hexanes gradient.
  • the product from that purification was then dissolved at 0° C in a 50% trifluoroacetic acid in dichloromethane solution (6 mL) that contained water (300 ⁇ L) and stirred for 1.5 hours.
  • the reaction mixture was then partitioned between ethyl acetate and 0.5 N aqueous sodium hydroxide. The pH of the aqueous layer was adjusted to 12 by adding solid sodium hydroxide.
  • IC 50 (KDR) 0.190 ⁇ M
  • IC 50 (FGFR) 0.621 ⁇ M.
  • the organic layer was coUected, dried over sodium ⁇ ' "1 ' J J oncentrated. The residue was then dissolved in anhydrous tetrahydrofuran (60 mL) and to this solution at 0 °C was added in smaU portions lithium aluminum hydride (216 mg, 5.70 mmol) (Aldrich). The slurry that formed was aUowed to slowly warm up to room temperature and after overnight stirring was poured slowly into a vigorously stirred mixture of ethyl acetate and saturated aqueous potassium sodium tartrate solution. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated.
  • This ester (3.15 g, 8.85 mmol) was dissolved in 3:1 tetrahydrofuran - methanol (30 mL) and saponified with aqueous sodium hydroxide (1.0 N, 10.0 mL, 10.0 mmol) overnight at ambient temperature. After concentration, the residue was partitioned between ethyl acetate and water and then acidified (to pH 4 - 5) with 0.5N aqueous hydrochloric acid. The organic phase was washed with water and brine, dried over sulfate and concentrated. Purification was carried out with multiple flash chromatography runs using the Biotage system.
  • the azide was dissolved in toluene (2 mL) and heated in an oU bath at 120 °C.
  • This intermediate urea was dissolved in anhydrous tetrahydrofuran (5 mL) and cooled in an ice - water bath. Potassium tert-butoxide (1.0 M in tetrahydrofuran, 1.5 mL, 1.50 mmol) was added dropwise and stirring continued in the cold for 15 minutes. The mixture was filtered through a bed of sUica gel and eluted with ethyl acetate.
  • the sUyl-protected product (0.43 g, 0.67 mmol) was dissolved in anhydrous tetrahydrofuran (5 mL) and treated with tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 2.70 mL, 2.70 mmol) (Aldrich) at room temperature for 5 hours. The reaction was then concentrated. The residue was redissolved in ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate and concentrated.
  • Example 14a supra and potassium carbonate (4.70 g, 34.0 mmol) in acetone (100 mL) was stirred at room temperature for 18 hours. The precipitate was filtered off and the solution was concentrated under reduced pressure. The residue was dUuted with ethyl acetate and washed with water and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. This residue was purified by flash chromatography eluting with ethyl acetate - hexanes (1:4) to give [(2,4- dichloropyrimidin-5-yl)methyl]-(4-methoxyphenyl)-amine. (Yield 3.99 g, 78%).
  • the mixture was stirred at -70 °C for 1 hour and then at room temperature for 3 hours. It was dUuted with ethyl acetate, washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure.
  • ICso (KDR) 0.018 ⁇ M
  • IC 50 (FGFR) 0.050 ⁇ M.
  • IC 50 (KDR) 0.041 ⁇ M
  • IC 50 (FGFR) 0.023 ⁇ M.
  • the reaction was stirred in a water bath that was maintained in the 25 - 35 °C range. The reaction was complete after 4 hours and was concentrated. The residue was redissolved in ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate and concentrated.
  • ICso (KDR) 0.045 ⁇ M
  • IC 50 (FGFR) 0.111 ⁇ M.
  • the crude urea intermediate was dissolved in anhydrous tetrahydrofuran (5 mL) and cooled in an ice-water bath. Potassium tert-butoxide (1.0 M in tetrahydrofuran, 1.4 mL, 1.4 mmol) (Aldrich) was added dropwise over about 5 minutes. The mixture was stirred in the cold for 15 minutes and then the bath was removed and stirring continued for an additional 3 - 4 minutes. The mixture was filtered through a sUica gel plug and eluted with ethyl acetate.
  • ICso (KDR) 0.013 ⁇ M
  • IC 50 (FGFR) 0.035 ⁇ M.
  • the protected ester (0.84 g, 2.36 mmol) was dissolved in 3:1 tetrahydrofuran - methanol and treated with aqueous sodium hydroxide (1.0 N, 3.0 mL, 3.00 mmol) at ⁇ 42 °C overnight. The reaction was concentrated. The residue was partitioned between ethyl acetate and water and acidified with 1 N aqueous hydrochloric acid. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated.
  • aqueous sodium hydroxide 1.0 N, 3.0 mL, 3.00 mmol
  • the methyl ester (1.33 g, 3.73 mmol) was dissolved in 3:1 tetrahydrofuran - methanol (12 mL) and treated with aqueous sodium hydroxide (1 N, 4.3 mL, 4.30 mmol) at 45 °C overnight.
  • the reaction mixture was concentrated after 17 hours.
  • the residue was partitioned between ethyl acetate and water and acidified with 1 N aqueous hydrochloric acid.
  • the organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated.
  • the purified urea intermediate (1.32 g) was dissolved in anhydrous tetrahydrofuran (5 L), cooled in an ice - brine bath and treated with potassium tert- butoxide (1.0 M in tetrahydrofuran, 2.1 mL, 2.1 mmol) (Aldrich). The mixture was stirred in the cold for 15 minutes and then the bath was removed and stirring continued for an additional 5 minutes. The mixture was filtered through a bed of silica gel and eluted with ethyl acetate. Purification [Biotage 40M, ethyl acetate - hexanes gradient (30
  • IC 50 (KDR) 0.137 ⁇ M
  • IC 50 (FGFR) 0.612 ⁇ M.
  • aqueous phase was acidified with cone, hydrochloric acid to pH 2 and extracted with dichloromethane (2 X 20 mL).
  • the combined organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give ds-3,5-bis-(tert-butyl-diphenyl- sUanyloxy)-cyclohexanecarboxylic acid. (Yield 2.54 g, 98%).
  • ICso (KDR) 0.075 ⁇ M
  • IC 50 (FGFR) 0.263 ⁇ M.
  • IC 50 (KDR) 0.208 ⁇ M
  • IC 50 (FGFR) 0.329 ⁇ M.
  • the antiproliferative activity of the compounds of the invention is demonstrated below in Examples 41 and 42. These activities indicate that the compounds of the present invention are useful in treating cancer, in particular solid tumors such as breast, lung, prostate and colon tumors, more particularly breast and colon tumors.
  • kinase assays were conducted using an HTRF (Homogeneous Time Resolved Fluorescence) assay. This assav is described in A. J. Kolb et. al., Drug Discovery Today, 1998, 3(7), p 333.
  • activation buffer 50 mM HEPES, pH 7.4, 1 mM DTT, 10% glycerol, 150 mM NaCl, 0.1 mM EDTA, 26 mM MgCl 2 , and 4 mM ATP.
  • the enzyme was incubated at 4 °C for 1 hour.
  • Kinase activity assays were performed in 96-weU polypropylene plates (Falcon) with a total volume of 90 ⁇ L in each weU.
  • Each weU contained 1 ⁇ M KDR substrate (Biotin-EEEEYFELVAKKKK), 1 nM activated KDR, and a test compound with one of 8 assay concentrations ranging from 100 ⁇ M to 128 pM (1:5 serial dilution).
  • the kinase activity assay was done in the presence of 100 mM HEPES, pH 7.4, 1 mM DTT, 0.1 mM Na 2 VO 4 , 25 mM MgCl 2 , 50 mM NaCl (from KDR stock solution), 1% DMSO (from compound), 0.3 mM ATP (at K m concentration) and 0.02% BSA.
  • the reaction was incubated at 37 °C for 30 minutes.
  • 72 ⁇ L of reaction mixture was transferred into a STOP plate containing 18 ⁇ L of revelation buffer (20 mM EDTA, 50 mM HEPES, pH 7.4, 0.02% BSA, 10 nM Eu-labeUed anti-pY antibody (final cone.
  • FGFR, EGFR, and PDGFR activity assays were carried out as described above for the KDR activity assay with the following differences.
  • GST-tagged FGFR enzyme was activated at room temperature for 1 hour in the foUowing activation buffer: 100 mM HEPES, pH 7.4, 50 mM NaCl, 20 mM MgCl 2 , and 4 mM ATP.
  • the EGFR kinase activity assay was performed with 1 ⁇ M substrate (Biotin- EEEEYFELV), 1.5 nM EGFR, test compounds, 100 mM HEPES, pH 7.4, 1 mM DTT, 5 mM MgCl 2 , 2 mM MnCl 2 , 1% DMSO, 0.5 ⁇ M ATP (K m for EGFR), 0.1 mM Na 2 VO 4 , and 0.02% BSA. The rest of the assay was performed in the same manner as the KDR assay.
  • the PDGFR kinase activity assay was performed with 1 ⁇ M substrate (Biotin- EEEEYFELV), 1.0 nM PDGFR, test compounds, 100 mM HEPES, pH 7.4, 1 mM DTT, 5 mM MgCl 2 , 2 mM MnCl 2 , 1% DMSO, 2.3 ⁇ M ATP (K m for PDGFR), 0.1 mM Na 2 VO 4 , and 0.02% BSA. The rest of the assay was performed in the same manner as the KDR assay.
  • the IC 50 value is the concentration of test compound that reduces by 50% the enzyme activity under the test conditions described.
  • IC50 values in the above-described enzyme inhibition assays for the compounds of the invention are as foUows: KDR less than 0.50 ⁇ M; FGFR less than 2 ⁇ M.
  • test compounds of this invention in ceU-based assays was evaluated by BrdU assay using the BrdU kit (Roche Biochemicals 1-647-229).
  • Human umbUical vein endothelial ceUs (Clonetics CC-2519) were cultured in EGM-2 (Clonetics CC-3162) medium and seeded at 10000 ceUs per weU in a volume of 200 ⁇ L of EGM-2 (Clonetics CC-3162) media in a 96-weU flat bottom plates (Costar 3595) overnight.
  • serum starvation media EBM-2 supplemented with 1% heat inactivated FBS (Clonetics CC-4102), 50 ⁇ g per mL gentamycin and 50 ng per mL of amphotericin-B (Clonetics CC-4083), 10 units per mL ofWyefh-Ayerstheparin (NDC0641-0391-25), and 2 mM L-glutamine (GIBCO 25030- 081).
  • serum starving the cells for 24 hours 20 ⁇ L of test compound at 10X test concentration in serum starvation medium with 2.5% DMSO was added to the appropriate wells.
  • the control wells contained 20 ⁇ L of serum starvation medium with 2.5% DMSO. Plates were returned to the incubator for 2 hours. After pre-incubating the ceUs with the test compounds for 2 hours, 20 ⁇ L of growth factors at 10X assay concentration diluted in serum starvation media, FGF at 50 ng per mL, or VEGF (R8?D systems 293-VE) at 200 ng per mL were added. The final concentration of FGF in the assay was 5 ng per L, and the final concentration of VEGF in the assays was 20 ng per mL. The growth factor free control weUs had 20 ⁇ L per weU of serum starvation media with the same amount of BSA as the wells with growth factors. The plates were returned to the incubator for an additional 22 hours. BrdU ELISA
  • the ceUs were labeled with BrdU (Roche Biochemicals 1-647-229), by adding 20 ⁇ L per weU of BrdU labeling reagent that has been dUuted (1:100) in serum starvation medium. The plates were then returned to the incubator for 4 hours. The labeling medium was removed by draining the medium onto paper towels. The ceUs were fixed and DNA denatured by adding 200 ⁇ L of fixation / denaturation solution to each weU and incubating at room temperature for 45 minutes. The fixation / denaturation solution was drained onto paper towels and to each weU was added 100 ⁇ L of anti-BrdU-POD and the weUs were incubated for 2 hours at room temperature.
  • BrdU Roche Biochemicals 1-647-229
  • the IC 5 o value is the concentration of test compound that inhibits by 50% BrdU labeling, and is a measure of inhibition of ceU proliferation.
  • the IC 50 is determined from the linear regression of a plot of the logarithm of the concentration versus percent inhibition.
  • IC 50 values of VEGF and FGF-stimulated HUVEC proliferation assays for the compounds of the invention measured as described herein are as follows: HUVEC/VEFG less than 1.00 ⁇ M; HUVEC/bFGF less than 1.00 ⁇ M.
  • Step 3 Pass the granulation from Step 3 through a suitable miUing equipment.
  • ⁇ Compound A represents a compound of the invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed are novel pyrimido compounds of the formula (I) that are selective inhibitors of both KDR and FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds and the use for treating cancer.

Description

Pyrimido compounds
The present invention is directed to novel pyrimido compounds of formula
Figure imgf000002_0001
wherein
R1 is selected from the group consisting of -H,
- (CH )n-heterocycle, alkyl, cycloalkyl, alkenyl, and alkynyl,
where n is 0, 1, 2, or 3, and the heterocycle, alkyl, cycloalkyl, alkenyl, and alkynyl groups are each independently, optionally substituted by up to 3 groups selected from
-OR9, -COR10, -CO2R10, -CONR10Rπ, -SO2NR10RU, -SO2R10, and -CN;
R2 and R3 are independently selected from the group consisting of -H, -OR9, -halogen, -COR10, -CO2R10 }
-(CH2)n-heterocycle, -alkyl, -cycloalkyl, -alkenyl, and
-alkynyl,
where n is 0, 1, 2, or 3, and the heterocycle, alkyl, cycloalkyl, alkenyl, and alkynyl groups are each independently, optionally substituted by up to 3 groups selected from -OR9, -halogen, -COR10, and ~CO2R10;
R4, R5, R6, R7 and R8 are each independently selected from the group consisting of -H,
-lower alkyl that optionally may be substituted by hydroxy or alkoxy, -OR12, -halogen,
-COR13, and -C02R13;
R9 is selected from the group consisting of -H, -COR10, lower alkyl that optionally may be substituted by hydroxy or alkoxy, cycloalkyl that optionally may be substituted by hydroxy, alkoxy, and lower alkyl, and heterocycle that optionally may be substituted by hydroxy, alkoxy or lower alkyl;
R10 and R11 are each independently selected from the group consisting of -H, lower alkyl that optionally may be substituted by hydroxy or alkoxy, cycloalkyl that optionally may be substituted by hydroxy, alkoxy or lower alkyl, and heterocycle that optionally may be substituted by hydroxy, alkoxy or lower alkyl;
R12 is selected from the group consisting of -H, lower alkyl and -COR13; and
R13 is selected from the group consisting of -H and lower alkyl;
or the pharmaceutically acceptable salts thereof. It has been found that compounds of formula I inhibit KDR (kinase insert domain- containing receptor) and FGFR (fibroblast growth factor receptor) kinases. These compounds and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. In addition these compounds have advantageous bioavailability profiles. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors.
Protein kinases are a class of proteins (enzymes) that regulate a variety of cellular functions. This is accomplished by the phosphorylation of specific amino acids on protein substrates resulting in conformational alteration of the substrate protein. The conformational change modulates the activity of the substrate or its ability to interact with other binding partners. The enzyme activity of the protein kinase refers to the rate at which the kinase adds phosphate groups to a substrate. It can be measured, for example, by determining the amount of a substrate that is converted to a product as a function of time. Phosphorylation of a substrate occurs at the active- site of a protein kinase.
Tyrosine kinases are a subset of protein kinases that catalyze the transfer of the terminal phosphate of adenosine triphosphate (ATP) to tyrosine residues on protein substrates. These kinases play an important part in the propagation of growth factor signal transduction that leads to cellular proliferation, differentiation and migration.
For example, fibroblast growth factor (FGF) and vascular endothelial growth factor (NEGF) have been recognized as important mediators of tumor promoted angiogenesis. NEGF activates endothelial cells by signaling through two high affinity receptors, one of which is the kinase insert domain-containing receptor (KDR). See Hennequin L. F. et. al., J. Med. Chem. 2002, 45(6), ppl300. FGF activates endothelial cells by signaling through the FGF receptor (FGFR). Solid tumors depend upon the formation of new bloodvessels (angiogenesis) to grow. Accordingly, inhibitors of the receptors FGFR and KDR that interfere with the growth signal transduction, and thus slow down or prevent angiogenesis, are useful agents in the prevention and treatment of solid tumors. See Klohs W.E. et. al., Current Opinion in Biotechnology 1999, 10, p.544.
There are several examples of small molecule inhibitors of protein kinase catalytic activity. In particular, small molecule inhibitors typically block the phosphorylation of substrates by tightly interacting with the protein kinase ATP binding site (or "active site"). See WO 98/24432 and Hennequin L. F. et. al., J. Med. Chem. 2002, 45(6), ppl300. Several of these compounds inhibit multiple targets. For example, WO99/61444 (Warner-Lambert) discloses bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines of formula
Figure imgf000005_0001
that are asserted to inhibit cyclin dependent kinases Cdkl, Cdk2 and Cdk4 as well as the growth factor receptor tyrosine kinase enzymes PDGFR and FGFR. Some compounds are also asserted to inhibit Cdk6.
US Patent No. 6,150,373 (Hoffmann-La Roche Inc.) discloses bicyclic nitrogen heterocycles of formula
Figure imgf000005_0002
that are stated to inhibit the T-cell tyrosine kinase p56 lck .
WO 01/29041 Al and WO 01/29042 (F. Hoffmann-La Roche AG) disclose alkylamino substituted bicyclic nitrogen heterocycles of formula
Figure imgf000005_0003
that are stated to inhibit p38 mediated cellular functions and are thus inhibitors of cellular proliferation.
WO 01/64679 Al (SmithKline Beecham) discloses l,5-disubstituted-3,4-dihydro- lH-pyrimido[4,5-D]pyrimidin-2-one compounds of formula
Figure imgf000006_0001
that are stated to be useful in treating CSBP/P38 kinase mediated diseases.
There continues to be a need for easily synthesized, small- molecule compounds effective in inhibiting the catalytic activity of protein kinases, in particular FGFR and KDR kinases for treating one or more types of solid tumors. It is particularly desirable to provide small molecule inhibitors that are selective for FGFR and KDR. This is desirable because of the potential concomitant toxicity and other undesirable complications that may follow from inhibiting multiple targets. It is preferable that such small molecule inhibitors also possess advantageous bioavailability profiles. It is thus an object of this invention to provide such compounds and pharmaceutical compositions containing these compounds.
The present invention relates to novel pyrimido compounds capable of selectively inhibiting the activity of KDR and FGFR. These compounds are useful in the treatment or control of cancer, in particular the treatment or control of solid tumors.
In particular this invention relates to compounds of formula
Figure imgf000006_0002
or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined below. The present invention also relates to pharmaceutical compositions comprising a therapeuticaUy effective amount of one or more compounds of formula I, and/or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
The present invention further relates to a method for treating or controlling solid tumors, in particular treatment or control of breast, lung, colon and prostate tumors, most particularly breast or colon tumors, by administering to a human patient in need of such therapy an effective amount of a compound of formula I and/ or a pharmaceutically acceptable salt thereof.
The present invention is further directed to a process of preparing compounds of formula I and to novel intermediate compounds useful in the preparation of compounds of formula I.
As used herein, the following terms shall have the following definitions.
"Alkyl" denotes a straight-chain or branched saturated aliphatic hydrocarbon having 1 to 10, preferably 1 to 6, and more preferably 1 to 4 carbon atoms. Alkyl groups having 1 to 6 carbon atoms are also referred to herein as "lower alkyl." Typical lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, 2 -butyl, pentyl and hexyl. As used herein the sample designation . alkyl means alkyl having from 1 to 4 carbon atoms.
"Alkenyl" denotes a straight-chain or branched aliphatic hydrocarbon having 2 to
10, preferably 2 to 6, carbon atoms, and at least one carbon-carbon double bond, for example vinyl, 2-butenyl, and 3-methyl-2-butenyl.
"Alkynyl" denotes a straight-chain or branched aliphatic hydrocarbon having 2 to 10, preferably 2 to 6, carbon atoms and at least one carbon-carbon triple bond, for example ethynyl, and 2-butynyl.
"Alkoxy" means an alkyl radical that is attached to the remainder of the molecule by oxygen (-OR), e.g. methoxy, ethoxy.
"Cycloalkyl" means a non-aromatic, partially or completely saturated cyclic aliphatic hydrocarbon group containing 3 to 10 atoms, preferably 3 to 6 atoms. Examples of cycloalkyl groups include cyclopropyl, cyclopentyl and cyclohexyl. "Effective amount" or "therapeuticaUy effective amount" means an amount of at least one compound for formula I, or a pharmaceuticaUy acceptable salt thereof, that significantly inhibits proliferation of tumor ceUs, including human tumor ceU lines.
"Halogen" means fluorine, chlorine, bromine or iodine, preferably chlorine or fluorine.
"Hetero atom" means an atom selected from N, O and S, preferably N. If the hetero atom is N, it can be present as -NH- or -N-lower alkyl-. If the hetero atom is S, it can be present as S, SO or SO2.
"Heterocycle" or "heterocyclyl" means a 3- to 10-membered saturated or partiaUy unsaturated non-aromatic monovalent cyclic radical having from one to 4 hetero atoms selected from nitrogen, oxygen or sulfur or a combination thereof. Examples of preferred heterocycles are piperidine, piperazine, pyrrolidine, and morpholine. In case a heteroatom of the heterocycle is sulfur it can be substituted by one or two oxygen atoms, thus meaning groups >S=O or >S(=O)2. A preferred heterocycle containing the >S(=O)2 group is 1,1-Dioxo-tetrahydrothiophene.
"Hydroxy" is a prefix indicating the presence of a monovalent OH group.
"IC5o" refers to the concentration of a particular compound according to the invention required to inhibit 50% of a specific measured activity. IC50 can be measured, inter alia, as is described in Examples 41 and 42, infra.
"Pharmaceutically acceptable salt" refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Sample base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethylammonium hydroxide. The chemical modification of a pharmaceutical compound (i.e. drug) into a salt is a technique weU known to pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. See, e.g., H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 196 and 1456-1457. "PharmaceuticaUy acceptable," such as pharmaceuticaUy acceptable carrier, excipient, etc., means pharmacologicaUy acceptable and substantiaUy non-toxic to the subject to which the particular compound is administered.
"Substituted," as in substituted alkyl, means that the substitution can occur at one or more positions and, unless otherwise indicated, that the substituents at each substitution site are independently selected from the specified options.
In one embodiment, the invention relates to compounds of formula
Figure imgf000009_0001
wherein
R1 is selected from the group consisting of
-H,
- ( CH2)π-heterocycle, alkyl, cycloalkyl, alkenyl, and alkynyl,
where n is 0, 1, 2, or 3, and the heterocycle, alkyl, cycloalkyl, alkenyl, and alkynyl groups are each independently, optionaUy substituted by up to 3 groups selected from
-ORy, -COR , l1u0, -C02R , i1U0,
Figure imgf000009_0002
-SO2R , 1ι0υ, and -CN;
R2 and R3 are independently selected from the group consisting of -H, -OR9, -halogen,
-con10. -CO2R10,
-(CH2)π-heterocycle, -alkyl, -cycloalkyl, -alkenyl, and
-alkynyl,
where n is 0, 1, 2, or 3, and the heterocycle, alkyl, cycloalkyl, alkenyl and alkynyl groups are each independently, optionaUy substituted by up to 3 groups selected from -OR9, -halogen, -COR10, and -CO2R10;
R4, R5, R6, R7 and R are each independently selected from the group consisting of -H,
-lower alkyl that optionaUy may be substituted by hydroxy or alkoxy, -OR12, -halogen,
-COR13, and -CO2R13;
R9 is selected from the group consisting of -H, -COR10, lower alkyl that optionaUy may be substituted by hydroxy or alkoxy, cycloalkyl that optionally may be substituted by hydroxy, alkoxy, and lower alkyl, and heterocycle that optionaUy may be substituted by hydroxy, alkoxy or lower alkyl;
R10 and R11 are each independently selected from the group consisting of -H, lower alkyl that optionaUy may be substituted by hydroxy or alkoxy, cycloalkyl that optionally may be substituted by hydroxy, alkoxy or lower alkyl, and heterocycle that optionaUy may be substituted by hydroxy, alkoxy or lower alkyl;
R12 is selected from the group consisting of -H, lower alkyl and -COR13; and
R13 is selected from the group consisting of -H and lower alkyl;
or the pharmaceuticaUy acceptable salts thereof. Compounds disclosed herein and covered by formula I above may exhibit tautomerism or structural isomerism. It is intended that the invention encompasses any tautomeric or structural isomeric form of these compounds, or mixtures of such forms (e.g. racemic mixtures), and is not limited to any one tautomeric or structural isomeric form depicted in formula I above.
In a preferred embodiment of the compounds of formula I, R1 is selected from cycloalkyl, cycloalkyl substituted by -OH, heterocycle, lower alkyl, and lower alkyl substituted by -OH.
In another preferred embodiment of the compounds of formula I, R2 is -H or - OCH3.
In another preferred embodiment of the compounds of formula I, R3 is -H, F or -
In another preferred embodiment of the compounds of formula I, R2 and R3 are both -H.
In another preferred embodiment of the compounds of formula I, R4, R5 and R7 are -H.
In another preferred embodiment of the compounds of formula I, R6is selected from OR12, preferably -OCH3, lower alkyl, preferably methyl, or halogen, preferably F.
In another preferred embodiment of the compounds of formula I, R8 is -H or -F.
In another preferred embodiment of the compounds of formula I, R9, R10 and R11 are independently selected from -H, lower alkyl, or lower alkyl substituted by hydroxy, most preferably -H.
In another preferred embodiment of the compounds of formula I, R12 and R13 are independently selected from -H and lower alkyl, most preferably -H.
In a particularly preferred embodiment, the invention relates to compounds of formula I wherein
R1 is selected from -H, . -lower alkyl substituted b -OH, COR10, -CN, -CQNH2, -(CH2)n-heterocycle,
-(CH2)n-heterocycle substituted by -COR10, -C02R10, (=O)2, cycloalkyl, and cycloalkyl substituted by -OH,
R2 is H or -OCH3;
R3 is H, F or -OCH3;
R4, R5 and R7 are H;
R6 is -OCH3 or lower alkyl;
R8 is H or F, preferably H;
R10 is lower alkyl substituted by alkoxy; and
n is 0 or 1, preferably 0.
The foUowing compounds are preferred embodiments according to the present invention:
l-cyclohexyl-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one (Example le),
3-(4-methoxy-phenyl)-7-phenylamino-l-piperidin-4-yl-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one (Example 2b),
l-(tr ns-4-hydroxy-cyclohexyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido [4,5-d]pyrimidin-2-one (Example 3c),
3-(4-methoxy-phenyl)-7-phenylamino-l-piperidin-3-yl-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one (Example 4b),
l-cyclopentyl-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d]ρyrimidin-2-one (Example 5),
l-(l,l-dioxo-tetrahydrothiophen-3-yl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 6),
3-[3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5- d]pyrimidin-l-yl]-piperidine-l-carbaldehyde (Example 7),
3-(4-methoxy-phenyl)-7-phenylamino-l-(tetrahydro-pyran-4-yl)-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one (Example 8), (±) - 1 - (tr ns-3-hydroxy-cyclopentyl) -3- (4-methoxy-phenyl) -7-phenyIamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 9d),
(±)- 5-l-(3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylaminθ 3,4-dihydro- lH-pyrimido[4,5-d]pyrimidin-2-one (Example lOe),
(R) -3- (4-methoxy-phenyl)-7-phenylamino- 1 - (tetrahydro-furan-3-yl) -3,4-dihydro- 1H- pyrimido[4,5-d]pyrimidin-2-one (Example lib),
(R)-3-(4-methoxy-phenyl)-7-phenylamino-l-pyrrolidin-3-yl-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one (Example 12),
(+) -7- (4-fluoro-phenylamino) - 1 - (frans-3-hydroxy-cyclopentyl) -3- (4-methoxy-phenyl)- 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 13c),
(+) -3- (2-fluoro-4-mefhoxy-phenyl)- 1 - ( trøns-3-hydroxy-cyclopentyl) -7-phenylamino- 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 14d),
(S)-(+)-l-(2-hydroxy-l-methyl-ethyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 15d),
(S) - (+) -7- (4-fluoro-phenylamino) - 1- (2-hydroxy- 1-methyl-ethyl) -3- (4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 16),
3-(2-fluoro-4-methoxy-phenyl)-l-(trαns-4-hydroxy-cyclohexyl)-7-(4-methoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 17d),
3-(2-fluoro-4-methoxy-phenyl)-l-(trαns-4-hydroxy-cyclohexyl)-7-(3,4-dimethoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 18),
3-(4-methoxy-phenyl)-l-(tr πs-4-hydroxy-cyclohexyl)-7-(3,4-dimethoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 19c),
3- (4-methoxy-phenyl) - 1 - (trøπs-4-hydroxy-cyclohexyl) -7- (4-methoxy-phenylamino) - 3,4-dihydro- lH-pyrimido[4,5-d]pyrimidin-2-one (Example 20b),
(S)-(+)-3-(2-fluoro-4-methoxy-phenyl)-7-(4-fluoro-phenylamino)-l-(2-hydroxy-l- methyl-ethyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 21b),
(S)-(+)-3-(2-fluoro-4-methoxy-phenyl)-l-(2-hydroxy-l-methyl-ethyl)-7-(4-methoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 22), (R)-(-)-l-(2-hydroxy-l-methyl-ethyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimiα,in-2-one (Example 23d), .
3-(4-methoxy-phenyl)-l-methyl-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidine-2-one (Example 24b),
l-(2-methoxy-ethoxymethyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one (Example 25),
3-[-3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-l-yl]-propionitrile (Example 26),
(+)-(lR,3R)-l-(3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 27f),
(R)-l-(2-hydroxy-propyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one (Example 28d),
(-)-(lS,3S)-l-(3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 29h),
3- [-3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-lH-pyrimido [4,5- d]pyrimidin-l-yl]-propionamide (Example 30),
(5)-(+)-l-(2-hydroxy-propyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one (Example 31d),
l-(cz5-3,5-dihydroxy-cyclohexyl)-3-(2-fluoro-4-methoxy-phenyl)-7-(4- methoxyphenylamino) -3,4-dihydro- lH-pyrimido[4,5-d]pyrimidin-2-one (Example 32f),
l-( s-3,5-dihydroxy-cyclohexyl)-3-(4-methoxy-phenyl)-7-(4-methoxy-phenylamino)- 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 33c),
l-(ci5-3i5-dihydroxy-cyclohexyl)-3-(4-methoxy-phenyl)-7-(4-fluoro-3-methoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 34f),
l-( s-3,5-dihydroxy-cyclohexyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro- . lH-pyrimido[4,5-d]pyrimidin-2-one (Example 35b),
l-( '5-3,5-dihydroxy-cyclohexyl)-3-(2-fluoro-4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 36b), l-(αs-3,5-dihydroxy-cyclohexyl)-3-(2-.fluoro-4-methoxy-phenyl)-7-(4-fluoro-3- methoxyphenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 37b),
(R)-3-(4-ethyl-phenyl)-7-(4-fluoro-phenylamino)-l-(2-hydroxy-l-methyl-ethyl)-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 38g),
(±)-3-(4-ethyl-phenyl)-7-(4-fluoro-phenylamino)-l-(tr ns-3-hydroxy-cyclopentyl)-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 39d), and
1 -cycloρropylmethyl-3 - (4-methoxy-phenyl)-7-phenylamino-3,4-dihydro- 1H- pyrimido[4,5-d]pyrimidine-2-one (Example 40).
The compounds of the invention are selective for FGF and KDR kinases. These compounds are useful in the treatment or control of cancer, in particular the treatment or control of solid tumors, specificaUy breast, lung, colon and prostate tumors. These compounds are highly permeable to ceU membranes and thus possess advantageous bioavailabUity profiles such as improved oral bioavailabUity.
In an alternative embodiment, the present invention relates to pharmaceutical compositions comprising at least one compound of formula I, and/or a pharmaceutically acceptable salt thereof, and a pharmaceuticauy acceptable carrier or excipient.
These pharmaceutical compositions can be administered oraUy, for example in the form of tablets, coated tablets, dragees, hard or soft gelatin capsules, solutions, emulsions or suspensions. They can also be administered rectally, for example, in the form of suppositories, or parenteraUy, for example, in the form of injection solutions.
The pharmaceutical compositions of the present invention comprising compounds of formula I, and/or the pharmaceutically acceptable salts thereof, maybe manufactured in a manner that is known in the art, e.g. by means of conventional mixing, encapsulating, dissolving, granulating, emulsifying, entrapping, dragee-making, or lyophUizing processes. These pharmaceutical preparations can be formulated with therapeuticaUy inert, inorganic or organic carriers. Lactose, corn starch or derivatives thereof, talc, steric acid or its salts can be used as such carriers for tablets, coated tablets, dragees and hard gelatin capsules. Suitable carriers for soft gelatin capsules include vegetable oils, waxes and fats. Depending on the nature of the active substance, no carriers are generaUy required in the case of soft gelatin capsules. Suitable carriers for the manufacture of solutions and syrups are water, polyols, saccharose, invert sugar and glucose. Suitable carriers for injection are water, alcohols, polyols, glycerine, vegetable oUs, phospholipids and surfactants. Suitable carriers for suppositories are natural or hardened oUs, waxes, fats and semi-liquid polyols.
The pharmaceutical preparations can also contain preserving agents, solubUizing agents, stabUizing agents, wetting agents, emulsifying agents, sweetening agents, coloring agents, flavoring agents, salts for varying the osmotic pressure, buffers, coating agents or antioxidants. They can also contain other therapeuticaUy valuable substances, including additional active ingredients other than those of formula I, in particular other oncological agents.
In a further embodiment, the present invention is directed to the use of a compound of formula I for treating cancer, in particular breast, colon, lung or prostate cancer, by administering to a human patient in need of such therapy an effective amount of a compound of formula I and/or its salt.
As mentioned above, the compounds of the present invention, including the compounds of formula I, and/or the pharmaceuticaUy acceptable salts thereof, are useful in the treatment or control of ceU proliferative disorders, in particular oncological disorders. These compounds and formulations containing said compounds are particularly useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors. Thus, the present invention is further directed to a method for treating such solid tumors by administering to a patient in need of such therapy an effective amount of a compound of formula I and/or a pharmaceuticaUy acceptable salt thereof.
A therapeuticaUy effective amount of a compound in accordance with this invention means an amount of compound that is effective to prevent, aUeviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeuticaUy effective amount is within the skill in the art.
The therapeuticaUy effective amount or dosage of a compound according to this invention can vary within wide limits and may be determined in a manner known in the art. Such dosage wiU be adjusted to the individual requirements in each particular case including the specific compound(s) being administered, the route of administration, the condition being treated, as weU as the patient being treated. In general, in the case of oral or parenteral administration to adult humans weighing approximately 70-75 Kg, a daUy dosage of about 10 mg to about 10,000 mg, preferably from about 200 mg to about 1,000 mg, most preferably 300 mg to 600 mg, should be appropriate, although the upper limit may be exceeded when indicated. The daUy dosage can be administered as a single dose or in divided doses, or for parenteral administration, it may be given as continuous infusion.
In another embodiment, the present invention is directed to a process for the preparation of a compound of formula I, which process comprises
reacting a compound of the formula
Figure imgf000017_0001
wherein X is Cl or SO2CH3, and R1, R4, R5, R6, R7 and R8 are as defined herein before, with an anUine derivative of the formula
Figure imgf000017_0002
wherein R and R are as defined herein before, to obtain a compound of the formula
Figure imgf000017_0003
and if desired, converting the compound of formula I into a pharmaceutically acceptable salt.
The present invention is also directed to the following novel intermediates useful in trip svnthpsis of compounds of formula I: 4-[3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5- d]pyrimidin-l-yl] -piperidine- 1 -carboxylic acid tert-butyl ester (Example 2a),
l-[tr n5-4-(tert-butyl-dimethyl-sUanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example 3b),
3-[3-(4-methoxy-ρhenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5- d]pyrimidin-l-yl]-piperidine-l-carboxylic acid tert-butyl ester (Example 4a),
(±)-3- s-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example lOd),
(R)-2-methylsulfanyl-4-(tetrahydro-furan-3-ylamino)-pyrimidine-5-carboxylic acid ethyl ester (Example 11a),
(±)-4-[tr ns-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentylamino]-2-methylsulfanyl- pyrimidine-5-carbaldehyde (Example 13a),
(±)-l-[traπs-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-methoxy-phenyl)-7- methylsulfanyl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 13b),
(±)-[3-tr πs-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-{5-[(2-fluoro-4-methoxy- phenylamino)-methyl]-2-methylsulfanyl-pyrimidin-4-yl}-amine (Example 14b),
(+)-l-[trans-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-methoxy-phenyl)-7- methylsulfanyl-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example 14c),
(S)-l-[2-(tert-butyl-diphenyl-sUanyloxy)-l-methyl-ethyl]-7-chloro-3-(4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 15c),
1 - [trans-4- (tert-butyl-dimethyl-sUanyloxy) -cyclohexyl] -7-chloro-3- (2-fluoro-4- methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 17c),
l-[trøns-4-(tert-butyl-dimethyl-sUanyloxy)-cyclohexyl]-7-chloro-3-(4-methoxy-phenyl)- 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 19a),
1- [tr ns-4-(tert-butyl-dimefhyl-sUanyloxy)-cyclohexyl] -3-(4-methoxy-phenyl)-7-(3,4- dimethoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 19b),
l-[tr πs-4-(tert-butyl-dimethyl-sUanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7-(4- mefhoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 20a), (S)-l-[2-(tert-butyl-diphenyl-silanyloxy)-l-methyl-ethyl]-7-chloro-3-(2-fluoro-4- methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 21a),
(R) - 1 - [2- (tert-butyl-diphenyl-sUanyloxy) - 1 -methyl-ethyl] -7-chloro-3- (4-methόxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 23c),
3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH-ρyrimido[4,5-d]pyrimidine-2- one (Example 24a),
(+)-( lR,3R)-4- [3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentylamino] -2-methylsulfanyl- pyrimidine-5-carboxylic acid ethyl ester (Example 27d),
(-)-(lR,3R)-l-[3-(tert-butyl-dimethyl-silanyloxy)-cycloρentyl]-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (Example 27e),
(R)-l-[2-(tert-butyl-diphenyl-sUanyloxy)-propyl]-7-chloro-3-(4-methoxy-phenyl)-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 28c),
(-)-( lS,3S)-4- [3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentylamino] -2-methylsulfanyl- pyrimidine-5-carboxylic acid ethyl ester (Example 29d),
(-)-(lS,3S)-4-[3-(tert-butyl-dimethyl-silanyloxy)-cyclopentylamino]-2-methylsulfanyl- pyrimidine-5-carbaldehyde (Example 29e),
(-)-(lS,35)-l-[3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-methoxy-phenyl)-7- methylsulfanyl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 29f),
(-)-(lS,3S)-l-[3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]ρyrimidin-2-one (Example 29g),
(S)-l-[2-(tert-butyl-diphenyl-sUanyloxy)-propyl]-7-chloro-3-(4-methoxy-phenyl)-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 31c),
l-[ s-3,5-bis-(tert-butyl-diphenyl-silanyloxy)-cyclohexyl]-7-chloro-3-(2-fluoro-4- methoxy-phenyl) -3,4-dihydro- lH-pyrimido [4,5-d]pyrimidin-2-one (Example 32d),
1- [ '5-3,5-bis-(tert-butyl-diphenyl-silanyloxy)-cyclohexyl] -3-(2-fluoro-4-methoxy- phenyl)-7-(4-methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 32e),
1 - [ 's-3,5-bis- (tert-butyl-diphenyl-sUanyloxy) -cyclohexyl] -7-chloro-3- (4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 33a), l-[ 's-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7-(4- metiιoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 33b),
1- [cz5-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl] -3-(4-mefhoxy-phenyl)-7-(4- fluoro-3-methoxy-ρhenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 34e),
l-[d5-3,5-bis-(tert-butyl-diphenyl-silanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] yrimidin-2-one (Example 35a),
l-[ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(2-fluoro-4-methoxy- phenyl)-7-phenylamino-3J4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 36a),
l-[cz5-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(2-fluoro-4-methoxy- phenyl)-7-(4-fluoro-3-methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one (Example 37a),
(2,4-dichloro-pyrimidin-5-ylmethyl)-(4-ethyl-phenyl)-amine (Example 38c),
(R) -3 - [2- (tert-butyl-dimethyl-silanyloxy) - 1 -methyl-ethyl] - 1 - (2,4-dichloro-pyrimidin-5- ylmethyl)-l-(4-ethyl-phenyl)-urea (Example 38d),
(R) - 1 - [2- (tert-butyl-dimethyl-silanyloxy) - 1 -methyl- ethyl] -7-chloro-3- (4-ethyl-phenyl) - 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 38e),
(R)-l-[2-(tert-butyl-dimethyl-sUanyloxy)-l-methyl-ethyl]-3-(4-ethyl-phenyl)-7-(4- fluoro-phenylamino)-3,4-dihydro- lH-pyrimido [4,5-d]pyrimidin-2-one (Example 38f),
(+)- [trans-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl] -{2-chloro-5- [(4-ethyl- phenylamino)-methyl]-pyrimidin-4-yl}-amine (Example 39a),
(+)-l-[trα«s-3-(tert-butyl-dimethyl-silanyloxy)-cyclopentyl]-7-chloro-3-(4-ethyl- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 39b), and
(±)-l-[tr n5-3-(tert-butyl-dimethyl-silanyloxy)-cyclopentyl]-3-(4-ethyl-phenyl)-7-(4- fluoro-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 39c). The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds are provided in the examples. GeneraUy, compounds of formula I can be prepared according to the below described synthetic routes.
Scheme 1
Figure imgf000021_0001
I
Alternatively, compounds of formula I may be obtained as foUows:
Scheme 2
'ci ArNH, „Ar
Cl' -N' -Cl Base Gl-^N^CI
2 4
Alternately, compounds of formula I can be synthesized as foUows.
Scheme 3
R1NH,
Figure imgf000022_0001
Commercial
Figure imgf000022_0002
Figure imgf000022_0003
Oxidation Ar'NH2
Figure imgf000022_0004
Figure imgf000022_0005
11 I
Alternatively, compound 6 ma be obtained from compound 4 as foUows:
Scheme 4
Figure imgf000022_0006
Compounds of Formula I may also be obtained from compound 4 as foUows:
Scheme 5
Figure imgf000022_0007
Examples
The foUowing examples Ulustrate preferred methods for synthesizing the compounds and formulations of the present invention.
Example 1
Example la
5- (Hydroxymethyl) - 1 ,3-dihydropyrimidine-2,4-dione
Figure imgf000023_0001
A 2-L, three-necked flask equipped with a mechanical stirrer, thermometer, condenser, and nitrogen-inlet bubbler was charged with uradl (185.0 g, 1650 mmol) (Aldrich), paraformaldehyde (61.50 g, 2050 mmol as formaldehyde) (Aldrich), and a solution of potassium hydroxide (86.9%, 59.95 g, 928.5 mmol) (Aldrich) in water (1.445 L). The mixture was stirred at 50 - 52 °C for 68 hours. TLC analysis indicated complete reaction. After concentration at 60 °C/14 mm Hg to a volume of ca. 500 mL, the residue was dfluted with acetone (500 mL). The resulting precipitate was coUected by filtration, washed with acetone, and dried by suction, then at 50 °C/25 mm Hg to give crude 5- (hydroxymethyl)-l,3-dihydropyrimidine-2,4-dione (250 g) as a white solid. The combined mother liquor and washes were concentrated to a volume of ca. 100 mL and a solution of hydrpxylamine hydrochloride (27.52 g, 396.0 mmol, Aldrich) in water (100 mL) was added. The resulting precipitate was coUected by filtration, washed with acetone, and dried by suction to give second crop of crude 5 -(hydroxymethyl) -1,3- dihydropyrimidine-2,4-dione (34 g) as a white solid. The two lots were combined (244 g, 4% overweight) and used directly in the next step.
Example lb
2,4-Dichloro-5-(chloromethyl)pyrimidine
•cι ci N Cl
A 1-L, three-necked flask equipped with a mechanical stirrer, addition funnel, thermometer and nitrogen-inlet bubbler was charged with crude 5-(hydroxymefhyl)-l,3- dihydropyrimidine-2,4-dione (50.25 g, ca. 340 mmol) (from Example la supra), phosphorous oxychloride (164.8 mL, 1768 mmol) (Aldrich), and toluene (100 mL). To 4-τ,: — ;„-,,,...„.
Figure imgf000023_0002
mL, 1060 mmol) (Aldrich) over 10 min, while maintaining the temperature of the mixture below 70 °C using a water bath. After completion of the addition, the coohng bath was removed and the mixture was heated to reflux (113 - 116 °C) for 1 hour. Some of the toluene (ca. 35 mL) was removed by distillation to increase the temperature of the reaction mixture to 120 °C and the mixture was stirred at 120 - 123 °C for 5 hours. TLC analysis indicated reaction was complete. After the mixture was allowed to cool to room temperature overnight, the mixture was cautiously added, over 67 minutes, to a stirred bi-phasic mixture of water (200 mL) and isopropyl acetate (150 mL), whfle maintaining the temperature between 17 °C to 21 °C using an ice-water bath. After stirring at 18 - 21 °C for 80 minutes with occasional ice-water cooUng, the mixture was extracted with toluene (4 x 150 mL). The combined organic layers were dried (sodium sulfate), filtered, then concentrated to dryness under reduced pressure to give crude 2,4-dichloro-5-(chloromethyl)pyrimidine as a white solid, containing polar impurities. (Yield 56.1 g, 83.6% yield from uracU).
Crude 2,4-dichloro-5-(chloromethyl)pyrimidine (70.39 g) was dissolved in dichloromethane (80 mL) and the resulting solution was filtered through a pad of TLC grade silica gel (100 g). The sUica gel was then washed with dichloromethane:hexanes (1 L, 7:3), and the combined filtrate and washes were concentrated to dryness under reduced pressure to give 2,4-dichloro-5-(chloromethyl)pyrimidine as a white solid. (Yield 58.77 g, 83.5% recovery, 69.8% overaU yield from uracil).
Example lc
2,4-Dichloro-5-(iodomethyl)pyrimidine
Figure imgf000024_0001
A 500-mL, round-bottom flask equipped with a magnetic stirrer, condenser, and nitrogen-inlet bubbler was charged with sodium iodide (38.5 g, 256.9 mmol) (Aldrich) and acetone (300 mL). After a clear solution was obtained, 2,4-dichloro-5-
(chloromethyl)pyrimidine (50.0 g, 253.2 mmol) (from Example lb supra) was added in one portion. After stirring at room temperature for 20 minutes, the mixture was heated to reflux for 15 minutes. NMR analysis indicated 98% conversion. After cooling to room temperature, the resulting precipitate (sodium chloride) was removed by filtration through a medium-sintered glass funnel and washed with acetone. The combined filtrate and washes were concentrated to a weight of ca. 75 g. The resulting concentrated solution of 2,4-dichloro-5-(iodomethyl)pyrimidine in acetone was dUuted with toluene (20 mL). After concentration to a weight of ca.85 g in order to remove the residual acetone, this concentrated solution of 2,4-dichloro-5-(iodomethyl)pyrimidine in toluene was used directly in the next step.
Example Id
[(2,4-Dichloropyrimidin-5-yl)methyl](4-methoxyphenyl)amine
Figure imgf000025_0001
A 500-mL, three-necked flask equipped with a magnetic stirrer, thermometer, and nitrogen-inlet bubbler was charged with a solution of 2,4-dichloro-5- (iodomethyl)pyrimidine (85 g, ca. 253.2 mmol) (from Example lc supra) in toluene (13.7 mL) from the previous step and toluene (96.3 mL, thus, a total of ca. 110 mL of toluene). After cooling with an ice-water bath, -anisidine (31.18 g, 253.2 mmol) (Aldrich) was added. After stirring for 30 minutes, a solution of sodium hydroxide (13.54 g, 331.7 mmol) in water (50 mL) was added dropwise over 8 minutes, whUe maintaining the temperature of the reaction mixture at 10 - 15 °C hexanes (55 mL) was added and the mixture was stirred at 10 - 15 °C for 45 minutes, then at room temperature for 22 hours to give a slurry. TLC analysis of the supernatant indicated complete reaction. The slurry was diluted with water (100 mL) and the solid was coUected by filtration, washed with cold water and cold (-50 °C) methanol (100 mL), and dried by suction to give [(2,4- dichloropyrimidin-5-yl)methyl] (4-methoxyphenyl)amine as an off-white solid, 97% pure by HPLC analysis. (Yield 59.87 g, 83.2%).
Example le
l-Cyclohexyl-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d] pyrimidin-2-one
Figure imgf000025_0002
A solution of [(2,4-dichloropyrimidin-5-yl)methyl](4-methoxyphenyl)amine (200 mg, 0.70 mmol) (from Example Id supra) in anhydrous tetrahydrofuran' (24 mL) was treated with n-butyllithium (1.6 M solution in hexanes, 0.53 mL, 0.84 mmol) (Aldrich) at - 78 °C. This was foUowed by addition of cyclohexyl isocyanate (90 μL, 88 mg, 0.70 mmol) (Aldrich). The resulting mixture was stirred and slowly warmed up to room temperature within a period of 2 hours. The reaction mixture was then partitioned between ethyl acetate and brine. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that was purified by chromatography with a sUica gel column using a 0 - 60% ethyl acetate in hexanes gradient. The intermediate that was obtained from this purification was dissolved in anUine (2 mL) (Aldrich), a catalytic amount of 4-(dimethylamino)pyridine (Aldrich) was added and the mixture was then heated at 100 °C. After stirring overnight the mixture was cooled, and purified by silica gel column chromatography with a 0 - 60% ethyl acetate in hexanes gradient. The solid obtained from this purification was dissolved in tetrahydrofuran and then precipitated with excess of pentane to give l-cyclohexyl-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one as a beige solid. (Yield 78 mg, 26%).
HRMS m/z calcd for C25H27N5O2 [M+]: 429.2165. Found: 429.2165.
IC50 (KDR) = 0.025 μM, IC50 (FGFR) = 0.049 μM.
Example 2a
4-[3-(4-Methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5- d]pyrimidin-l-yl] -piperidine- 1 -carboxylic acid tert-butyl ester
Figure imgf000026_0001
A solution of l-N-Boc-4-amino piperidine (300 mg, 1.49 mmol) (Astatech) and triethylamine (840 μL, 606 mg, 5.99 mmol) (Aldrich) in anhydrous dichloromethane (10 mL) was treated at 0 °C with a 20% solution of phosgene in toluene (1.47 mL, 2.99 mmol) (Fluka). After stirring for 30 minutes the mixture was partitioned between 0.5 M aqueous hydrochloric acid and dichloromethane. The organic layer was then coUected, washed with brine, dried over sodium sulfate and concentrated. The residue was dissolved in diethyl ether (approx. 6 mL) and the resulting solution was filtered and concentrated. The residue was then dissolved in a smaU volume of anhydrous tetrahydrofuran (approx. 3 mL) and transferred via cannula to a -78 °C solution of [(2,4- dichloropyrimidin-5-yl)methyl](4-methoxyphenyl)amine (300 mg, 1.06 mmol) (from Example Id supra) and n-butyUithium (2.5 M solution in hexanes, 0.51 mL, 1.27 mmol) ;« ni^^r nc +«t kydrof ran (20 mL). The reaction mixture was aUowed to slowly warm to room temperature and stirred for 4 hours before it was partitioned between ethyl acetate and brine. The organic layer was then coUected, dried over sodium sulfate, filtered, concentrated and the residue was purified by chromatography on a sUica gel column with 0 - 60% ethyl acetate in hexanes. The product from this purification was then dissolved in aniline (2 mL) (Aldrich) and the resulting solution was heated at 80 °C for a period of 12 hours. The reaction mixture was then cooled, and purified by sUica gel column chromatography using a 0 - 70% ethyl acetate in hexanes gradient to afford the product. After a precipitation out of THF with excess of pentane, 4- [3-(4-methoxy- phenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-l-yl]- piperidine- 1 -carboxylic acid tert-butyl ester was isolated as an off white solid. (Yield 74 mg, 13%).
HRMS m/z Calculated for C29H34N6O4 [M+]: 530.2641. Found: 530.2640.
Example 2b
3-(4-Methoxy-phenyl)-7-ρhenylamino-l-piperidin-4-yl-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one
Figure imgf000027_0001
4-[3-(4-Methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5- d]pyrimidin-l-yl] -piperidine- 1 -carboxylic acid tert-butyl ester (70 mg, 0.13 mmol) (from Example 2a supra) was dissolved at 0 °C in a 50% solution of trifluoroacetic acid in dichloromethane (6 mL) that contained 100 μL of water. After stirring for 1.5 hours the mixture was partitioned between ethyl acetate and 1 N aqueous sodium hydroxide and the pH of the aqueous layer was adjusted to 12 by the addition of solid sodium hydroxide. The organic layer was then washed with water, dried over sodium sulfate, filtered and concentrated. The crude material was purified by precipitation out of tetrahydrofuran with excess of pentane to give 3-(4-methoxy-phenyl)-7-phenylamino-l- piperidin-4-yl-3,4-dihydro-lH-ρyrimido [4,5-d] pyrimidin-2-one as an off white solid. (Yield 42 mg, 75%).
HRMS m/z Calculated for C2 H27N6θ2 [(M+H)+]: 431.2190. Found: 431.2190. Example 3a
trans-4- ( tert-Butyl- dimethyl-sUanyloxy) - cyclohexylamine
Figure imgf000028_0001
To a solution of trøtts-4-aminocyclohexanol (5.0 g, 43.4 mmol) (TCI US) in dichloromethane (100 mL) was added imidazole (14.78 g, 0.22 mol) (Aldrich) and tert- butyldimethylsUyl chloride (19.63 g, 0.13 mol) (Avocardo Research Chemicals). The reaction mixture was stirred at room temperature for 1 day and then was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic layer was washed with IN sodium hydroxide solution, water and brine, dried over magnesium sulfate, filtered and concentrated to give trans-4- (tert-butyl-dimethyl-sUanyloxy)-cyclohexylamine. (Yield 7.62 g, 76.5%).
Example 3b
l-[tr π5-4-(tert-Butyl-dimethyl-silanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000028_0002
A solution of trαtts-4-(tert-butyl-dimethyl-sflanyloxy)-cyclohexylamine (350 mg, 1.53 mmol) (from Example 3a supra) in dichloromethane (10 L) was treated with triethylamine (850 μL, 630 mg, 6.10 mmol) (Aldrich) and then at 0 °C with a solution of phosgene in toluene (20%, 1.49 mL, 3.05 mmol) (Fluka). After stirring for 30 minutes the reaction mixture was partitioned between dichloromethane and 0.5 M aqueous hydrochloric acid. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was dissolved in diethyl ether and the resulting solution was filtered and concentrated. The residue obtained was then dissolved in a smaU volume of anhydrous tetrahydrofuran (approx. 3 mL) and transferred via cannula to a -78 °C solution of (2,4-dichloro- pyrimidin-5yl-methyl)- (4-methoxy-phenyl) -amine (340 mg, 1.19 mmol) (from Example ld supra) and n-butyUithium (2.5 M solution in hexanes, 0.61 mL, 1.52 mmol) (Aldrich) in anhydrous tetrahydrofuran (25 mL). The reaction mixture was allowed to slowly warm to room temperature and stirred for 2 hours and 15 minutes. The mixture was then partitioned between ethyl acetate and brine. The organic layer was separated, dried over sodium sulfate, filtered, concentrated and the residue was purified by chromatography on a sUica gel column with 0 - 60% ethyl acetate in hexanes gradient. The intermediate from this purification was dissolved in anUine (3 L) (Aldrich) and the resulting solution was heated at 80 °C for 12 hours. The mixture was then cooled and purified by sUica gel column chromatography using a 0 - 50% ethyl acetate in hexanes gradient to afford the product. After a precipitation out of diethyl ether with excess of pentane 1- [fr ns-4-(tert-butyl-dimethyl-sUanyloxy)-cyclohexyl] -3- (4-methoxy-phenyl) - 7-phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one was isolated as an off- white solid. (Yield 139 mg, 21%).
HRMS m/z Calculated for C3iH42N5O3Si [(M+H)+]: 560.3052. Found: 560.3056.
Example 3 c
l-(tr π5-4-Hydroxy-cyclohexyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000029_0001
1 - [trans-4- ( fert-Butyl-dimethyl-sflanyloxy) -cyclohexyl] -3- (4-methoxy-phenyl) -7- phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (from Example 3b supra) (139 mg, 0.25 mmol) was dissolved at 0 °C in a 50% solution of trifluoroacetic acid in dichloromethane (5 mL) that contained water (330 μL). After stirring for 1.5 hours the reaction mixture was partitioned between ethyl acetate and 1 N aqueous sodium hydroxide and the pH of the aqueous layer was adjusted to 12 by adding solid sodium hydroxide. The organic layer was then washed with water, dried over sodium sulfate, filtered and concentrated to the crude product. Purification by sUica gel column chromatography with 0 - 100% ethyl acetate in hexanes gradient foUowed by a precipitation out of tetrahydrofuran with excess of pentane afforded l-(trαns-4-hydroxy- cyclohexyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one as an off-white solid. (Yield 72 mg, 65%). HRMS m/z calcd for C25H27N5O3 [M+]: 445.2114. Found: 445.2122.
Example 4a
3-[3-(4-Methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5- d]pyrimidin-l-yl]-piperidine-l-carboxylic acid tert-butyl ester
Figure imgf000030_0001
A mixture of l-N-BOC-3-aminopiperidine (350 mg, 1.75 mmol) (Astatech) and triethylamine (710 mg, 970 μL, 7.00 mmol) (Aldrich) in dichloromethane (10 mL) at 0 °C was treated with a 20% phosgene solution in toluene (1.7 mL, 3.47 mmol) (Fluka). After stirring for 30 minutes the reaction mixture was filtered and the filtrate was concentrated to a smaU volume. Benzene (5 mL) was added and the resulting mixture was filtered again and concentrated. The residue was dissolved in a small volume of anhydrous tetrahydrofuran (approx. 3 mL) and transferred via cannula to a -78 °C solution of (2,4-dichloro-pyrimidin-5ylmethyl)-(4-methoxyphenyl)-amine (340 mg, 1.19 mmol) (from Example Id supra) and n-butyUithium (2.5 M solution of in hexanes, 0.70 mL, 1.75 mmol) (Aldrich) in anhydrous tetrahydrofuran (20 mL). The resulting mixture was allowed to warm up slowly to room temperature and stirred overnight. The next morning the reaction mixture was partitioned between ethyl acetate and water. The organic layer was collected, dried over sodium sulfate, filtered, concentrated and the residue was purified by chromatography on a sUica gel column with a 0 - 70% ethyl acetate in hexanes gradient. The product from this purification was dissolved in aniline (3 mL) and the mixture heated at 80 °C for 12 hours. The mixture was then cooled and purified by sUica gel column chromatography using a 0 - 100% ethyl acetate in hexanes to 0-50% tetrahydrofuran in ethyl acetate gradient to afford the product. After a precipitation out of THF with excess of pentane 3-[3-(4-methoxy-phenyl)-2-oxo-7- phenylamino-3,4-dihydro-2H-pyrimido [4,5-d] pyrimidin- 1-yl] -piperidine- 1 -carboxylic acid tert-butyl ester was isolated as an off-white solid. (Yield 70 mg, 10%).
HRMS m/z calcd for C29H34Ν6O4 [(M+H)+]: 531.2715. Found: 531.2725. Example 4b
3-(4-Methoxy-phenyl)-7-phenyIamino-l-piperidin-3-yl-3,4-dihydro-lH-pyrimido[4,5- d] pyrimidin-2 -one
Figure imgf000031_0001
3- [3-(4-Methoxy-ρhenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido [4,5- d]pyrimidin-l-yl]-piperidine-l-carboxylic acid tert-butyl ester (70 mg, 0.13 mmols) (from Example 4a supra) was dissolved at 0 °C in a 50% trifluoroacetic acid in dichloromethane solution (5 mL) that contained water (300 μL). After stirring for 1.5 hours the reaction mixture was partitioned between ethyl acetate and 1 N aqueous sodium hydroxide and the pH of the aqueous layer was adjusted to 12 by adding solid sodium hydroxide. The organic layer was then washed with water, dried over sodium sulfate, filtered and concentrated to the crude product. This material was dissolved in tetrahydrofuran and precipitated with an excess of pentane to give 3-(4-methoxy- phenyl)-7-phenylamino-l-piperidin-3-yl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2- one as an off-white solid. (Yield 47 mg, 84%).
HRMS m/z calculated for C2 H27N6O2 [(M+H)+]: 431.2190. Found: 431.2193
IC50 (KDR) = 0.107 μM, IC50 (FGFR) = 0.158 μM.
Example 5
l-Cyclopentyl-3-(4-methoxy-phenyl)-7-ρhenylamino-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one
Figure imgf000031_0002
A solution of (2,4-dichloro-pyrimidin-5-yl-methyl)-(4-methoxyphenyl)-amine (350 mg, 1.23 mmol) (from Example Id supra) in anhydrous tetrahydrofuran (30 mL) was treated with π-butyllithium (2.5 M solution in hexanes, 590 μL, 1.48 mmol) ( ΔirW αt -78 °C. Then cyclopentyl isocyanate (170 μL, 164 mg, 1.48 mmol) (Aldrich) was added and the solution was aUowed to slowly warm up to room temperature and stirred for 5 hours. The reaction mixture was then partitioned between ethyl acetate and brine and the organic layer was coUected, dried over sodium sulfate, filtered and concentrated and the residue was purified on a sUica gel column with a 0 - 50% ethyl acetate in hexanes gradient. The intermediate from this purification was dissolved in aniline (3 mL) (Aldrich), a catalytic amount of 4-(dimethylamino)pyridine (Aldrich) was added and the resulting solution stirred at 100 °C for 17 hours. The reaction mixture was then cooled and purified by sUica gel column chromatography with a 0 - 50% ethyl acetate in hexanes gradient to give the product. After a precipitation out of THF with an excess of pentane, l-cyclopentyl-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro- lH-ρyrimido[4,5-d]pyrimidin-2-one was isolated as an off-white solid. (Yield 49 mg, 9%).
HRMS m/z calcd for C24H25N5O2 [M+]: 415.2008. Found: 415.2014.
Example 6
1 - ( 1 , 1 -Dioxo-tetrahydrothiophen-3-yl) -3- (4-methoxy-phenyl) -7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000032_0001
A mixture of l,l-dioxidotetrahydrothien-3-ylamine (200 mg, 1.48 mmol) (Salor) and triethylamine (590 mg, 820 μL, 5.9 mmol) (Aldrich) in dichloromethane (9 mL) was treated with a 20% phosgene solution in toluene (1.80 mL, 3.70 mmol) (Fluka) at 0 °C. After 30 minutes the mixture was filtered and the filtrate was concentrated to a smaU volume. Benzene (5 mL) was added, the mixture was filtered again and the filtrate was added to a solution of (2,4-dichloro-pyrimidin-5yl-methyl)-(4-methoxyphenyl)-amine (230 mg, 1.43 mmol) (from Example Id supra) in benzene (15 mL). The resulting solution was heated at reflux overnight. The next morning the solvent was evaporated under reduced pressure to a residue that was chromatographed with a sflica gel column using a 0 - 100% ethyl acetate in hexanes gradient. The intermediate isolated from this purification was then dissolved in anhydrous tetrahydrofuran (15 mL) and the resulting solution was cooled at -78 °C and treated with π-butyUithium (2.5 M solution in hexanes, 330 μL, 0.82 mmol) (Aldrich). The mixture was aUowed to warm up slowly to room temperature, stirred for 5.5 hours, and then partitioned between ethyl acetate and brine. The organic layer was coUected, dried'over sodium sulfate, filtered, concentrated and the resulting residue was dissolved in anUine (3 mL) (Aldrich). A catalytic amount of 4- (dimethylamino)pyridine (Aldrich) was added, and the mixture was stirred at 75 °C for 14 hours. The mixture was then cooled and purified by sUica gel column chromatography using a 0 - 100% ethyl acetate in hexanes gradient to afford the product. After precipitation out of methylene chloride with excess of pentane the product, 1-(1,1- dioxo-tetrahydro1_hiophen-3-yl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one, was isolated as an off-white solid. (Yield 152 mg, 23%).
HRMS m/z calcd for C23H23N5O4S [M+]: 465.1471. Found:465.1477.
ICso (KDR) = 0.075 μM, IC50 (FGFR) = 0.226 μM.
Example 7
3-[3-(4-Methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5- d] pyrimidin- 1 -yl] -piperidine- 1 -carbaldehyde
Figure imgf000033_0001
3 - (4-Methoxy-phenyl) -7-phenylamino- 1 -ρiperidin-3 -yl-3,4-dihydro- 1H- pyrimido[4,5-d]pyrimidin-2-one (95 mg, 0.22 mmol) (from Example 4b supra) was dissolved at room temperature in methylformate (5 mL) (Aldrich). After stirring overnight the reaction mixture was concentrated to the crude product, which was purified by sUica gel column chromatography with a 0 - 100% ethyl acetate in hexanes and then a 0 - 20% tetrahydrofuran in ethyl acetate gradient. After a precipitation out of dichloromethane with excess of pentane, 3-[3-(4-methoxy-phenyl)-2-oxo-7- phenylamino-3,4-dihydro-2H-pyrimido [4,5-d] pyrimidin- 1 -yl] -piperidine-1 - carbaldehyde was isolated as an off-white solid. (Yield 90 mg, 89%).
HRMS m/z calcd for C25H26N603 [M+] : 458.2066. Found: 458.2062. Example 8
3-(4-Methoxy-phenyl)-7-phenylamino-l-(tetrahydro-pyran-4-yl)-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000034_0001
A mixture of 4-aminotetrahydropyran (300 mg, 2.88 mmol) (Combi-Blocks) and triethylamine (1.61 mL, 11.52 mmol) (Aldrich) in dichloromethane (6 mL) was treated with a 20% phosgene solution in toluene (1.4 mL, 5.76 mmol) (Fluka) at 0 °C. After stirring for 30 min the mixture was filtered and the filtrate was concentrated to a smaU volume. Benzene (5mL) was added and the mixture was filtered again. The filtrate was concentrated and the residue was dissolved in anhydrous tetrahydrofuran (approximately 3 mL) and transferred via a cannula to a -78 °C solution of (2,4-dichloro-pyrimidin-5yl- methyl)-(4-methoxyphenyl)-amine (300 mg, 1.44 mmol) (from Example Id supra) and n-butyUithium (2.5 M solution in hexanes, 460 μL, 1.44 mmol) (Aldrich) in tetrahydrofuran (15 mL). The reaction mixture was aUowed to warm up slowly to room temperature, stirred overnight and then partitioned between ethyl acetate and brine. The ethyl acetate layer was coUected, dried over sodium sulfate, filtered, concentrated and the residue was purified by chromatography with a sUica gel column using a 0 - 70% ethyl acetate in hexanes gradient. The intermediate obtained from this purification was dissolved in anUine (2 mL) (Aldrich). A catalytic amount of 4-(dimethylamino)pyridine was added and the resulting solution stirred at 110 °C for 11 hours. The reaction mixture was then cooled and purified by sUica gel column chromatography using a 0 - 100% ethyl acetate in hexanes gradient to afford the product. After a precipitation out of dichloromethane with excess of pentane the product, 3-(4-methoxy-phenyl)-7- phenylamino- 1 - (tetrahydropyran-4-yl) -3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2- one, was isolated as an off-white solid. (Yield 15 mg, 2% ).
HRMS m/z calcd for 4H25N5O3 [M+]: 431.1957. Found:431.1948. Example 9a
(±) -ds-3- (tert-Butyl-dimethyl-sUanyloxy) -cyclopentanol
Figure imgf000035_0001
(+)-ds-tert-Butyl-dimethyl-(6-oxa-bicyclo[3.1.0]hex-3-yloxy)-sUane (2.15 g, 9.99 mmol) (prepared according to the procedure of Hendrie, S. K., Leonard, J. Tetrahedron, 1987, 43 (14), 3289-3294) was dissolved in ethanol (70 mL). To this solution was added 10% Pd/C (500 mg) (Aldrich) and the mixture was hydrogenated under 1 atmosphere of hydrogen for 24 hours and at 50 psi for another 24 hours. Another portion of 10% Pd/C (500 mg) was added and the mixture was hydrogenated again at 55 psi for 24 hours. The hydrogenation mixture was then filtered, the solids were washed with tetrahydrofuran (approx. 60 mL) and the combined organic layer was concentrated. The residue was purified by chromatography on a sUica gel column with 0 - 100% diethyl ether in hexanes to give (±)-ds-3-(tert-butyl-dimethyl-sUanyloxy)-cycIopentanol as a colorless viscous oU. (Yield 1.81 g, 83%).
HRMS m/z calcd for CnH2402Si [(M+H)+]: 217.1618. Found: 217.1619.
Example 9b
(+) -trans- (3 -Azido-cyclopentyloxy) -tert-butyl-dimethyl-sUane
Figure imgf000035_0002
To a mixture of (±)-ds-3- (tert-butyl-dimethyl-silanyloxy) -cyclopentanol (1.5 g, 6.93 mmol) (from Example 9a supra) and triphenylphosphine (1.99 g, 7.63 mmol) (Aldrich) in anhydrous tetrahydrofuran (60 L) was added dropwise diethyl azodicarboxylate (1.2 mL, 1.32 g, 7.63 mmol) (Aldrich) at 0 °C. Then after 2 minutes this was foUowedby the addition of diphenylphosphoryl azide (1.6 mL, 2.09 g, 7.63 mmol) (Aldrich) and the resulting solution was aUowed to slowly warm up to room temperature. After stirring overnight the reaction mixture was partitioned between diethyl ether and water. The organic layer was coUected, dried over sodium sulfate, filtered, and concentrated and the residue was purified by chromatography on a silica gel column using a 0 - 20% diethyl ether in hexanes gradient to give (±)-trø«s-(3-azido- cyclopentyloxy)-tert-butyl-dimethyl-sUane as a colorless liquid. (Yield 1.2 g, 72%).
Example 9c
(±)-trβ«5-3-(tert-Butyl-dimefhyl-sUanyloxy)-cyclopentylamine
Figure imgf000036_0001
A mixture of (±)-tr ns-(3-azido-cyclopentyloxy)-tert-butyl-dimethyl-sUane (400 mg, 1.66 mmol) (from Example 9b supra) and platinum oxide (38 mg, 0.17 mmol) (Aldrich) in ethanol (6 L) was stirred under 1 atmosphere of hydrogen pressure for 2 hours. The reaction mixture was then filtered. The solids were washed with tetrahydrofuran (approx. 40 mL) and the combined organic layer was evaporated under reduced pressure to give (±)-tr ns-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentylamine as a colorless liquid. (Yield 270 mg, 76%).
HRMS m/z calcd for CπH25NOSi [(M+H)+]: 216.1778. Found: 217.1780.
Example 9d
(+)-l-(trfl -3-Hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000036_0002
A solution of (±)-t n5-3-(tert-butyl-dimethyl-silanyloxy)-cyclopentylamine (270 mg, 1.25 mmol) (from Example 9b supra) and triethylamine (1.15 L, 840 mg, 8.30 mmol) (Aldrich) in dichloromethane (5 mL) was treated at 0 °C with a 20% solution of phosgene in toluene (2 mL, 4.15 mmol) (Fluka). After stirring for 30 minutes the mixture was filtered and the filtrate was concentrated to a smaU volume. Benzene (5 mL) was added and the mixture was filtered again. The filtrate was concentrated, the residue was dissolved in a small volume of anhydrous tetrahydrofuran (approx. 3 mL) and then transferred via a cannula to a -78 °C solution of (2,4-dichloro-pyrimidin-5yl-methyl)-(4- methoxyρhenyl)-amine (180 mg, 0.63 mmol) (from Example Id supra) and n- butyUithium (2.5 M solution in hexanes, 250 μL, 0.63 mmol) (Aldrich) in anhydrous tetrahydrofuran (15 mL). The reaction mixture was aUowed to slowly warm up to room temperature, stirred for 5.5 hours and then partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered, concentrated and the residue was purified by chromatography on a sUica gel column with a 0 - 40% ethyl acetate in hexanes gradient. The intermediate obtained from this purification was dissolved in anUine (2 mL) (Aldrich), a catalytic amount of 4-(dimethylamino) pyridine (Aldrich) was added and the resulting solution was stirred for 7 hours at 80 °C. The mixture was then cooled and purified by sUica gel column chromatography using a 0 - 40% ethyl acetate in hexanes gradient. The product from this purification was dissolved in acetonitrUe (3 mL), 5% aqueous hydrofluoric acid (50 μL) was added and the mixture was stirred for 21 hours. The reaction mixture was then concentrated to a smaU volume and purified by sUica gel column chromatography using a 0 - 100% tetrahydrofuran in hexanes gradient to afford the product. After a precipitation out of dichloromethane with excess of pentane, the product, (±)-l-(trαns-3-hydroxy-cyclopentyl)-3-(4-metiιoxy- phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one, was isolated as a white solid. (Yield 23 mg, 8%)..
HRMS m/z calculated for CAs [(M+H)]+: 480.1467. Found: 480.1471.
Example 10a
(±)-tr πs-3-(tert-Butyl-dimefhyl-sUanyloxy)-cyclopentanol
Figure imgf000037_0001
To a mixture of 1,3-cyclopentanediol (5.0 g, 48.9 mmol) (cis/trans mixture, Aldrich) and imidazole (3.3 g, 48.5 mmol) in tetrahydrofuran (100 mL) at 0 °C was added tert-butyldimethylsUyl chloride (5.2 g, 34.3 mmol) (Aldrich) in portions (250 mg every 15 minutes). When all additions were completed the reaction mixture was aUowed to slowly warn to room temperature. After stirring overnight the mixture was partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on a silica gel column with a 0 - 20% ethyl acetate in hexanes gradient to give (±)-trans-3- (tert-butyl-dimethyl-silanyloxy)-cyclopentanol as a colorless viscous oU, (Yield 4.23 g, 57%), and (±)-ds-3-(tert-butyl-dimethyl-silanyloxy)-cyclopentanol (Yield 420 mg, 6%).
HRMS m/z calcd for CnH2 O2Si [M+H]+: 217.1618. Found: 217.1621. Example 10b
(±)-ds-2-[3-(tert-Butyl-dimethyI-sUanyloxy)-cycIopentyl]-isoindole-l,3-dione
Figure imgf000038_0001
A solution of (±)-tr ns-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentanol (1.1 g, 5.08 mmol) (from Example 10a supra), triphenylphosphine (3.2 g, 12.20 mmol)
(Aldrich) and phthalimide (1.8 g, 12.20 mmol) (Aldrich) in anhydrous tetrahydrofuran (45 mL) was cooled to 0 °C. To this was added dropwise diethyl azodicarboxylate (2.1 L, 2.3 g, 12.20 mmol) (Aldrich) and the resulting solution was aUowed to slowly warm to room temperature. After stirring overnight the reaction mixture was partitioned between ethyl acetate and water. The organic layer was collected, dried over sodium sulfate, filtered and concentrated and the residue was purified by chromatography on a sUica gel column using a 0 - 35% ethyl acetate in hexanes gradient to give (±)-ds-2-[3- (tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-isoindole-l,3-dione as a white solid. (Yield 1.52 g, 87%).
HRMS m/z calcd for C19H27NO3Si [M-CH3]+:330.1525. Found: 330.1523.
Example 10c
(±)-ds-3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentylamine
Figure imgf000038_0002
To a mixture of (±)-ds-2-[3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]- isoindole-l,3-dione (1.03 g, 2.98 mmol) (from Example 10b supra) in ethanol/tetrahydrofuran (2:1, 20 mL) was added anhydrous hydrazine (1.2 mL, 38.90 mmol) (Aldrich). After stirring overnight the reaction mixture was filtered. The solids were washed with diethyl ether (approx. 30 mL) and the combined filtrate was concentrated. The residue was treated with diethyl ether again (approx. 30 L) and the resulting mixture was filtered again and concentrated to give (+)~ds-3-(tert-butyl- dimethyl-sUanyloxy)-cyclopentylamine as a colorless oU. (Yield 570 mg, 88%). HRMS m/z calcd for CuH25NOSi [M+H]+: 216.1778. Found: 216.1780.
Example lOd
(+)-3-d5-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentyl-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000039_0001
A solution of (±)-d5-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentylamine (500 mg, 2.32 mmol) (from Example 10c supra) and triethylamine (1.62 mL, 1.2 g, 11.64 mmol) (Aldrich) in dichloromethane (15 mL) at 0 °C was treated with a 20% solution of phosgene in toluene (2.8 mL, 5.80 mmol) (Fluka). After stirring for 30 minutes the mixture was filtered and the filtrate was concentrated to a smaU volume. Benzene (5 mL) was added and this mixture was filtered again. The filtrate was then concentrated, the residue was dissolved in anhydrous tetrahydrofuran (approximately 3 mL) and then transferred via cannula to a -78 °C solution of (2,4-dichloro-pyrimidin-5yl-methyl)-(4- methoxyphenyl)-amine (330 mg, 1.16 mmol) (from Example Id supra) an n- butyUithium (2.5 M solution in hexanes, 460 μL, 1.16 mmol) (Aldrich) in anhydrous tetrahydrofuran (25 mL). The reaction mixture was aUowed to slowly warm up to room temperature, stirred for 48 hours and then partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated and the residue was purified by sUica gel column chromatography using a 0 - 30% ethyl acetate in hexanes gradient. The intermediate that was obtained from this purification was dissolved in aniline (2 mL) (Aldrich). A catalytic amount of 4-(dimetbyl- amino)pyridine (Aldrich) was added and the resulting solution was stirred for 8 hours at 80 °C. The reaction mixture was then cooled and purified by silica gel column chromatography using a 0 - 100% ethyl acetate in hexanes gradient to give (±)-3-ds-(tert- butyl-dimethyl-sUanyloxy)-cyclopentyl-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one as a white solid. (Yield 100 mg, 16%).
HRMS m/z calcd for
Figure imgf000039_0002
[M+H]+: 546.2895. Found: 546.2901. Example lOe
(±)-ds-l-(3-Hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro- lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000040_0001
To a solution of (+)-3-ds-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl-3-(4- methoxy-phenyl) -7-phenylamino-3 ,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (100 mg, 0.18 mmol) (from Example lOd supra) in acetonitrile (3 mL) was added a 5% aqueous hydrofluoric acid solution (110 μL, 0.275 mmol). After stirring overnight the reaction mixture was concentrated to a smaU volume (~1 mL) and purified by sUica gel column chromatography using a 0 - 100% ethyl acetate in hexanes gradient. After a precipitation out of methylene chloride with excess of pentane, the product, (±)-d5-l- (3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one, was isolated as a white solid. (Yield 60 mg, 77%).
HRMS m/z calcd for C24H25N5O3 [M+H]+: 432.2030. Found:432.2033.
Example 11a
(R)-2-Methyls fanyl-4-(tetrahydrofuran-3-ylamino)-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000040_0002
A solution of ethyl 4-chloro-2-methylfhio-5-pyrimidinecarboxylate (897 mg, 3.86 mmol) (Aldrich) and triethylamine (1.2 mL, 870 mg, 8.49 mmol) (Aldrich) in dioxane (20 mL) was treated with (R)-3-aminotetiahydrofuranp-toluene-sulfonic acid salt (1.0 g, 3.86 mmol) (Fluka). The mixture was stirred at reflux for 1 hour, then cooled and partitioned between brine and ethyl acetate. The organic layer was dried over sodium sulfate, filtered, concentrated and the residue was purified by chromatography with a sUica gel column using a 0 - 100% ethyl acetate in hexanes gradient to give (R)-2- methylsulfanyl-4-(tetrahydrofuran-3-ylamino)-pyrimidine-5-carboxylic acid ethyl ester as a colorless viscous oU. (Yield 1.0 g, 92%).
HRMS m/z calcd for Cι2Hι7N303S [M+]: 283.0991. Found: 283.0989.
Example lib
(R) -3- (4-Methoxy-phenyl) -7-phenylamino- 1 - (tetrahydrofuran-3-yl) -3,4-dihydro- 1H- pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000041_0001
To a solution of (R)-2-methylsulfanyl-4-(tetrahydrofuran-3-ylamino)-pyrimidine- 5-carboxylic acid ethyl ester (1.0 g, 3.55 mmol) (from Example 11a supra) at 0 °C in anhydrous tetrahydrofuran (60 mL) was added in portions solid lithium aluminum hydride (400 mg, 10.65 mmol) (Aldrich). The resulting slurry was aUowed to slowly warm up to room temperature. After overnight stirring the slurry was poured slowly into a vigorously stirred mixture of ethyl acetate and saturated aqueous potassium sodium tartrate solution. The organic layer was separated, dried over sodium sulfate, filtered and concentrated to give the crude reduction product. This crude intermediate was dissolved in dichloromethane (30 mL) and treated with manganese dioxide (2.9 g, 34.27 mmol) (Aldrich). After stirring for 2 hours the solids were filtered, washed with tetrahydrofuran (approx. 30 mL), the combined filtrate was concentrated and the residue was dissolved in toluene (40 mL). The solution was then treated with -anisidine (470 mg, 3.77 mmol) (Aldrich), a catalytic amount of p-toluenesulfonic acid mono-hydrate (Aldrich) was added and the mixture was heated at reflux using a Dean-Stark apparatus for 3 hours. The mixture was then cooled and partitioned between ethyl acetate and saturated aqueous potassium carbonate. The ethyl acetate layer was coUected, dried over sodium sulfate, filtered, and concentrated to a residue that was then dissolved in tetrahydrofuran (40 mL). The resulting solution was treated at 0 °C with lithium aluminum hydride (390 mg, 10.28 mmol) (Aldrich). The slurry was aUowed to slowly warm to room temperature arid after stirring for 13.5 hours was poured slowly into a vigorously stirred mixture of ethyl acetate and saturated aqueous potassium sodium tartrate solution. The organic layer was separated, dried over sodium sulfate, filtered, concentrated and the resulting residue was purified by sUica gel column chromatography using a 0 - 70% ethyl acetate in hexanes gradient. The intermediate isolated from this purification was dissolved in tetrahydrofuran (50 mL). Triethylamine (1 mL) (Aldrich) was added and the solution was cooled to 0 °C. FoUowed a dropwise addition of 20% phosgene in toluene solution (1.3 mL, 2.71 mmol) (Fluka) and stirring at 0 °C for 1.5 hours. The mixture was then partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that was purified by chromatography on a silica gel column with a 0 - 40% ethyl acetate in hexanes gradient. The intermediate isolated from this purification was dissolved in tetrahydrofuran (50 mL) and the resulting solution was cooled at 0 °C and treated with 3- chloroperoxybenzoic acid (75%, 1.13 g, 4.93 mmol) (Aldrich). The reaction mixture was allowed to slowly warm up to room temperature and after stirring overnight was partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated. The residue was dissolved in anUine (10 mL) (Aldrich), a catalytic amount of aniline hydrochloride (Aldrich) was added and the resulting solution was stirred for 4.5 hours at 95 °C. The mixture was then cooled and purified by sUica gel column chromatography using a 0 - 100% ethyl acetate in hexanes gradient to afford the product. Trituration with pentane yielded (R)-3-(4-methoxy- phenyl)-7-phenylamino-l-(tetrahydroftιran-3-yl)-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one as an off-white solid. (Yield 740 mg, 50%).
HRMS m/z calcd for C23H23N5O3 [M+H+]: 418.1874. Found: 418.1877.
IC50 (KDR) = 0.091 μM, IC50 (FGFR) = 0.257 μM.
Example 12
(R)-3-(4-Methoxy-phenyl)-7-phenylamino-l-pyrrolidin-3-yl-3,4-dihydro-lH- pyrimido [4,5-d]pyrimidin-2-one
Figure imgf000042_0001
A solution of (R)-l-N-Boc-3-aminopyrrolidine (350 mg, 1.88 mmol) (AstaTech Inc.) and triethylamine (1.31 mL, 0.95 g, 9.4 mmol) (Aldrich) in dichloromethane (6 mL) at 0 °C was treated with 20% phosgene in toluene solution (1.84 mL, 3.76 mmol) (Fluka). After stirring for 30 minutes the reaction mixture was filtered and concentrated to a smaU volume. Benzene (5 mL) was added and the mixture was filtered again. The filtrate was concentrated, dissolved in a small volume of anhydrous tetrahydrofuran (approx. 3 mL) ■_τ,A trcncfp rf-rl via cannula to a -78° C solution of (2,4-dicHoro-pyrimidin-5yl-methyι)- (4-methoxyphenyl)-amine (270 mg, 0.94 mmol) (from Example Id supra) and n- butyUithium (2.5 M solution in hexanes, 380 μL, 0.94 mmol) (Aldrich) in anhydrous tetrahydrofuran (12 mL). The reaction mixture was aUowed to slowly warm up to room temperature stirred overnight and then partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered, concentrated and the resulting residue was purified by chromatography on a sUica gel column using a 0 - 70% ethyl acetate in hexanes gradient. The intermediate obtained from that purification was then dissolved in anUine (2 mL) (Aldrich), a catalytic amount of aniline hydrochloride (Aldrich) was added and the solution was stirred at 85 °C for 8 hours. The mixture was then cooled and purified by sUica gel column chromatography with a 0 - 70% ethyl acetate in hexanes gradient. The product from that purification was then dissolved at 0° C in a 50% trifluoroacetic acid in dichloromethane solution (6 mL) that contained water (300 μL) and stirred for 1.5 hours. The reaction mixture was then partitioned between ethyl acetate and 0.5 N aqueous sodium hydroxide. The pH of the aqueous layer was adjusted to 12 by adding solid sodium hydroxide. The organic layer was then coUected, dried over sodium sulfate, filtered and concentrated to the crude product which was purified by chromatography with a sUica gel column using a 0 - 100% methanol in tetrahydrofuran to 0 - 20% triethylamine in methanol gradient. The fractions containing the product were concentrated to a solid that was then dissolved in dichloromethane (approximately 5 mL). That solution was filtered and treated with excess of pentane to precipitate (R)-3-(4-methoxy-phenyl)-7-phenylamino-l-pyrrolidin-3-yl-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one as an off-white solid. (Yield 14 mg, 2%).
HRMS m/z calcd for C23H24N6O2 [M+H+]: 417.2034. Found: 417.2038.
IC50 (KDR) = 0.190 μM, IC50 (FGFR) = 0.621 μM.
Example 13a
(±)-4-[trflns-3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentylamino]-2-mefhylsulfanyl- pyrimidine-5-carbaldehyde
Figure imgf000043_0001
A solution of 4-chloro-2-methylthio-5-pyrimidinecarboxylate (900 mg, 3.87 mmol) (Aldrich) and triethylamine (1.1 mL, 870 mg, 7.74 mmol) (Aldrich) in dioxane (50 mL) was treated with (±)-tr n5-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentylamine (840 mg, 3.87 mmol) (from Example 9c supra). The mixture was stirred at reflux for 1 hour, then cooled and partitioned between brine and ethyl acetate. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that was purified by sUica gel column chromatography using a 0 - 20% ethyl acetate in hexanes gradient. The product isolated from this purification was then dissolved in anhydrous tetrahydrofuran (80 mL) and the resulting solution was cooled to 0 °C. FoUowed addition in-portions of lithium aluminum hydride (440 mg, 11.61 mmol) (Aldrich) and the resulting mixture was aUowed to warm to room temperature. After overnight stirring the reaction mixture was poured slowly into a vigorously stirred mixture of ethyl acetate and saturated aqueous potassium sodium tartrate solution. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to an off white solid. This intermediate was then dissolved in dichloromethane (80 mL) and the resulting solution was treated with manganese dioxide (3.36 g, 38.70 mmol) (Aldrich). After overnight stirring the solids were filtered off, washed with tetrahydrofuran (approximately 30 mL) and the combined organic layer was concentrated to a residue that upon a sUica gel column purification with 0 - 50% diethyl ether in hexanes gradient gave (±)-4-[tr ns-3-(tert-butyl-dimethyl- silanyloxy)-cyclopentylamino] -2-methylsulfanyl-pyrimidine-5-carbaldehyde as a viscous colorless oU. (Yield 888 mg, 62%).
HRMS m/z calcd for C17H29N3O2SSi [M+H]+: 368.1823. Found:368.1826.
Example 13b
(±)-l-[trflπs-3-(tert-Butyl-dimethyl-silanyloxy)-cyclopentyl]-3-(4-methoxy-phenyl)-7- methylsulfanyl-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000044_0001
A mixture of (±)-4- [tr ns-3-(tert-butyl-dimefhyl-sUanyloxy)-cyclopentyl-amino] -2- methylsulfanyl-pyrimidine-5-carbaldehyde (700 mg, 1.90 mmol) (from Example 13a supra), p-anisidine (230 mg, 1.90 mmol) (Aldrich) and -toluenesulfonic acid mono- hydrate' (50 mg) (Aldrich) in benzene was refluxed using a Dean-Stark apparatus for 6 hours. The mixture was then cooled and partitioned between ethyl acetate and saturated aqueous potassium carbonate. The organic layer was coUected, dried over sodium ι ' "1' J J oncentrated. The residue was then dissolved in anhydrous tetrahydrofuran (60 mL) and to this solution at 0 °C was added in smaU portions lithium aluminum hydride (216 mg, 5.70 mmol) (Aldrich). The slurry that formed was aUowed to slowly warm up to room temperature and after overnight stirring was poured slowly into a vigorously stirred mixture of ethyl acetate and saturated aqueous potassium sodium tartrate solution. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated. The residue was purified by HPLC using 50% diethyl ether in hexanes as the elution solvent. The intermediate obtained from this purification was dissolved in dichloromethane (100 mL), foUowedby addition of triethylamine (500 μL, 660 mg, 6.52 mmol) (Aldrich) and cooled at 0 °C. A 20% phosgene in toluene solution (640 μL, 1.31 mmol) (Fluka) was then added dropwise and the resulting mixture was stirred for 30 minutes at 0 °C and lhour at room temperature. The mixture was then partitioned between ethyl acetate and water. The organic layer was separated, dried over sodium sulfate, filtered and concentrated to a residue that was purified by chromatography on a sUica gel column with a 0 - 60% ethyl acetate in hexanes gradient to give (±)-l-[tr ns-3-(tert-bu1yl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-methoxy- phenyl)-7-methylsulfanyl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one as a white solid. (Yield 543 mg, 57%).
HRMS m/z calcd for C25H36N4O3SSi [M+H]+: 501.2350. Found:501.2353.
Example 13c
(±)-7-(4-Fluoro-phenylamino)-l-(tr πs-3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)- 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000045_0001
A solution of (±)-l-[tr πs-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4- methoxy-phenyl)-7-methylsulfanyl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (40 mg, 0.08 mmol) (from Example 13b supra) in tetrahydrofuran (6 mL) was treated with 3-chloroperoxybenzoic acid (75%, 39 mg, 0.17 mmol) (Aldrich) at room temperature. After stirring for 3 hours the reaction mixture was partitioned between ethyl acetate and saturated aqueous potassium carbonate. The organic layer was separated, dried over sodium sulfate, filtered and concentrated. The residue was dissolved in 4-fluoroanUine (3 mL) (Aldrich) and the solution was stirred for 8 hours at m mixture was then cooled and purified by sUica gel column chromatdgraphy using a 0 - 70% ethyl acetate in hexanes gradient. The product isolated from this purification was dissolved at 0 °C in a 20% trifluoroacetic acid in dichloromethane solution (5 mL) that contained water (500 μL). After stirring for 30 minutes the reaction mixture was partitioned between ethyl acetate and aqueous IN sodium hydroxide solution. The pH of the aqueous layer was adjusted to 12 via the addition of solid sodium hydroxide. The organic layer was separated, dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography with a sUica gel column using a 0 - 100% ethyl acetate in hexanes gradient to afford the product. After a precipitation out of methylene chloride with excess of pentane (+)-7-(4-fluoro- phenylamino)-l-(t s-3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one was isolated as a white solid. (Yield 25 mg, 69%).
HRMS m/z calcd for C24H24FN5θ3 [M+H]+: 450.1936. Found:450.1940.
Example 14a
2-Fluoro-4-methoxyanuine
Figure imgf000046_0001
3-Fluoro-4-nitrophenol (10.17 g, 64.7 mmol) (Aldrich) was dissolved in dimethylformamide (210 mL). Potassium carbonate (45 g, 323 mmol) and methyl iodide (5 mL, 77.64 mmol) (Aldrich) were added and the reaction mixture was stirred at room temperature overnight. (TLC: 20% ethyl acetate in hexanes showed complete conversion). The reaction mixture was filtered through a bed of Celite®, and concentrated under reduced pressure. The crude material was triturated with ether and insoluble materials were removed by filtration. The filtrate was concentrated under reduce pressure to afford an orange solid. This material (11.43 g) was dissolved in methanol (150 mL) and hydrogenated for 1.5 hours in a Parr apparatus at 50 psi, in the presence of 10% paUadium on carbon (1.5 g) (Aldrich). (TLC: 20% ethyl acetate in hexanes showed complete conversion). The reaction mixture was filtered through Celite® washed with ethyl acetate, then concentrated under reduced pressure to afford 2- fluoro-4-methoxyanUine as a solid. (Yield 3.81 g, 26.99 mmol). Example 14b
(±)- [3-tr n5-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentyl] -{5- [(2-fluoro-4-methoxy- phenylamino) -methyl] -2-methylsulfanyl-pyrimidin-4-yl}-amine
Figure imgf000047_0001
A mixture of (±)-4-[t πs-3-(tert-butyl-dimethyl-silanyloxy)-cyclopentyl-amino]-2- methylsulfanyl-pyrimidine-5-carbaldehyde (171 mg, 0.46 mmol) (from Example 13a supra), -toluenesulfonic acid mono-hydrate (10 mg) (Aldrich) and 2-fluoro-4- methoxyamline (79 mg, 0.56 mmol) (from Example 14a supra) in benzene (30 mL) was refluxed in a Dean-Stark apparatus for 8 hours. The mixture was then cooled and partitioned between ethyl acetate and saturated aqueous potassium carbonate. The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The residue was dissolved in anhydrous tetrahydrofuran (50 mL) and to this solution was added in smaU portions lithium aluminum hydride (53 mg, 1.40 mmol) (Aldrich) at 0 °C. The slurry was aUowed to slowly warm up to room temperature and after overnight stirring was poured slowly into a vigorously stirred mixture of ethyl acetate and saturated aqueous potassium sodium tartrate solution. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that upon purification by silica gel column chromatography with a 0 - 60% ethyl acetate in hexanes gradient gave (±)-[3- tr ns-(tert-butyl-dime1-hyl-sUanyloxy)-cyclopentyl]-{5-[(2-fluoro-4-methoxy- phenylamino) -methyl] -2-methylsulfanyl-pyrimidin-4-yl}-amine as a colorless viscous oU. (Yield 187 mg, 83%).
HRMS m/z calculated for C24H37FN402SSi [M+H]+: 493.2464. Found: 493.2472. Example 14c
(±)-l-[tr ns-3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-methoxy-phenyl)-7- methylsulfanyl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000048_0001
To a mixture of (±)-[3-tr n5-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-{5-[(2- fluoro-4-mefhoxy-phenylamino) -methyl] -2-methylsulfanyl-pyrimidin-4-yl}-amine ( 179 mg, 0.36 mmol) (from Example 14b supra) and triethylamine (152 μL, 110 mg, 1.08 mmol) (Aldrich) in dichloromethane (30 mL) cooled to 0 °C was added dropwise a 20% phosgene in toluene solution (265 μL, 0.54 mmol) (Fluka). The resulting mixture was aUowed to slowly warm to room temperature and stirred for 4.5 hours. The mixture was then partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that was purified by chromatography on a sUica gel column with a 0 - 10% diethyl ether in toluene gradient to give (±)- 1- [tmπs-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl] -3-(4-methoxy-phenyl)- 7-methylsulfanyl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one as an off white foamy solid. (Yield 84 mg, 45%).
HRMS m/z calcd for C25H35FN4O3SSi [M+H]+: 519.2256. Found: 519.2263.
Example 14d
(+)-3-(2-Fluoro-4-methoxy-phenyl)-l-(trflπs-3-hydroxy-cyclopentyl)-7-phenylamino- 3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000048_0002
To a solution of (±)-l-[tr n5-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4- methoxy-phenyl)-7-methylsulfanyl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (80 mg, 0.15 mmol) (from Example 14c supra) in dichloromethane (15 mL) was added n :oic acid (75%, 75 mg, 0.32 mmol) (Aldrich). The reaction mixture was stirred for 5.5 hours and then partitioned between ethyl acetate and saturated •aqueous solution of potassium carbonate. The organic layer was separated, dried over sodium sulfate, filtered, concentrated and the residue that resulted was dissolved in anUine (2 mL) (Aldrich). This solution was stirred for 8 hours at 90 °C then cooled and purified by sUica gel column chromatography using a 0 - 50% ethyl acetate in hexanes gradient. This was dissolved at 0 °C in a 20% trifluoroacetic acid in dichloromethane solution (5 mL) that contained water (300 μL). After stirring for 25 minutes the mixture was partitioned between ethyl acetate and 0.5N aqueous sodium hydroxide solution. The pH of the aqueous layer was adjusted to 12 by adding solid sodium hydroxide. The organic layer was then separated, dried over sodium sulfate, filtered and concentrated to the crude product. After purification by sihca gel column chromatography with a 0 - 100% ethyl acetate in hexanes and a precipitation out of methylene chloride with excess of pentane the product, (±)-3-(2~fluoro-4-methoxy-phenyl)-l-(trαns-3-hydroxy- cyclopentyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one was isolated as a white solid. (Yield 45 mg, 65%).
HRMS m/z calculated for C24H24FN5O3 [M+H]+: 450.1935. Found: 450.1941.
Example 15a
(S)-3-(tert-Butyl-diphenyl-silanyloxy)-2-methylpropionic acid
Figure imgf000049_0001
Methyl (S)-(+)-3-hydroxy-2-methylpropionate (1.06 g, 8.99 mmol) (Aldrich) was dissolved in dichloromethane (10 mL, dried over molecular sieves). Imidazole (0.85 g, 12.41 mmol) (Aldrich) and tert-butyldiphenylsilyl chloride (2.30 mL, 8.85 mmol) (Aldrich) were added and the mixture was stirred at ambient temperature for three hours. The reaction was diluted with additional dichloromethane, washed with water and brine, dried over anhydrous sodium sulfate and concentrated to yield methyl (S)-3- (tert-butyl-diphenyl-sUanyloxy)-2-methyl-propionate as an oU. (Yield 3.17g, 98.8%).
This ester (3.15 g, 8.85 mmol) was dissolved in 3:1 tetrahydrofuran - methanol (30 mL) and saponified with aqueous sodium hydroxide (1.0 N, 10.0 mL, 10.0 mmol) overnight at ambient temperature. After concentration, the residue was partitioned between ethyl acetate and water and then acidified (to pH 4 - 5) with 0.5N aqueous hydrochloric acid. The organic phase was washed with water and brine, dried over sulfate and concentrated. Purification was carried out with multiple flash chromatography runs using the Biotage system. Pure fractions from each run were combined and concentrated to yield (S)-3-(tert-butyl-diphenyl-silanyloxy)-2- methylpropionic acid as an oU that solidified to a tacky white solid in the cold. (Yield 2.10 g, 69.2%).
Example 15b
(S)-tert-Butyl-2-isocyanato-propoxydiphenylsUane
Figure imgf000050_0001
(S)-3-(fert-Butyl-diphenyl-silanyloxy)-2-methylpropionic acid (0.44 g, 1.20 mmol) (from Example 15a supra) was dissolved in dichloromethane (3 mL, dried over molecular sieves). Triethylamine (0.36 mL, 2.58 mmol) (Aldrich) was added and the solution was cooled in an ice- water bath. Ethyl chloroformate (0.16 mL, 1.67 mmol) (Aldrich) was added dropwise and the mixture was stirred in the cold for 1 hour. The mixture was then diluted with additional dichloromethane, washed with water and brine, dried over anhydrous sodium sulfate, and concentrated to give the crude mixed anhydride.
To a solution of the mixed anhydride intermediate in acetone (4 mL) was added a solution of sodium azide (0.25 g, 3.85 mmol) in water (4 mL). The mixture was stirred for 10 minutes and then dUuted with dichloromethane and water. The organic phase was washed with brine, dried over magnesium sulfate, and concentrated to give (S)-3-(tert- butyl-diphenyl-silanyloxy) -2-methylpropionyl azide.
The azide was dissolved in toluene (2 mL) and heated in an oU bath at 120 °C.
Vigorous nitrogen gas evolution quickly resulted yielding the desired (S)-tert-butyl-2- isocyanato-propoxy-diphenylsilane by the Curtius rearrangement. Example 15c
(S)-l-[2-(tert-Butyl-diphenyl-sUanyloxy)-l-methyl-ethyl]-7-chloro-3-(4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000051_0001
(S)-tert-Butyl-2-isocyanato-propoxy-diphenylsUane (generated in situ from 0.55 g,
1.61 mmol of (S)-3-(tert-butyl-diphenyl-sUanyloxy)-2-methylpropionic acid) (from Example 15b supra) in hot toluene (2.5 mL) at 120 °C was treated with [(2,4- dichloropyrimidin-5-yl)methyl](4-methoxy-phenyl)amine (0.41 g, 1.45 mmol) (from Example Id supra). The solution was heated at 120 °C for 35 minutes and then cooled to room temperature and concentrated to give an intermediate urea.
This intermediate urea was dissolved in anhydrous tetrahydrofuran (5 mL) and cooled in an ice - water bath. Potassium tert-butoxide (1.0 M in tetrahydrofuran, 1.5 mL, 1.50 mmol) was added dropwise and stirring continued in the cold for 15 minutes. The mixture was filtered through a bed of sUica gel and eluted with ethyl acetate. Further purification by flash chromatography (Biotage 40 M, 25:75 ethyl acetate - hexanes) gave (S)-l-[2-(tert-butyl-diphenyl-silanyloxy)-l-methyl-efhyl]-7-chloro-3-(4-methoxy- phenyl)-4-methyl-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one along with the uncyclized intermediate, (S)-3-[2-tert-butyl-diphenyl-silanyloxy-l-methyl-ethyl]-l-(2,4- dichloropyrimidin-5-yl-mefhyl)-l-(4-methoxyphenyl)-urea, in ~2:1 ratio of the product to intermediate urea.
This mixture (0.66 g) was dissolved in anhydrous tetrahydrofuran (5 mL) and cooled in an ice - water bath. To this solution was added potassium tert-butoxide (1.0 M in tetrahydrofuran, 1.0 mL, 1.00 mmol). The mixture was stirred in the cold for 15 minutes and then the bath was removed and stirring continued for another 5 minutes. The mixture was filtered through a bed of sUica gel and eluted with ethyl acetate.
Purification by flash chromatography (Biotage 40 M, 40:60 ethyl acetate - hexanes) gave (S) - 1 - [2- (tert-butyl-diphenyl-silanyloxy) - 1 -methyl-ethyl] -7-chloro-3- (4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.38 g, 40.2%). Example 15d
(S) - (+) - 1 - (2-Hydroxy- 1 -methyl-ethyl) -3 - (4-methoxy-phenyl) -7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000052_0001
(S) - 1 - [2- (tert-Butyl-diphenyl-sUanyloxy) - 1 -methyl-ethyl] -7-chloro-3- (4-methoxy- phenyl) -3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (0.50 g, 0.85 mmol) (from Example 15c supra) was combined with anUine (0.50 mL, 5.49 mmol) (Aldrich) and heated in an oU bath at 85 °C for 3 hours. The mixture was cooled to room temperature, dUuted with ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate and concentrated. Purification by flash chromatography (Biotage 40S, ethyl acetate - hexanes gradient [20-40% ethyl acetate]) gave (S)-l-(2-tert- butyl-diphenyl-silanyloxy-l-methyl-ethyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 0.44 g, 76.1%).
The sUyl-protected product (0.43 g, 0.67 mmol) was dissolved in anhydrous tetrahydrofuran (5 mL) and treated with tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 2.70 mL, 2.70 mmol) (Aldrich) at room temperature for 5 hours. The reaction was then concentrated. The residue was redissolved in ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate and concentrated. Purification by flash chromatography (Biotage 40S, ethyl acetate - hexanes gradient [75-90% ethyl acetate] ) followed by crystallization from ethyl acetate - hexanes gave (S)-(+)-l-(2-hydroxy-l-methyl-ethyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.209 g, 77.2%). Melting Point: 140 - 147 °C.
HR-MS(ES+) m/z Calculated for C22H23N503 [M+H]+: 406.1874. Found: 406.1878.
IC50 (KDR) = 0.042 μM, IC50 (FGFR) = 0106 μM. Example 16
(S)-(+)-7-(4-Fluoro-phenylamino)-l-(2-hydroxy-l-methyl-ethyl)-3-(4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000053_0001
(S)-l-[2-(tert-Bu1yl-diphenyl-sUanyloxy)-l-methyl-ethyl]-7-chloro-3-(4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.38 g, 0.64 mmol) (from Example 15c supra) was combined with 4-fluoroamline (0.30 mL, 3.20 mmol) (Aldrich) and heated in an oU bath at 95 °C for 4.5 hours. The mixture was cooled to room temperature and triturated with hexanes. The oUy residue was dissolved in ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate and concentrated. Purification by flash chromatography (Biotage 40M, ethyl acetate - hexanes gradient [35-45% ethyl acetate]) gave (S)-7-(4-fluoro-phenylamino)-l- (2-tert-butyl-diphenyl-silanyloxy-l-methyl-ethyl)-3-(4-methoxy-phenyl)-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 0.306g, 72.3%).
(S) -7- (4-Fluoro-phenylamino) - 1 - (2-tert-butyl-diphenyl-sUanyloxy- 1 -methyl- ethyl)-3-(4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido [4,5-d]pyrimidin-2-one (0.30 g, 0.45 mmol) was dissolved in anhydrous tetrahydrofuran (3.5 mL) and treated with tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 1.80 mL, 1.80 mmol) (Aldrich) at room temperature for 6 hours. The reaction was then concentrated. The residue was redissolved in ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate and concentrated. Purification by flash chromatography (Biotage 40S, ethyl acetate - hexanes gradient [60-100% ethyl acetate]) foUowed by crystallization from ethyl acetate - hexanes gave (S)-(+)-l-(2-hydroxy-l- methyl-ethyl)-3-(2-fluoro-4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido [4,5-d] pyrimidin-2-one. (Yield 0.13 g, 66.2%). Melting Point: 188-198° C.
HR-MS(ES+) m/z Calculated for C22H22FN5O [M+H]+: 424.1780. Found: 424.1783. Example 17a
[(2,4-DicMoropyrimidin-5-yl)methyl]-(4-riiethoxyphenyl)-amine
Figure imgf000054_0001
A mixture of 2,4-dichloro-5-chloromethyl-pyrimidine (3.70 g, 18.7 mmol) (from Example lb supra), 2-fluoro-4-methoxy-phenylamine (2.40 g, 17.0 mmol) (from
Example 14a supra) and potassium carbonate (4.70 g, 34.0 mmol) in acetone (100 mL) was stirred at room temperature for 18 hours. The precipitate was filtered off and the solution was concentrated under reduced pressure. The residue was dUuted with ethyl acetate and washed with water and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. This residue was purified by flash chromatography eluting with ethyl acetate - hexanes (1:4) to give [(2,4- dichloropyrimidin-5-yl)methyl]-(4-methoxyphenyl)-amine. (Yield 3.99 g, 78%).
Example 17b
tert-Butyl-(trαns-4-isocyanato-cyclohexyloxy)-dimethyl-sUane
Figure imgf000054_0002
To a solution of trans-4-(tert-butyl-dimethyl-silanyloxy)-cyclohexylamine (1.0 g, 4.36 mmol) (from Example 3a supra) and triethylamine (3.04 mL, 21.8 mmol) (Burdick & Jackson) in dichloromethane (30 mL) at 0 °C was added phosgene (~ 20% in toluene, 6.4 mL, 13.1 mmol) (Fluka) in one portion. The reaction mixture was stirred at 0 °C for 40 minutes, followed by addition of 0.5N aqueous hydrochloric acid (50 mL). The organic phase was washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (1:9) to give tert-butyl-(tr ns-4-isocyanato- cyclohexyloxy)-dimethyl-sUane. (Yield 0.90 g, 81%). Example 17c
l-[tr ns-4-(tert-Butyl-dimethyl-sUanyIoxy)-cyclohexyl]-7-chloro-3-(2-fluoro-4- mefhoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000055_0001
To a solution of (2,4-dichloro-pyrimidin-5-yl-methyl)-(2-fluoro-4-methoxy- phenyl)amine (1.1 g, 3.64 mmol) (from Example 17a supra) in tetrahydrofuran (50 mL) at -78 °C was added n-butyllithium (2.5 M in hexanes, 1.75 mL, 4.37 mmol) (Aldrich). After stirring at -78 °C for 40 minutes, tert-buιyl-(tr -4-isocyanato-cyclohexyloxy)- dimethyl-silane (1.12 g, 4.37 mmol) (from Example 17b supra) was added. The mixture was stirred at -70 °C for 1 hour and then at room temperature for 3 hours. It was dUuted with ethyl acetate, washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (3:7 then 2:3) to give l-[trøns-4-(tert-butyl-dimethyl- sUanyloxy)-cyclohexyl]-7-chloro-3-(2-fluoro-4-methoxy-phenyl)-3,4-dihydro-lH- pyrimido [4,5-d] pyrimidin-2-one. (Yield 0.60 g, 33%).
Example 17d
3- (2-Fluoro-4-methoxy-phenyl) - 1 - (tr n5-4-hydroxy-cyclohexyl) -7- (4-methoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000055_0002
A mixture of l-[tr ns-4-(tert-butyl-dimethyl-sUanyloxy)-cyclohexyl]-7-chloro-3-(2- fluoro-4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.20 g, 0.38 mmol) (from Example 17c supra), -anisidine (61.5 mg, 0.50 mmol) (Aldrich) and -toluenesulfonic acid monohydrate (95.1 mg, 0.50 mmol) (Aldrich) in 2-propanol (4 mL) was placed in a microwave reactor (SmithSynthesizer™). The reaction mixture was heated at 160 °C for 15 minutes. After cooling, it was concentrated under reduced pressure and purified by RP-HPLC (C-18, eluted with acetonitrUe - water) to give 3-(2- fluoro-4-methoxy-phenyl) - 1 - ( tr πs-4-hydroxy-cyclohexyl) -7- (4-methoxy- phenylamino)-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 0.12 g, 61%).
HRMS m/z Calculated for C26H28FN5O4 [(M+H)+]: 494.2198. Found: 494.2206.
ICso (KDR) = 0.018 μM, IC50 (FGFR) = 0.050 μM.
Example 18
3-(2-Fluoro-4-methoxy-ρhenyl)-l-(trflns-4-hydroxy-cyclohexyl)-7-(3,4-dimethoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000056_0001
A mixture of l-[tr n5-4-(tert-butyl-dimethyl-sUanyloxy)-cyclohexyl]-7-chloro-3- (2-fluoro-4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (0.20 g, 0.38 mmol) (from Example 1 'c supra), 4-amino-veratrole (76.6 mg, 0.50 mmol) (Aldrich) and -toluenesulfonic acid monohydrate (95.1 mg, 0.50 mmol) (Aldrich) in 2- propanol (4 mL) was placed in a microwave reactor (SmithSynthesizer™). The reaction mixture was heated at 160 °C for 15 minutes. After cooling, it was concentrated under reduced pressure and purified by RP-HPLC (C-18, eluted with acetonitrUe - water) to give 3-(2-fluoro-4-methoxy-phenyl)-l-(trαns-4-hydroxy-cyclohexyl)-7-(3,4-dimethoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.13 g, 63%).
HRMS m/z Calculated for C27H30FN5O5 [(M+H)+]: 524.2304. Found: 524.2311. Example 19a
1- [trαns-4-(tert-Butyl-dimethyl-sUanyloxy)-cyclohexyl] -7-chloro-3-(4-methoxy-phenyl)- 3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000057_0001
To a solution of [ (2,4-dichloropyrimidin-5-yl)methyl] (4-methoxy-phenyl)amine ( 1.0 g, 3.52 mmol) (from Example Id supra) in tetrahydrofuran (50 mL) at -78 °C was added n- butyUithium (2.5 M in hexanes, 1.7 mL, 4.22 mmol) (Aldrich). After stirring at -78 °C for 20 minutes, tert-butyl-(trøns-4-isocyanato-cyclohexyloxy)-dimethyl-sUane (1.1 g, 4.22 mmol) (from Example 17b supra) was added. The mixture was stirred at -70 °C for 1 hour and then at room temperature for 3 hours. The reaction mixture was dUuted with ethyl acetate, washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (3:7 then 2:3) to give l-[trøπs-4-(tert-butyl-dimethyl-silanyloxy)- cyclohexyl]-7-chloro-3-(4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one. (Yield 0.61 g, 34%).
Example 19b
l-[tr ns-4-(tert-Butyl-dimethyl-silanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7-(3,4- dimethoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000057_0002
A mixture of 1- [tr πs-4-(tert-butyl-dimethyl-silanyloxy)-cyclohexyl] -7-chloro-3-(4- methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.20 g, 0.40 mmol) (from Example 19a supra) and 4-amino-veratrole (80.0 mg, 0.52 mmol) (Aldrich) in 2- propanol (4 mL) was placed in a microwave reactor (SmithSynthesizer™). The reaction mixture was heated at 160 °C for 10 minutes. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (3:7 then 2:3) to give l-[tr ns-4-(tert-butyl-dimethyl-sUanyloxy)- cyclohexyl] -3-(4-methoxy-phenyl)-7-(3,4-dimethoxy-phenylamino)-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.09 g, 36%).
Example 19c
3-(4-Methoxy-phenyl)-l-(tr n5-4-hydroxy-cyclohexyl)-7-(3,4-dimethoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000058_0001
To a solution of l-[tr ns-4-(tert-butyl-dimethyl-silanyloxy)-cyclohexyl]-3-(4-methoxy- phenyl)-7-(3,4-dimethoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2- one (90 mg, 0.24 mmol) (from Example 19b supra) in dichloromethane (5 mL) was added trifluoroacetic acid (2.0 mL) (Aldrich) at 0 °C. The mixture was stirred at 0 °C for 2 hours. The reaction mixture was dUuted with ethyl acetate (15 mL) and washed with saturated aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate to give crude product which was recrystallized from ethyl acetate - hexanes to give 3-(4-methoxy-phenyl)-l-(tr ns-4-hydroxy- cyclohexyl)-7-(3,4-dimethoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one. (Yield 41 mg, 59%).
HRMS m/z Calculated for C27H3iN5O5 [(M+H)+]: 506.2398. Found: 506.2404. Example 20a
1 - [trans-4- (tert-Butyl-dimethyl-sUanyloxy) -cyclohexyl] -3- (4-methoxy-phenyl)-7- (4- methoxy-phenylamino)-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000059_0001
A mixture of 1- [trøns-4-(tert-butyl-dimethyl-silanyloxy)-cyclohexyl] -7-chloro-3-(4- methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.20 g, 0.40 mmol) (from Example 19a supra) and -anisidine (63.6 mg, 0.52 mmol) (Aldrich) in 2-propanol (4 mL) was placed in a microwave reactor (SmithSynthesizer™). The reaction mixture was heated at 160 °C for 10 minutes. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (3:7 then 2:3) to give l-[tr π5-4-(tert-butyl-dimethyl-silanyloxy)-cyclohexyl]-3- (4-methoxy-phenyl) -7- (4-methoxy-phenylamino) -3,4-dihydro- lH-pyrimido [4,5 - d]pyrimidin-2-one. (Yield 0.14g, 58%).
Example 20b
3-(4-Methoxy-phenyl)-l-(tr π5-4-hydroxy-cyclohexyl)-7-(4-methoxy-phenylamino)- 3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000059_0002
To a solution of l-[tr ns-4-(tert-butyl-dimethyl-sUanyloxy)-cyclohexyl]-3-(4-methoxy- phenyl)-7-(4-melhioxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.14 g, 0.15 mmol) (from Example 20a supra) in dichloromethane (5 mL) was added trifluoroacetic acid (2.5 mL) at 0 °C. The mixture was stirred at 0 °C for 2 hours. The reaction mixture was diluted with ethyl acetate (15 mL) and washed with saturated aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate to give crude product which was recrystaUized from ethyl acetate - hexanes to give 3- (4-methoxy-phenyl) -l-(trøn5-4-hydroxy- cyclohexyl)-7-(4-methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2- one. (Yield 61 mg, 55%).
HRMS m/z Calculated for C26H29N5O [(M+H)+] : 476.2293. Found: 476.2299.
IC50 (KDR) = 0.041 μM, IC50 (FGFR) = 0.023 μM.
Example 21a
(S)-l-[2-(tert-Butyl-diphenyl-sUanyloxy)-l-me1-hyl-ethyl]-7-chloro-3-(2-fluoro-4- methoxy-phenyl)-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000060_0001
(S)-tert-Butyl-2-isocyanato-propoxy-diphenylsUane [generated in situ from 1.05 g, 3.07 mmol of (S)-3-(tert-butyl-diphenyl-sUanyloxy)-2-methylpropionic acid) (from Example 15b supra)} in hot toluene (5 mL) at 120 °C was treated with (2,4-dichloro- pyrimidin-5-ylmethyl)-(2-fluoro-4-methoxy-phenyl)-amine (0.84 g, 2.77 mmol) (from Example 17a supra). The solution was heated at 120 °C for 40 minutes and then cooled to room temperature and concentrated to give crude (S)-3-[2-tert-butyl-diphenyl- sUanyloxy- 1 -methyl-ethyl] - 1 - (2,4-dichloropyrimidin-5-yl- methyl)- 1 - (2-fluoro-4- methoxyphenyl)-urea. This urea was dissolved in anhydrous tetrahydrofuran (10 mL) and cooled in an ice - water bath. Potassium tert-butoxide (1.0 M in tetrahydrofuran, 3.2 mL, 3.20 mmol) (Aldrich) was added dropwise. The mixture was stirred in the cold for 15 minutes and then the bath was removed and stirring continued for another 5 minutes. The mixture was filtered through a bed of sUica gel and eluted with ethyl acetate. The NMR of the crude product showed ~2:1 ratio of product to the uncyclized intermediate (S) -3 - [2-tert-butyl-diphenyl-sUanyloxy- 1 -methyl-ethyl] - 1 - (2,4-dichloropyrimidin-5-yl- methyl) - 1 - (2-fluoro-4-methoxyphenyl) -urea.
The crude mixture was redissolved in anhydrous tetrahydrofuran (10 mL) and cooled in an ice - water bath. Potassium tert-butoxide (1.0 M in tetrahydrofuran, 1.5 mL, 1.50 mmol) (Aldrich) was added and mixture stirred in the cold for 15 minutes. The cooling bath was removed and stirring continued for an additional 5 minutes. The mixture was filtered through a bed of sUica gel and eluted with ethyl acetate. Purification by flash chromatography (Biotage 40S, ethyl acetate - hexanes gradient [25 - 38% ethyl acetate]) gave (S)-l-[2-(tert-butyl-diphenyl-sUanyloxy)-l-methyl-ethyl]-7-chloro-3-(2- fluoro-4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.53 g, 31.7%).
A portion of (S)-l-[2-(tert-butyl-diphenyl-silanyloxy)-l-methyl-ethyl]-7-chloro-3- (2-fluoro-4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one stiU contained about 20% of the intermediate urea. This material was cycled through another treatment with potassium tert-butoxide (1.0 M in tetrahydrofuran, 0.65 mL, 0.65 mmol) to give (tS)-l- [2-(tert-butyl-diphenyl-sUanyloxy)-l-methyl-ethyl] -7-chloro-3-(2-fluoro- 4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.19 g, 11.2%).
Example 21b
(S)-(+)-3-(2-Fluoro-4-methoxy-ρhenyl)-7-(4-fluoro-phenylamino)-l-(2-hydroxy-l- methyl-ethyl) -3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000061_0001
(S)-l-[2-(tert-Butyl-diphenyl-sUanyloxy)-l-methyl-ethyl]-7-chloro-3-(2-fluoro-4- methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.40 g, 0.66 mmol) (from Example 21a supra) was combined with 4-fluoroaniline (0.50 mL, 5.28 mmol) (Aldrich) and heated in an oil bath at 105 °C for 2 hours. The mixture was cooled to room temperature and triturated with hexanes. The insoluble residue was then taken up in ethyl acetate and the anUine hydrochloride was filtered off. The filtrate was purified by flash chromatography (Biotage 40S, 30:70 ethyl acetate - hexanes). The impure fractions were recycled through another flash chromatography. This purified material was stiU contaminated with a small amount of the 4-fluoroaniline. This was removed by another trituration with hexanes to give (S)-3-(2-fluoro-4-methoxy-phenyl)-7-(4-fluoro- phenylamino)-l-(2-tert-butyl-diphenyl-sUanyloxy-l-methyl-ethyl)-3,4-dihydro-lH- pyrimido [4,5-d] pyrimidin-2-one. (Yield 0.34 g, 71.8%). (S)-.3-(2-Fluoro-4-methoxy-phenyl)-7-(4-fluoro-phenylamino)-l-(2-tert-butyl- diphenyl-sUanyloxy-l-methyl-ethyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.33 g, 0.46 mmol) was dissolved in anhydrous tetrahydrofuran (3.5 mL). and treated with tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 1.90 mL, 1.90 mmol) (Aldrich). The reaction was stirred in a water bath that was maintained in the 25 - 35 °C range. The reaction was complete after 4 hours and was concentrated. The residue was redissolved in ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate and concentrated. Purification by flash chromatography (Biotage 40S, 75:25 ethyl acetate - hexanes) followed by crystallization from ethyl acetate - hexanes gave (S)-(+)-3-(2-fluoro-4-methoxy-phenyl)-7-(4-fluoro- phenylamino)-l-(2-hydroxy-l-methyl-ethyl)-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one as a white solid. (Yield 0.18 g, 83.5%). Melting Point: 173 - 177 °C.
HR-MS(ES+) m/z Calculated for C22H2ιF2N5O3 [M+H]+: 442.1685. Found: 442.1691.
Example 22
(S)-(+)-3-(2-Fluoro-4-methoxy-phenyl)-l-(2-hydroxy-l-methyl-ethyl)-7-(4-methoxy- phenylamino)-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000062_0001
(S)-l-[2-(tert-Butyl-diphenyl-sUanyloxy)-l-methyl-ethyl]-7-chloro-3-(2-fluoro-4- methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.30 g, 0.50 mmol) (from Example 21a supra) was dissolved in toluene (0.5 mL) and treated with -anisidine (0.15 g, 1.19 mmol) in an oU bath at 105 °C. After two hours, a significant amount of starting material was still present. Additional p-anisidine (0.11 g, 0.92 mmol) was added and heating continued for another two hours. The mixture was then cooled to room temperature and triturated with hexanes to remove excess -anisidine. The insoluble residue was purified by flash chromatography (Biotage 40M, ethyl acetate - hexanes gradient [25 - 40% ethyl acetate]). This purified material was stiU contaminated with a small amount of -anisidine. This was removed by another trituration with hexanes to give (S)-3 - (2-fluoro-4-methoxy-phenyl) - 1 - (2-tert-butyl-diphenyl-sUanyloxy- 1 -methyl- e1hyl)-7-(4-met-hoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.26 g, 72.2%). (S) -3- (2-Fluoro-4-methoxy-phenyl) - 1 - (2-tert-butyl-diphenyl-sUanyloxy- 1 -methyl- ethyl) -7- (4-methoxy-phenylamino) -3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (0.25 g, 0.35 mmol) was dissolved in anhydrous tetrahydrofuran (2.5 mL) and treated with tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 1.40mL, 1.400 mmol). The reaction was stirred in a water bath that was maintained in the 30 - 40 °C range. The reaction was complete after 4 hours and was concentrated. This residue was redissolved in ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate, concentrated and then purified by flash chromatography (Biotage 40S, 75:25 ethyl acetate - hexanes) to give (S)-(+)-3-(2-fluoro-4-methoxy- phenyl)-l-(2-hydroxy-l-methyl-ethyl)-7-(4-mefhoxy-phenylamino)-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one as a pale yeUow foam. (Yield 0.14 g, 85.1%).
HR-MS(ES+) m/z Calculated for C23H24FN5O4 [M+H]+: 454.1885. Found: 454.1890.
ICso (KDR) = 0.045 μM, IC50 (FGFR) = 0.111 μM.
Example 23a
(R)-3-(tert-Butyl-diphenyl-silanyloxy)-2-methylpropionic acid
Figure imgf000063_0001
Methyl (R)-(-)-3-hydroxy-2-methylpropionate (0.82 g, 6.92 mmol) (Aldrich) was dissolved in dichloromethane (8 mL, dried over molecular sieves). Imidazole (0.67 g, 9.68 mmol) (Aldrich) was added. When all had dissolved, tert-butyldiphenysilyl chloride (1.80 mL, 6.92 mmol) (Aldrich) was added and the mixture was stirred at ambient temperature for 3 hours. The reaction was diluted with additional dichloromethane, washed with water and brine, dried over anhydrous sodium sulfate and concentrated to give methyl (R)-3-(tert-butyl-diphenyl-silanyloxy)-2-methyl-propionate as an o . (Yield 2.42 g, 98%).
Methyl (R)-3-(tert-butyl-diphenyl-silanyloxy)-2-methyl-propionate (2.42 g, 7.05 mmol) was dissolved in 3:1 tetrahydrofuran - methanol (24 mL) and saponified with aqueous sodium hydroxide (1.0 N, 7.9 mL, 7.90 mmol) at 40 °C for 3 hours and then overnight at ambient temperature. The reaction mixture was concentrated. The residue was dissolved in ethyl acetate and then acidified with 1.0 N aqueous hydrochloric acid (~ 8 mL). The organic phase was washed with brine (3x), dried over anhydrous sodium sulfate and concentrated. Purification by flash chromatography (Biotage 40L, 20:80 ethyl acetate -hexanes) gave (R)-3-(tert-butyl-diphenyl-sUanyloxy)-2-methylpropionic acid as an oU that solidified to a tacky white solid. (Yield 1.60 g, 67.6%).
Example 23b
(R)-tert-Butyl-2-isocyanato-propoxydiphenylsUane
Figure imgf000064_0001
(R)-3-(tert-Butyl-diphenyl-sUanyloxy)-2-methylpropionic acid (0.51 g, 1.48 mmol) (from Example 23a supra) was dissolved in dichloromethane (4 mL, dried over molecular sieves). Triethylamine (0.42 mL, 2.98 mmol) (Aldrich) was added and the solution was cooled in an ice - water bath. Ethyl chloroformate (0.17 mL, 1.78 mmol) (Aldrich) was added dropwise and the mixture was stirred in the cold for 50 minutes. The reaction mixture was dUuted with additional dichloromethane and washed with water and then brine. The organic phase was dried over sodium sulfate and concentrated to give the mixed anhydride.
To a solution of this mixed anhydride in acetone (5 mL) was added a solution of sodium azide (0.29 g, 4.41 mmol) (Aldrich) in water (5 mL). The mixture was stirred at room temperature for 10 minutes and then dUuted with additional dichloromethane and water. The organic phase was washed with brine, dried over magnesium sulfate and concentrated to give (R)-3-(tert-butyl-diphenyl-sUanyloxy)-2-methylpropionyl azide.
(R)-3-(tert-Butyl-diphenyl-silanyloxy)-2-methylpropionyl azide was dissolved in toluene (~ 5 mL, dried over 4A molecular sieves) and heated in an oil bath at 120 °C. Vigorous nitrogen gas evolution quickly resulted to give (R)-tert-butyl-2-isocyanato- propoxy-diphenylsilane by the Curtius rearrangement. This was used without further purification. Example 23c
(R)-l-[2-(tert-Butyl-diphenyl-sUanyloxy)-l-methyl-ethyl]-7-chloro-3-(4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000065_0001
(R)-tert-Butyl-2-isocyanato-propoxy-diphenylsUane [generated in situ from 0.51 g,
1.48 mmol of (R)-3-(tert-butyl-diphenyl-sUanyloxy)-2-methylpropionic acid)] in hot toluene (~ 5 mL) (from Example 23b supra) at 120 °C was treated with [(2,4- dichloropyrimidin-5-yl)methyl] (4-methoxyphenyl)amine (0.38 g, 1.34 mmol) (from Example Id supra). The solution was heated at 120 °C for 45 - 50 minutes and then cooled to room temperature and concentrated to give the intermediate urea.
The crude urea intermediate was dissolved in anhydrous tetrahydrofuran (5 mL) and cooled in an ice-water bath. Potassium tert-butoxide (1.0 M in tetrahydrofuran, 1.4 mL, 1.4 mmol) (Aldrich) was added dropwise over about 5 minutes. The mixture was stirred in the cold for 15 minutes and then the bath was removed and stirring continued for an additional 3 - 4 minutes. The mixture was filtered through a sUica gel plug and eluted with ethyl acetate. The crude product was purified by flash chromatography (Biotage 40M, ethyl acetate - hexanes gradient [30 - 40% ethyl acetate]) to give (R)-l-[2- (tert-butyl-diphenyl-sUanyloxy)-l-methyl-ethyl]-7-chloro-3-(4-methoxy-phenyl)-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one as a foam. (Yield 0.57 g, 62.4%).
Example 23d
(R) - (-)- 1 - (2-Hydroxy- 1 -methyl-ethyl) -3 - (4-methoxy-phenyl) -7-phenylamino-3,4- dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000065_0002
l-[2-(tert-Butyl-diphenyl-silanyloxy)-l-metlιyl-ethyl]-7-chloro-3-(4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.56 g, 0.92 mmol) (from Example 23c supra) was combined with anUine (0.50 mL, 5.49 mmol) (Aldrich) and heated in an oU bath at 110 °C for 1.5 hours. The mixture was cooled to room temperature and triturated with hexanes. The residue was dissolved in ethyl acetate and filtered to remove the insoluble anUine hydrochloride. The nitrate was purified by flash chromatography (Biotage 40M, 40:60 ethyl acetate - hexanes). The product was stUl contaminated with a smaU amount of anUine. This was removed with another trituration with hexanes to give (R)-l-(2-tert-butyl-diphenyl-sUanyloxy-l-methyl-ethyl)-3-(4- methoxy-ρhenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.55 g, 89.1%).
(R) - 1 -(2-tert-Butyl-diphenyl-sUanyloxy- 1 -methyl-ethyl) -3- (4-methoxy-phenyl) -7- phenylamino-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (0.55 g, 0.80 mmol) was dissolved in anhydrous tetrahydrofuran (6 mL) and treated with tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 3.2 mL, 3.20 mmol) (Aldrich) at 40 °C for 3 hours and then at room temperature for 2 hours. The reaction was concentrated. The residue was redissolved in ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate and concentrated. Purification by flash chromatography (Biotage 40M, ethyl acetate - hexanes gradient [75 - 85% ethyl acetate] ) foUowed by crystaUization from ethyl acetate - hexanes gave (R)-(-)-l-(2-hydroxy-l- methyl-ethyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one as a white solid. (Yield 0.26 g, 79.9%). Melting Point: 156 - 163 °C.
HR-MS(ES+) m/z Calculated for C22H23N5O3 [M+H]+: 406.1874. Found: 406.1878.
Example 24a
3-(4-Methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidine-2- one
Figure imgf000066_0001
To a suspension of [(2,4-dichloropyrimidin-5-yl)methyl] (4-methoxy- phenyl)amine (2.84 g, 10.0 mmol) (from Example Id supra) in tert-butyl methyl ether (30 mL) was added benzoyl isocyanate (90 %, 1.80 g, 11.0 mmol) (Aldrich) and the reaction mixture was heated at reflux overnight. The reaction mixture was concentrated under reduced pressure to give the crude urea derivative which was dissolved in dry tetrahydrofuran (20 mL) and the solution was cooled to 0 °C. To this solution was added potassium tert-butoxide (1.0 M in tetrahydrofuran, 10 mL, 10.0 mmol) (Aldrich) and the reaction mixture was stirred at room'temperature for 4 hours. The reaction mixture was then dUuted with ethyl acetate (150 mL) and successively washed with saturated aqueous ammonium chloride solution (50 mL), water (30 mL) and brine(30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash column to give the mono-chloride as a white solid. (Yield 1.15 g, 29.1%, 2 steps).
A mixture of this mono chloride (0.40 g, 1.0 mmol) and anUine (0.28 g, 3.0 mmol)
(Aldrich) was heated at 120 °C for 10 min. The reaction mixture was then diluted with ethyl acetate (50 mL) and water (30 mL). The suspension thus obtained was filtered and the solid was coUected and washed with acetone, ethyl acetate and diethyl ether to give 3- (4-methoxy-phenyl)-7-phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidine-2-one as a white solid. (Yield 201 mg, 57.9 %). The filtrate was concentrated partially under reduced pressure and filtered to give l-benzoyl-3-(4-methoxy-phenyl)-7-phenylamino- 3,4-dihydro-lH-pyrimido [4,5-d] pyrimidine-2-one as a white solid. (Yield 86.0 mg, 19.0 %)•
Example 24b
3-(4-Met-hoxy-ρhenyl)-l-methyl-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d] pyrimidine-2-one
Figure imgf000067_0001
Method A:
To the suspension of 3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido [4,5-d]pyrimidin-2-one (34.7 mg, 0.1 mmol) (from Example 24a supra) in tetrahydrofuran (5 mL) was added sodium hydride (60%, 10 mg, 0.25 mmol) (Aldrich) followed by methyl iodide (0.032 mL, 0.5 mmol) (Aldrich) in one portion. The reaction mixture was stirred at room temperature overnight and then heated under reflux for 5 hours. The reaction was then quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were filtered to give 3-(4-meihoxy-phenyl)-l-methyl-7-phenylamino-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidine-2-one as a white solid. (Yield 20.9 mg, 57.9 %).
Method B:
To a solution of [ (2,4-dichloropyrimidin-5-yl)methyl] (4-methoxy-phenyl)amine (198 mg, 0.7 mmol) (from Example Id supra) in n-butanol (5 mL) was added methyl amine (20% solution in methanol, 0.7 mL, 1.4 mmol) (Aldrich) foUowed by N,N- diisopropyethylamine (130 mg) (Aldrich) in one portion. The reaction mixture was stirred at room temperature overnight, and then quenched with water and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were successively washed with water (10 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude mono chloride as a colorless oU which was used in the next step without further purification.
To a solution of this crude mono chloride (195 mg, 0.7 mmol) in dichloromethane (20 mL) was added triethylamine (0.3 mL, 2.1 mmol) (Aldrich) foUowed by phosgene in toluene (20% solution, 0.5 mL, 0.98 mmol) (Fluka) dropwise. The reaction mixture was stirred at room temperature for 15 minutes. The reaction mixture was then poured into ice - cold water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were successively washed with water (10 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude intermediate which was dissolved again in dichloromethane (5 mL) and heated under reflux in the presence of 4-(dimethylamino)pyridine (20 mg) (Aldrich) overnight. The reaction mixture was quenched with water and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were successively washed with water (10 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product which was purified by preparative thin layer chromatography to give 7-chloro-3-(4-methoxy-phenyl)-l-methyl-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidine-2-one. (Yield 79 mg, 37 %, 3 steps).
The mixture of 7-chloro-3-(4-methoxy-phenyl)-l-methyl-3,4-dihydro-lH- pyrimido [4,5-d] pyrimidine-2-one (65 mg, 0.21 mmol) in aniline (1.0 mL) (Aldrich) was heated to 120 °C for 1 hour. After cooling, the reaction mixture was washed with hexanes (100 mL x 4) and the crude product was re-crystallized from ethyl acetate - hexanes to give 3-(4-methoxy-ρhenyl)-l-methyl-7-phenylamino-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidine-2-one as an off-white solid. (Yield 76.0 mg, 98.7%). Example 25
1 - (2-methoxy-ethoxymethyl) -3 - (4-methoxy-phenyl) -7-phenylamino-3,4-dihydro- 1H- pyrimido [4,5-d]pyrimidin-2-one
Figure imgf000069_0001
To the suspension of 3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido [4,5-d] pyrimidin-2-one (70 mg, 0.2 mmol) (from Example 24a supra) in tetrahydrofuran (10 mL) was added sodium hydride (60%, 20 mg, 0.5 mmol) (Aldrich) foUowed by 2-methoxyethoxymethyl chloride (0.032 mL, 2.4 mmol) (Aldrich) in one portion. The reaction mixture was heated at reflux for 5 hours to give a yeUow solution. The reaction was then quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were filtered to give the starting material as a white solid (33.1 mg, 47.1 %) and the filtrate was successively washed with water (10 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product which was purified by preparative thin layer chromatography to give 1 - (2-methoxy- . ethoxymethyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one as a white amorphous solid. (Yield 30.5 mg, 35.0%).
Example 26
3-[-3-(4-Methoxy-phenyl)-2-oxo-7-ρhenylamino-3,4-dihydro-lH-pyrimido[4,5- d] pyrimidin- l-yl]-propionitrUe
Figure imgf000069_0002
To the solution of [(2,4-dichloropyrimidin-5-yl)methyl] (4-methoxyphenyl)amine (198 mg, 0.7 mmol) (from Example Id supra) in n-butanol (5 mL) was added 3- aminopropionitrUe (98 mg, 1.4 mmol) (Fluorochem Ltd.) foUowed by addition of N,N-
Figure imgf000069_0003
(o.i3 m ) (Aldrich) in one portion. The reaction mixture was stirred at room temperature overnight, and then quenched with water and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were successively washed with water (10 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude mono chloride as a colorless oU (Yield 220 mg) which was used in the next step without further purification.
To a solution of this crude mono chloride (212 mg) in dichloromethane (20 mL) at 0 °C was added triethylamine (0.29 mL, 2.1 mmol) (Aldrich) foUowed by phosgene in toluene (20% solution, 1.44 mL, 2.94 mmol) (Fluka) dropwise. The reaction mixture was stirred at 0 °C for 10 minutes and then at room temperature for 1.5 hours. The reaction mixture was then poured into ice - cold water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were successively washed with water (10 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a crude intermediate. This intermediate was dissolved in dichloromethane (5 mL) and heated under reflux in the presence of 4- (dimethylamino)pyridine (120 mg, 0.98 mmol) (Aldrich) for 1.5 hours. The reaction mixture was quenched with water and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were successively washed with water (10 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product which was purified by preparative thin layer chromatography to give 7-chloro- l-cyclopropylmethyl-3-(4-methoxy-phenyl)-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidine-2-one. (Yield 104 mg, 43.2 %, 3 steps).
A mixture of 7-chloro- l-cyclopropylmethyl-3-(4-methoxy-phenyl)-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidine-2-one (104 mg, 0.30 mmol) in anUine (2.0 mL) (Aldrich) was heated to 120 °C for 1.5 hours. After cooling, the reaction mixture was washed with hexanes (4 x 100 mL) and the crude product was purified by recrystallization from methanol - ethyl acetate to give 3-[-3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4- dihydro- lH-pyrimido [4,5-d] pyrimidin- 1-yl] -propionitrUe as a white solid. (Yield 111 mg, 91.7 %).
Example 27a
(-)-(lj ,4S)-4-(tert-Butyl-dimethyl-sUanyloxy)-cyclopent-2-enol
Figure imgf000070_0001
To a.solution of (lR,3S)-(+)-4-cyclopentene-l,3-diol 1-acetate (1.0 g, 7.03 mmol) (Aldrich) and imidazole (960 mg, 14.06 mmol) (Aldrich) in tetrahydrofuran (35 mL) was added tert-butyldimethylsUyl chloride (1.27 g, 8.44 mmol) (Aldrich). The mixture was aUowed to warm slowly to room temperature, stirred overnight and then partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that was dissolved in methanol (45 mL). To this solution was added potassium carbonate (1.17 g, 8.44 mmol) and the mixture stirred overnight. The next morning the reaction mixture was partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that was purified by silica gel column chromatography with a 0 - 30% diethyl ether in hexanes gradient to give (-)-(lR,4S)-4-(tert-butyl-dimethyl- sUanyloxy)-cyclopent-2-enol as a colorless oU. (Yield 1.29 g, 85%).
HRMS m/z calcd for CnH22O2Si [M+Na]+: 237.1281. Found: 237.1284.
Example 27b -
(-)-(lS,3R)-3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentanol
Figure imgf000071_0001
A solution of (-)-(lR,4S)-4-(tert-butyl-dimethyl-sUanyloxy)-cyclopent-2-enol (1.2 g, 5.6 mmol) (from Example 27a supra) and Wilkinson's catalyst (520 mg, 0.56 mmol) (Aldrich) in toluene (50 mL) was subjected to hydrogenation at atmospheric pressure for 16 hours. The reaction mixture was filtered and partitioned between ethyl acetate and water. The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The resulting residue was purified by chromatography on a sUica gel column using a 0 - 30% diethyl ether in hexanes gradient to give (-)-(lS,3R)-3-(tert- butyl-dimethyl-sUanyloxy)-cyclopentanol as a colorless oil. (Yield 790 mg, 65%).
HRMS m/z calculated for CnH24O2Si [M+Na]+: 239.1438. Found: 239.1441. Example 27c
( -) - ( 1R,3R) - (3-Azido-cyclopentyloxy) -tert-butyl-dimethyl-sUane
Figure imgf000072_0001
To a mixture of (-)-(lS,3R)-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentanol (670 mg, 3.09 mmol) (from Example 27b supra) and triphenyl phosphine (1.06 g, 4.02 mmol) (Aldrich) in anhydrous tetrahydrofuran (60 mL) cooled at 0 °C was added dropwise diethyl azodicarboxylate (640 μL, 0.70 g, 4.02 mmol) (Aldrich). After 2 to 3 minutes, foUowed a dropwise addition of diphenylphosphoryl azide (860 μL, 1.1 g, 4.02 mmol) (Aldrich). The mixture was aUowed to slowly warm up to room temperature and after overnight stirring was partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate filtered and concentrated to a residue that was purified by chromatography with a sUica gel column using a 0 - 20% diethyl ether in hexanes gradient to give (-)-(lR,3R)-(3-azido-cyclopentyloxy)-tert-butyl-dimethyl-sUane as a colorless liquid. (Yield 540 mg, 72%).
Example 27d
(+)-(lR,3R)-4-[3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentylamino]-2-methylsulfanyl- pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000072_0002
, To a solution of (-)-(lR,3R)-(3-azido-cyclopentyloxy)-tert-butyl-dimethyl-silane (540 mg, 2.24 mmol) (from Example 27c supra) in ethanol (30 mL) was added platinum oxide (51 mg, 0.22 mmol) (Aldrich) and the mixture was hydrogenated under 1 atmosphere of hydrogen overnight. The mixture was then filtered, the solids- were - washed with tetrahydrofuran (approximately 25 mL) and the combined filtrate was concentrated to a residue that was dissolved in dioxane (50 mL). To that solution was added triethylamine (620 μL, 450 mg, 4.48 mmol) (Aldrich) and ethyl 4-chloro-2- methylthio-5-pyrimidinecarboxylate (520 mg, 2.24 mmol) (Aldrich) and the mixture was stirred at reflux for 1 hour. The reaction mixture was then cooled and partitioned between ethyl acetate and water. The ethyl acetate layer was coUected, dried over sodium "sulfate and concentrated to a residue that was purified by sUica gel column chromatography with a 0 - 20% ethyl acetate in hexanes gradient to give (+) - ( 1R,3R) -4- [3-(tert-bu1yl-dimethyl-sUanyloxy)-cyclopen1ylan- no]-2-methylsulfanyl-pyrimidine-5- carboxylic acid ethyl ester as a colorless viscous oU. (Yield 710 mg, 77%).
Example 27e
(-)-(lR,3R)-l-[3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-methoxy-phenyl)- 7-phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000073_0001
To a mixture of (+)-(lR,3R)-4-[3-(tert-butyl-dimethyl-silanyloxy)- cyclopentylamino]-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester (710 mg, 1.73 mmol) (from Example 27d supra) in anhydrous tetrahydrofuran (50 mL) at 0 °C was added in portions lithium aluminum hydride (196 mg, 5.19 mmol) (Aldrich). The slurry that resulted was aUowed to slowly warm up to room temperature and after stirring for 5.5 hours was poured in portions to a vigorously stirred mixture of ethyl acetate and saturated aqueous potassium sodium tartrate solution. The organic layer was then collected, dried over sodium sulfate, filtered and concentrated to a solid residue that was dissolved in dichloromethane (50 mL). To this solution was added manganese dioxide (1.5 g, 17.30 mmol) (Aldrich) and the resulting slurry was stirred for 3.5 hours and then filtered. The solids were washed with tetrahydrofuran (approximately 30 mL) and the combined filtrate was concentrated to a residue that was dissolved in benzene (60 mL). That solution was treated wit -anisidine (180 mg, 1.49 mmol) (Aldrich) and - toluenesulfonic acid mono-hydrate (25 mg) (Aldrich) and refluxed using a Dean Stark apparatus overnight. The mixture was then cooled, partitioned between ethyl acetate and water and the organic layer was collected, dried over sodium sulfate, filtered and concentrated. The residue was dissolved in anhydrous tetrahydrofuran (50 mL) and the solution that resulted was cooled at 0 °C. To this solution was added lithium aluminum hydride (150 mg, 4.08 mmol) in smaU portions and the slurry that formed was aUowed to slowly warm up to room temperature. After stirring overnight the slurry was poured in portions into a mixture of ethyl acetate and saturated aqueous potassium sodium tartrate solution. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated and the residue was purified by chromatography on a sUica gel column with a 0 - 30% ethyl acetate in hexanes gradient. The intermediate obtained from that purification was then dissolved in dichloromethane (80 mL) and that solution was treated with triethylamine (490 μL, 0.35 g, 3.47 mmol) (Aldrich) and cooled at 0 °C. This was foUowed by a dropwise addition of a 20% phosgene in toluene solution (570 μL, 1.16 mmol) (Fluka). The reaction mixture was stirred at 0 °C for 20 minutes and at room temperature for 1 hour and then partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on a sUica gel column with a 0 - 30% ethyl acetate in hexanes gradient. The intermediate from this purification was dissolved in tetrahydrofuran (50 mL). This solution was then treated with 3-chloroperoxy-benzoic acid (75%, 320 mg, 1.43 mmol) (Aldrich) stirred overnight and partitioned between ethyl acetate and saturated aqueous potassium carbonate solution. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a solid residue. This residue was dissolved in anUine (3 mL) (Aldrich) and stirred at 75 °C for 16.5 hours. The mixture was then cooled, and purified by sUica gel column chromatography with a 0 - 20% diethyl ether in toluene gradient to give (-)-(lR,3R)-l-[3-(tert-butyl-dimethyl- sUanyloxy)-cyclopentyl]-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido [4,5-d] pyrimidin-2-one as an off-white solid. (Yield 152 mg, 68%).
HRMS m/z calcd for C3oH39N5O3Si [M+H]+: 546.2895. Found: 546.2901.
Example 27f
(+)-( 1R,3R) - 1 - (3-Hydroxy-cyclopentyl) -3- (4-methoxy-phenyl) -7-phenylamino-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000074_0001
(-)-(lR,3R)-l-[3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-methoxy- phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (148 mg, 0.27 mmol) (from Example 27e supra) was dissolved at 0 °C in a 25% trifluoroacetic acid in dichloromethane solution (5 mL) that contained water (300 μL). After stirring for 30 minutes the reaction mixture was partitioned between ethyl acetate and 0.5 N aqueous sodium hydroxide. The pH of the aqueous layer was adjusted to 12 via the addition of solid sodium hydroxide. The organic layer was then coUected, dried over sodium sulfate, filtered and concentrated to give the crude product. Purification by sUica gel column chromatography using a 0 - 100% ethyl acetate in hexanes to 0 - 40% tetrahydrofuran in ethyl acetate gradient foUowed by a precipitation out of dichloromethane with excess pentane afforded (+) - ( 1R,3R) - 1 - (3-hydroxy-cyclopentyl) -3- (4-methoxy-phenyl) -7- phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one as a white solid. (Yield 92 mg, 86%).
HRMS m/z calcd for C2 H25N5O3 [M+H]+: 432.2030. Found: 432.2035.
ICso (KDR) = 0.013 μM, IC50 (FGFR) = 0.035 μM.
Example 28a
(R)-3-(tert-Butyl-diphenyl-sUanyloxy)-butyric acid
Figure imgf000075_0001
Methyl (R)-(-)-3-hydroxybutyrate (0.31 g, 2.61 mmol) (Aldrich) was dissolved in dichloromethane (3.5 mL, dried over molecular sieves). Imidazole (0.25 g, 3.66 mmol) (Aldrich) was added. When all had dissolved, tert-butyldiphenylsUyl chloride (0.69 mL, 2.63 mmol) (Aldrich) was added dropwise and the mixture was stirred at room temperature for 4.5 hours. The reaction mixture was diluted with additional dichloromethane, washed with water (2x) and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Purification by flash chromatography (Biotage 40M, 5:95 ethyl acetate - hexanes) gave (R)-3-(tert-butyl-diphenyl-sUanyloxy)-butyric acid methyl ester. (Yield 0.85 g, 91.2%).
The protected ester (0.84 g, 2.36 mmol) was dissolved in 3:1 tetrahydrofuran - methanol and treated with aqueous sodium hydroxide (1.0 N, 3.0 mL, 3.00 mmol) at ~ 42 °C overnight. The reaction was concentrated. The residue was partitioned between ethyl acetate and water and acidified with 1 N aqueous hydrochloric acid. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. Purification by flash chromatography (Biotage 40M, 20:80 ethyl acetate - hexanes) gave (R)-3-(tert-butyl-diphenyl-sUanyloxy)-butyric acid. (Yield 0.63 g, 69.9%). Example 28b
(R)-tert-Butyl-(2-isocyanato-l-methyl-ethoxy)-diphenyl-sUane
Figure imgf000076_0001
(R)-3-(tert-Butyl-diphenyl-sUanyloxy)-butyric acid (0.81 g, 2.25 mmol) (from Example 28a supra) was dissolved in dichloromethane (8 mL, dried over molecular sieves). Triethylamine (0.63 mL, 4.52 mmol) (Aldrich) was added and the resulting solution was cooled in an ice - water bath. Ethyl chloroformate (0.26 mL, 2.72 mmol) (Aldrich) was then added dropwise and the mixture was stirred in the cold for 50 minutes. The reaction mixture was dUuted with additional dichloromethane and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to give the intermediate mixed anhydride.
The intermediate mixed anhydride was dissolved in acetone (8 mL) and treated with a solution of sodium azide (0.44 g, 6.76 mmol) (Aldrich). After stirring at room temperature for 10 minutes, the reaction was dUuted with dichloromethane and water. The organic phase was washed with brine, dried over magnesium sulfate, filtered and concentrated to give (R)-3-(tert-butyl-diphenyl-sUanyloxy)-butyryl azide. This crude azide was dissolved in toluene (6 mL) and heated in an oU bath at 120 °C. Vigorous nitrogen gas evolution quickly resulted yielding the desired (R)-tert-butyl-(2-isocyanato- l-methyl-ethoxy)-diphenyl-silane by the Curtius rearrangement. This material was used as is in the next step.
Example 28c
(R)-l-[2-(tert-Butyl-diphenyl-sUanyloxy)-propyl]-7-chloro-3-(4-methoxy-phenyl)-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000076_0002
(R)-tert-Butyl-(2-isocyanato-l-methyl-ethoxy)-diphenyl-sUane (generated in situ from 0.81 g, 2.25 mmol of (R)-3-(tert-butyl-diphenyl-sUanyloxy)-butyric acid) (from Example 28b supra) in hot toluene (6 mL) was treated with [(2,4-dichloropyrimidin-5- yl)methyl](4-methoxyphenyl)amine (0.57 g, 2.02 mmol) (from Example Id supra). The solution was heated at 120 °C for 45 minutes and then cooled to room temperature and concentrated to give the intermediate urea.
This urea was dissolved in anhydrous tetrahydrofuran (7.5 mL) and cooled in an ice - brine bath. Potassium tert-butoxide (1.0 N in tetrahydrofuran, 2.15 mL, 2.15 mmol) (Aldrich) was added dropwise. The mixture was stirred in the cold for 15 minutes and then the bath was removed and stirring continued for another 5 minutes. The reaction mixture was filtered through a bed of sUica gel and eluted with ethyl acetate. Purification by flash chromatography (Biotage 40M, ethyl acetate - hexanes gradient [20 - 40% ethyl acetate] ) gave the desired intermediate, contaminated with the uncyclized urea intermediate.
The purified mixture (1.02 g) was dissolved in anhydrous tetrahydrofuran (6 mL) and treated again with potassium tert-butoxide (1.4 mL, 1.40 mmol) as above. Purification (Biotage 40M, ethyl acetate - hexanes gradient (30 - 40% ethyl acetate) gave (R)-l-[2-(tert-butyl-diphenyl-sUanyloxy)-propyl]-7-chloro-3-(4-methoxy-phenyl)-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 0.78 g, 65.0%).
Example 28d
(R)-l-(2-Hydroxy-propyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000077_0001
. (R)-l-[2-(tert-Butyl-diphenyl-sUanyloxy)-propyl]-7-chloro-3-(4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.71 g, 1.15 mmol) (from Example 28c supra) was combined with anUine (1.00 mL, 10.97 mmol) (Aldrich) and heated in an oil bath at 110 °C for 75 minutes. Upon cooling to room temperature, the residue was triturated with hexanes. The supernatant was discarded and the residue was dissolved in ethyl acetate, washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Purification by flash chromatography (Biotage 40M, ethyl acetate - hexanes gradient [20-40% ethyl acetate]) gave the intermediate (R)-l-(2- tert-butyl-diphenyl-sUanyloxy-propyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.73 g, 91.9%).
(R)-l-(2-tert-Butyl-diphenyl-sUanyloxy-propyl)-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one was dissolved in anhydrous tetrahydrofuran (7 mL) and treated with tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 4.2 mL, 4.20 mmol) (Aldrich) in an oil bath at 45 °C overnight. The reaction mixture was concentrated and the residue dissolved in ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by flash chromatography (Biotage 40M, 80:20 ethyl acetate - hexanes) and crystaUized from ethyl acetate - hexanes to give (R)-(-)-l-(2-hydroxy-propyl)-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.25 g, 58.9%). Melting Point: 189 - 193 °C.
HR-MS(ES+) m/z Calculated for C22H23N5O3 [M+H]+: 406.1874. Found: 406.1878.
Example 29a
(+)-(lS,4R)-4-(tert-Butyl-dimethyl-sUanyloxy)-cyclopent-2-enol
Figure imgf000078_0001
To a solution of (lR,4S)-4-acetoxy-2-cyclopenten-l-ol (1.0 g, 7.03 mmol) (Fluka) and imidazole (960 mg, 14.06 mmol) (Aldrich) in tetrahydrofuran (65 mL) at 0 °C was added tert-butyldimethylsilyl chloride (1.27 g, 8.44 mmol) (Aldrich). The mixture was aUowed to warm slowly to room temperature, stirred overnight and then partitioned between ethyl acetate and water. The organic layer was collected, dried over sodium sulfate, filtered and concentrated to a residue that was dissolved in methanol (approximately 45 mL). To this solution was added potassium carbonate (1.17 g, 8.44 mmol) and the mixture stirred overnight. The reaction mixture was then partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that was purified by sUica gel column chromatography with a 0 - 30% diethyl ether in hexanes gradient to give (+)-(lS,4R)-4- (tert-butyl-dimethyl-silanyloxy)-cyclopent-2-enol as a colorless oU. (Yield 1.43 g, 95%). Example 29b
(+)-(lR,3S)-3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentanol
Figure imgf000079_0001
A solution of (+)-( lS,4R)-4-(tert-butyl-dimethyl-sUanyloxy)-cyclopent-2-enol (1.43 g,.6.67 mmol) (from Example 29a supra) and Wilkinson's catalyst (1.23 g, 1.33 mmol) (Aldrich) in toluene (55 mL) was subjected to atmospheric pressure hydrogenation for 16.5 hours. The reaction mixture was then filtered, concentrated to a small volume, and purified by silica gel column chromatography with a 0 - 25% ethyl acetate in hexanes gradient to give (+)-(lR,3S)-3-(tert-butyl-dimethyl-sUanyloxy)- cyclopentanol as a colorless oU. (Yield 745 mg, 61%).
Example 29c
(+)-(lS,35)-(3-Azido-cyclopentyloxy)-tert-butyl-dimethyl-sUane
Figure imgf000079_0002
To a 0 °C solution of (+)-(lR,35)-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentanol (745 mg, 3.44 mmol) (from Example 29b supra) and triphenyl phosphine (1.17 g, 4.47 mmol) (Aldrich) in anhydrous tetrahydrofuran (60 mL) was added dropwise diethyl azodicarboxylate (710 μL, 780 mg, 4.47 mmol) (Aldrich). After 2 to 3 minutes foUowed a dropwise addition of diphenylphosphoryl azide (950 μL, 1.23 g, 4.47 mmol) (Aldrich). The mixture was allowed to warm up slowly to room temperature stirred overnight and then partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered, concentrated and the resulting residue was chromatographed on a sUica gel column with a 0 - 20% diethyl ether in hexanes gradient to give (+)-(lS,3S)-(3-azido-cyclopentyloxy)-tert-butyl-dimethyl-sUane as a colorless liquid. (Yield 589 mg, 70%).
HRMS m/z calcd for ιH23N3OSi [M]+: 241.1610. Found: 241.1613. Example 29d
(-)-(lS,3S)-4-[3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentylamino]-2-methylsulfanyl- pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000080_0001
To a solution of (+)-(lS,3S)-(3-azido-cyclopentyloxy)-tert-butyl-dimethyl-sUane
(580 mg, 2.40 mmol) (from Example 29c supra) in ethanol (30 mL) was added platinum oxide (55 mg, 0.24 mmol) (Aldrich). The mixture was hydrogenated under 1 atmosphere of hydrogen overnight. The reaction mixture was then filtered, the solids were washed with tetrahydrofuran (approximately 30 mL) and the combined filtrate was concentrated to a residue that was dissolved in dioxane (50 mL). To this solution was added triethylamine (970 μL, 705 mg, 6.96 mmol) (Aldrich) and ethyl 4-chloro-2- methylthio-5-pyrimidinecarboxylate (594 mg, 2.55 mmol) (Aldrich) and the mixture was heated at reflux for 45 minutes then cooled and partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that was purified by chromatography on a sUica gel column with a 0 - 20% ethyl acetate in hexanes gradient to give (-)-(lS,3S)-4-[3-(tert-butyl- dimethyl-sUanyloxy)-cyclopentylamino] -2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester as a colorless viscous oil. (Yield 910 mg, 95%).
HRMS m/z calcd for Cι9H33N3O3SSi [M+H]+: 412.2085. Found: 412.2088.
Example 29e
(-)-(lS,3S)-4-[3-(tert-Butyl-dimethyl-silanyloxy)-cyclopentylamino]-2-methylsulfanyl- pyrimidine-5-carbaldehyde
Figure imgf000080_0002
To a solution of (-)-(lS,3S)-4-[3-(tert-butyl-dimethyl-sUanyloxy)- cyclopentylamino] -2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester (910 mg, 2.21 mmol) (from Example 29d supra) in tetrahydrofuran (55 mL) at 0 °C was added in portions lithium aluminum hydride (250 mg, 6.63 mmol) (Aldrich). The reaction mixture was aUowed to slowly warm up to room temperature. After stirring overnight the reaction mixture was poured in portions into a vigorously stirred mixture of ethyl acetate and saturated aqueous potassium sodium tartrate solution. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a solid that was then dissolved in dichloromethane (55 mL). To this solution was added manganese dioxide (1.92 g, 22.11 mmol) (Aldrich) and the mixture was stirred overnight. The slurry was filtered, the solids were washed with tetrahydrofuran (approximately 25 mL) and the combined organic layer was evaporated to a residue that was purified by chromatography on a silica gel column with a 0 - 50% diethyl ether in hexanes gradient to give (-)-(lS,3S)- 4-[3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentylamino]-2-methylsulfanyl-pyrimidine- 5-carbaldehyde as a viscous colorless oU. (Yield 615 mg, 76%).
HRMS m/z calcd for C17H29N302SSi [M+H]+: 368.1823. Found: 368.1825.
Example 29f
(-)-( 1S,3S)-1- [ 3- (tert-Butyl-dimethyl-sUanyloxy) -cyclopentyl] -3-(4-methoxy-phenyl)-7- methylsulfanyl-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000081_0001
A mixture of (-)-(lS,3S)-4-[3-(tert-butyl-dimethyl-silanyloxy)-cyclopentylamino]- 2-methylsulfanyl-pyrimidine-5-carbaldehyde (596 mg, 1.62 mmol) (from Example 29e supra), -anisidine (210 mg, 1.70 mmol) (Aldrich) and a catalytic amount oip- toluenesulfonic acid mono-hydrate (25 mg) (Aldrich) was heated at reflux using a Dean Stark apparatus for 16 hours. The mixture was then cooled and partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated. The residue was dissolved in anhydrous tetrahydrofuran (60 mL) and the solution that resulted was cooled to 0 °C. This was followed by the addition of lithium aluminum hydride (184 mg, 4.87 mmol) in portions and the slurry formed was aUowed to slowly warm up to room temperature. After stirring overnight the reaction mixture was added in portions to a vigorously stirred mixture of ethyl acetate and saturated aqueous potassium sodium tartrate solution. The organic layer was coUected, dried over sodium sulfate, filtered, concentrated and the residue was purified by chromatography with a silica gel column using a 0 - 30% ethyl acetate in hexanes gradient. The product from this purification was dissolved in dichloromethane (50 mL). To this solution was added triethylamine (910 μL, 0.66 g, 6.54 mmol) (Aldrich) and the mixture was cooled to 0 °C. FoUowed a dropwise addition of a 20% phosgene in toluene solution (670 μL, 1.37 mmol) (Fluka). After stirring for 20 minutes at 0 °C and 1 hour at room temperature the reaction mixture was partitioned between ethyl acetate and water. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a residue that was purified by chromatography on a sUica gel column with 0 - 30% ethyl acetate in hexanes gradient to give (-)-(lS,3S)-l-[3-(tert-butyl-dimethyl-sUanyloxy)- cyclopentyl] -3-(4-methoxy-phenyl)-7-methylsulfanyl-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one as an off-white foamy solid. (Yield 620 mg, 76%).
HRMS m/z calcd for C25H36N403SSi [M+H]+: 501.2350. Found: 501.2358.
Example 29g
(-) - ( 1S,3S) - 1 - [3- ( tert-Butyl-dimethyl-sUanyloxy) -cyclopentyl] -3- (4-methoxy-phenyl) -7- phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000082_0001
A solution of (-)-( 1S,3S)-1- [3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl] -3-(4- methoxy-phenyl)-7-methylsulfanyl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (610 mg, 1.22 mmol) (from Example 29f supra) in dichloromethane (50 mL) was treated with 3-chloroperoxybenzoic acid (75%, 590 mg, 2.56 mmol) (Aldrich). After stirring overnight the mixture was partitioned between ethyl acetate and saturated aqueous potassium carbonate solution. The organic layer was coUected, dried over sodium sulfate, filtered and concentrated to a solid that was dissolved in anUine (7 mL) (Aldrich). This solution was stirred at 95 °C for 6 hours then cooled and chromatographed with a silica gel column using a 0 - 20% diethyl ether in toluene gradient to give (-)-(lS,3S)-l- [3- ( tert-butyl-dimethyl-sUanyloxy) -cyclopentyl] -3- (4-methoxy-phenyl) -7-phenylamino- 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one as a white solid. (Yield 450 mg, 68%).
HRMS m/z calculated for C30H39N5θ3Si [M+H]+: 546.2895. Found: 546.2902. Example 29h
(-)-(lS,3S)-l-(3-Hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000083_0001
(-)-( 1S,3S)-1- [3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentyl] -3-(4-methoxy- phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (445 mg, 0.82 mmol) (from Example 29g supra) was dissolved in a 25% trifluoroacetic acid in dichloromethane solution (5 mL) and water (300 μL) at 0 °C. After stirring for 30 minutes the mixture was partitioned between ethyl acetate and 1 N aqueous sodium hydroxide and the pH of the aqueous layer was adjusted to 12 via the addition of solid sodium hydroxide. The organic layer was collected, dried over sodium sulfate, filtered and concentrated to a residue that was purified by chromatography with a sUica gel column and a 0 - 100 ethyl acetate in hexanes to 0 - 40% tetrahydrofuran in ethyl acetate gradient to give (-)-(lS,3S)-l-(3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one as a white solid. (Yield 307 mg, 86%).
HRMS m/z calcd for C24H25N5O3 [M+H]+: 432.2030. Found: 432.2036.
Example 30
3-[-3-(4-Methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d] pyrimidin- 1 -yl] -propionamide
Figure imgf000083_0002
To the solution of 3-[-3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin- l-yl]-propionitrile (60 mg, 0.15 mmol) (from Example 26 supra) in dimethyl sulfoxide (2 mL) at 0 C was added 1.0 N aqueous sodium hydroxide solution (0.42 mL, 0.42 mmol) foUowed by 35% aqueous hydrogen peroxide (0.35 mL) (Fisher). The reaction mixture was stirred at 0 °C for 2 hours and then at room temperature overnight. The reaction was diluted with ethyl acetate (50 mL) and washed with water (3 x 20 mL). The organic layer was washed with brine (10 mL) and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude solid (71 mg) which was purified by recrystaUization from hexanes - ethyl acetate to give 3-[-3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d] pyrimidin- l-yl]-propionamide as a gray solid. (Yield 28.3 mg, 45.1%).
Example 31a
(S)-3-(tert-Butyl-diphenyl-sUanyloxy)-butyric acid
Figure imgf000084_0001
Methyl (S)-(+)-3-hydroxybutyrate (0.48 g, 4.04 mmol) (Aldrich) was dissolved in dichloromethane (6 mL, dried over molecular sieves). Imidazole (0.39 g, 5.65 mmol) (Aldrich) was added. When aU had dissolved, tert-butyldiphenylsUyl chloride (1.05 mL, 4.04 mmol) was added dropwise and the mixture was stirred at room temperature for 4.5 hours. The reaction mixture was diluted with additional dichloromethane, washed with water (2x) and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Purification by flash chromatography (Biotage 40M, 5:95 ethyl acetate - hexanes) gave (S)-3-(tert-butyl-diphenyl-sUanyloxy)-butyric acid methyl ester. (Yield 1.33 g, 92.4%).
The methyl ester (1.33 g, 3.73 mmol) was dissolved in 3:1 tetrahydrofuran - methanol (12 mL) and treated with aqueous sodium hydroxide (1 N, 4.3 mL, 4.30 mmol) at 45 °C overnight. The reaction mixture was concentrated after 17 hours. The residue was partitioned between ethyl acetate and water and acidified with 1 N aqueous hydrochloric acid. The organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated. Purification by flash chromatography (Biotage 40M, 20:80 ethyl acetate - hexanes) gave (S)-3-(tert-butyl-diphenyl-sUanyloxy)-butyric acid. (Yield 0.89 g, 62.2%). Example 31b
(S)-tert-Butyl-(2-isocyanato-l-methyl-ethoxy)-diphenyl-sUane
Figure imgf000085_0001
(S)-3-(tert-Butyl-diphenyl-silanyloxy)-butyric acid (0.88 g, 2.51 mmol) (from Example 31a supra) was dissolved in dichloromethane (8 mL, dried over molecular sieves). Triethylamine (0.71 mL, 5.06 mmol) (Aldrich) was added and the resulting solution was cooled in an ice - water bath. Ethyl chloroformate (0.29 mL, 3.03 mmol) (Aldrich) was added dropwise and the mixture was stirred in the cold for 50 minutes. The reaction mixture was dUuted with additional dichloromethane and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to give the crude mixed anhydride.
The intermediate mixed anhydride was dissolved in acetone (10 mL) and treated with a solution of sodium azide (0.50 g, 7.53 mmol) (Aldrich). After stirring at room temperature for 15 minutes, the reaction was diluted with dichloromethane and water. The organic phase was washed with brine, dried over magnesium sulfate, filtered, concentrated and dried briefly under high vacuum to give (S)-3-(tert-butyl-diphenyl- silanyloxy)-butyryl azide.
The crude azide was dissolved in toluene (7 mL) and heated in an oU bath at 115 - 120 °C for 70 minutes. Vigorous nitrogen gas evolution quickly resulted to give (S)-tert- butyl- (2-isocyanato- 1 -methyl-ethoxy) -diphenyl-sUane by the Curtius rearrangement. This material was used without further treatment in the next step.
Examρle 31c
(S) - 1- [2- (,tert-Butyl-diphenyl-sUanyloxy)-propyl] -7-chloro-3 - (4-methoxy-phenyl) -3 ,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
(S)-tert-Butyl-(2-isocyanato-l-methyl-ethoxy)-diphenyl-silane (generated in situ from 0.88 g, 2.51 mmol of (S)-3-(tert-butyl-diphenyl-sUanyloxy)-butyric acid) (from Example 31b supra) in hot toluene (7 mL) was treated with [(2,4-dichloropyrimidin-5- yl) methyl] (4-methoxyphenyl)amine (0.63 g, 2.23 mmol) (from Example Id supra). The solution was heated at 120 °C for 50 minutes and then cooled to room temperature. The reaction mixture was purified by flash chromatography (Biotage 40M, 30:70 ethyl acetate
- hexanes) to give the urea intermediate.
The purified urea intermediate (1.32 g) was dissolved in anhydrous tetrahydrofuran (5 L), cooled in an ice - brine bath and treated with potassium tert- butoxide (1.0 M in tetrahydrofuran, 2.1 mL, 2.1 mmol) (Aldrich). The mixture was stirred in the cold for 15 minutes and then the bath was removed and stirring continued for an additional 5 minutes. The mixture was filtered through a bed of silica gel and eluted with ethyl acetate. Purification [Biotage 40M, ethyl acetate - hexanes gradient (30
- 35% ethyl acetate)] gave (S)-l-[2-(tert-butyl-diphenyl-sUanyloxy)-propyl]-7-chloro-3- (4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.97 g, 59.4%).
Example 3 Id
(S)-(+)-l-(2-Hydroxy-propyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- p}τimido[4,5-d]pyrimidin-2-one
Figure imgf000086_0002
(S) - 1 - [2- ( tert-Butyl-diphenyl-sUanyloxy) -propyl] -7-chloro-3- (4-methoxy-phenyl) - 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.97 g, 1.65 mmol) (from Example 31c supra) was combined with anUine (1.00 mL, 10.97 mmol) (Aldrich) and heated in an oU bath at 110 °C. After 75 minutes, the reaction mixture was cooled to room temperature, diluted with ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was combined with material from another experiment. The combined lot was purified by flash chromatography (Biotage 40M, ethyl acetate - hexanes gradient [20 - 35% ethyl acetate] ) and then crystaUized from ethyl acetate - hexanes to give the intermediate (S)-l-(2-tert-butyl-diphenyl-silanyloxy-propyl)-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 0.70 g, 59.1%).
The intermediate (S)-l-(2-tert-butyl-diphenyl-sUanyloxy-propyl)-3-(4-methoxy- phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.69 g, 1.08 mmol) was dissolved in anhydrous tetrahydrofuran (7 mL). Tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 4.3 mL, 4.30 mmol) (Aldrich) was added and the reaction mixture was heated in an oU bath at 43 - 50°C overnight. After cooling to room temperature, the reaction was concentrated. The residue was then taken up in ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium acetate. The material was purified by flash chromatography (Biotage 40M, 80:20 ethyl acetate - hexanes) and crystaUized from ethyl acetate - hexanes. The product was stiU contaminated with a more polar impurity. This material was combined with comparable material from another reaction and recrystallized from ethyl acetate to give (S)-(+)-l-(2-hydroxy-propyl)-3-(4-methoxy-ρhenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one as a white solid. (Yield 0.19 g, 28.1%). Melting Point: 188 - 193 °C.
HR-MS(ES+) m/z Calculated for C22H23N5O3 [M+H]+: 406.1874. Found: 406.1878.
IC50 (KDR) = 0.137 μM, IC50 (FGFR) = 0.612 μM.
Example 32a
d5-3,5-Bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexanecarboxylic acid methyl ester
Figure imgf000087_0001
To a solution of ds-3,5-dihydroxy-cyclohexanecarboxylic acid methyl ester (1.0 g,
5.74 mmol) (prepared according to J. C. Pascal et al, U.S. Patent 6191292, February 20, 2001) in dimethylformamide (5 mL) was added imidazole (1.02 g, 14.92 mmol) (Aldrich) and tert-butyl-diphenylsUyl chloride (3.58 mL, 13.8 mmol) (Hiils America). The reaction mixture was stirred at room temperature for 1 day then dUuted with ethyl acetate (20 mL) and water (20mL). The aqueous phase was extracted with ethyl acetate (3X10 mL). The combined ethyl acetate layer was washed with water, and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (5:95) to give cis- 3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexanecarboxylic acid methyl ester. (Yield
3.75 g, 100%).
Example 32b
ds-3,5-Bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexanecarboxylic acid
Figure imgf000088_0001
ds-3,5-Bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexanecarboxylic acid methyl ester (2.65 g, 4.07 mmol) (from Example 32a supra) was dissolved in a mixture of methanol (13 mL), tetrahydrofuran (13 mL) and water (4 mL). Aqueous sodium hydroxide solution (2.5 N, 1.8 mL, 4.5 mmol) was added. The mixture was stirred at room temperature for 3 days then concentrate under reduced pressure. The residue was diluted with water and dichloromethane. The aqueous phase was acidified with cone, hydrochloric acid to pH 2 and extracted with dichloromethane (2 X 20 mL). The combined organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give ds-3,5-bis-(tert-butyl-diphenyl- sUanyloxy)-cyclohexanecarboxylic acid. (Yield 2.54 g, 98%).
Example 32c
ds-l,3-Bis-(tert-butyl-diphenyl-sUanyoxy)-5-isocyanato-cyclohexane
Figure imgf000088_0002
To a solution of ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexanecarboxylic acid (1.06 g, 1.66 mmol) (from Example 32b supra) in acetone (10 mL) at 0 °C was added triethylamine (0.28 mL, 2.0 mmol) (Burdick & Jackson) and ethyl chloroformate (0.19 mL, 2.00 mmol) (Aldrich). After the mixture was stirred for 40 minutes at 0 °C, a solution of sodium azide (1.06 g, 1.66 mmol) (Aldrich) in water (5 mL) was added. The mixture was stirred at 0 °C for one more hour, then poured into ice - water (50 mL). It was extracted with ethyl acetate (3 X 30 mL) and the combined organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was dissolved in toluene and heated at 110 °C for 4 hours and concentrated under reduced pressure to give ds-l,3-bis-(tert-butyl-diphenyl-sUanyoxy)- 5-isocyanato-cyclohexane. (Yield 0.91 g, 87%).
Example 32d
l-[ds-3,5-Bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-7-chloro-3-(2-fluoro-4- methoxy-phenyl) -3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000089_0001
A mixture of (2,4-dichloro-pyrimidin-5-yl-methyl)-(2-fluoro-4-methoxy-phenyl)- amine (0.24 g, 0.73 mmol) (from Example 17a supra) and ds-l,3-bis-(tert-butyl- diphenyl-sUanyoxy)-5-isocyanato-cyclohexane (0.46 g, 0.73 mmol) (from Example 32c supra) in toluene (10 mL) were heated to 110 °C overnight. It was concentrated under reduced pressure. The residue was dissolved in tetrahydrofuran (5 mL) and cooled to - 30 °C. Potassium tert-butoxide (0.9 mL, 1 M in tetrahydrofuran, 0.9 mmol) (Aldrich) was added. The mixture was stirred at room temperature overnight. It was filtered through sUica gel and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (1:4) to give l-[ds-3,5-bis- (ført-butyl-diphenyl-sUanyloxy)-cyclohexyl]-7-chloro-3-(2-fluoro-4-methoxy-phenyl)- 3,4-dihydro-lH-pyrimido [4,5-d] ρyrimidin-2-one. (Yield 0.21 g, 29%). Example 32e
l-[ds-3,5-Bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(2-fluoro-4-methoxy- phenyl) -7- (4-methoxy-phenylamino) -3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000090_0001
A mixture of 1- [d5-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl] -7-chloro-
3-(2-fluoro-4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.10 g, 0.11 mmol) (from Example 32d supra) and -anisidine (17.7 mg, 0.14 mmol) (Aldrich) in 2-propanol (4 mL) was placed in a microwave reactor (SmithSynthesizer™). The reaction mixture was heated at 160 °C for 10 minutes. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - dichloromethane (5:95) to give l-[ds-3,5-bis-(tert-butyl-diphenyl- silanyloxy)-cyclohexyl]-3-(2-fluoro-4-methoxy-phenyl)-7-(4-methoxy-phenylamino)- 3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 0.09 g, 60%).
Example 32f
l-(d5-3,5-Dihydroxy-cyclohexyl)-3-(2-fluoro-4-methoxy-phenyl)-7-(4- methoxyphenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000090_0002
A solution of l-[ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(2- fluoro-4-methoxy-phenyl) -7- (4-methoxy-phenylamino) -3,4-dihydro- lH-pyrimido [4,5- d]pyrimidin-2-one (0.40 g, 0.041 mmol) (from Example 32e supra) and tetrabutylammonium fluoride (0.12 mL, 1.0 M solution in tetrahydrofuran, 0.12 mmol) (Aldrich) in tetrahydrofuran (5 mL) was heated at reflux for 3 hours. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - dichloromethane (5:95) to give l-(d5-3,5- dihydroxy-cyclohexyl)-3-(2-fluoro-4-methoxy-phenyl)-7-(4-methoxyphenylamino)-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 10.0 mg, 48 %).
Example 33a
1- [ds-3,5-Bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl] -7-chloro-3-(4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000091_0001
A mixture of [(2,4-dichloropyrimidin-5-yl)methyl](4-methoxyphenyl)amine (0.21 g, 0.75 mmol) (from Example Id supra) and ds-l,3-bis-tert-butyl-(5-isocyanato- cyclohexyloxy)-diphenyl-sUane (0.45g, 0.68 mmol) (from Example 32c supra) in toluene (10 mL) was heated to 110 °C overnight. It was concentrated under reduced pressure. The residue was dissolved in tetrahydrofuran (5 mL) and cooled to - 30 °C. Potassium tert-butoxide (0.9 mL, 1 M in tetrahydrofuran, 0.9 mmol) (Aldrich) was added. The mixture was stirred at room temperature overnight. It was filtered through sUica gel and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (1:4) to give l-[ds-3,5-bis-(tert-butyl-diphenyl- silanyloxy)-cyclohexyl]-7-chloro-3-(4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one. (Yield 0.29 g, 44%).
Example 33b
l-[ds-3,5-Bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7-(4- methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000091_0002
A mixture of l-[ci5-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-7-chloro- 3-(4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.15 g, 0.16 mmol) (from Example 33a supra) and -anisidine (25.9 mg, 0.21 mmol) (Aldrich) in 2- propanol (4 mL) was placed in a microwave reactor (SmithSynthesizer™). The reaction mixture was heated at 160 °C for 10 minutes. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (3:7 then 2:3) to give l-[d5-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)- cyclohexyl]-3-(4-methoxy-phenyl)-7-(4-methoxy-phenylamino)-3,4-dihydro-lH- pyrimido [4,5-d] pyrimidin-2-one. (Yield 0.09 g, 60%).
Example 33c
l-(ds-3,5-Dihydroxy-cyclohexyl)-3-(4-methoxy-phenyl)-7-(4-methoxy-phenylamino)- 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000092_0001
A solution of l-[ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(4- me1j oxy-phenyl)-7-(4-methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one (0.09 g, 0.09 mmol) (from Example 33b supra) and tetrabutylammonium fluoride (0.28 mL, 1.0 M solution in tetrahydrofuran, 0.28 mmol) (Aldrich) in tetrahydrofuran (5 mL) was heated at reflux for 3 hours. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - dichloromethane (5:95) to give l-(ds-3,5- dihydroxy-cyclohexyl)-3-(4-methoxy-phenyl)-7-(4-methoxy-phenylamino)-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 18.0 mg, 39 %).
Example 34a
4-Fluoro-3-methoxybenzoic acid methyl ester
Figure imgf000092_0002
4-Fluoro-3-hydroxybenzoic acid (4.33 g, 27.7 mmol) (Aldrich) was dissolved in anhydrous dimethylformamide (Aldrich). Potassium carbonate (38.3 g, 277 mmol) and methyl iodide (8.6 mL, 138.5 mmol) (Aldrich) were successively added at room temperature and the mixture was stirred overnight. After filtration, the solution was washed with water and extracted with ethyl acetate. The layers were separated and the organic layer was successively washed with water, 1 N aqueous sodium hydroxide, water i and brine. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 4-fluoro-3-methoxybenzoic acid methyl ester as a pale yeUow oU that solidified upon standing. (Yield 4.72 g, 92%).
Example 34b
4-Fluoro-3-methoxybenzoic acid
Figure imgf000093_0001
4-Fluoro-3-methoxybenzoic acid methyl ester (2.55 g, 13.85 mmol) (from Example 34a supra) was dissolved in a mixture of tetrahydrofuran (140 mL) and water (70 mL). Lithium hydroxide monohydrate (5.8 g, 138.5 mmol) was added and the mixture was heated at reflux for 3.5 hours. After quenching with 1 N aqueous hydrochloric acid (150 mL), the solution was extracted with dichloromethane. The phases were separated and the organic layer was dried over anhydrous sodium sulfate. Concentration under reduced pressure gave 4-fluoro-3-methoxybenzoic acid as an off-white solid. (Yield 2.26g, 96%).
Example 34c
(tert-Butoxy)-N-(4-fluoro-3-methoxyphenyl)carboxamide
" r
4-Fluoro-3-methoxybenzoic acid (1.00 g, 5.87 mmol) (from Example 34b supra) was dissolved in toluene (30 mL). Triethylamine (3.2 mL, 23.48 mmol) (Fisher), diphenyl phosphoryl azide (2.5 mL, 11.74 mmol) (Aldrich) and tert-butanol (6 mL) (Fisher) were successively added at room temperature. The reaction mixture was heated at reflux for 2 hours, then quenched at room temperature with 1 Ν aqueous hydrochloric acid (20 mL). The mixture was extracted with ethyl acetate and the layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate solution and brine, then dried over anhydrous sodium sulfate and filtered. Concentration under reduced pressure gave a yeUow oU that was purified by flash chromatography (20% ethyl acetate in hexanes) to give (tert-butoxy)-N-(4-fluoro-3-methoxyphenyl)carboxamide as a white solid. (Yield 0.98 g, 70%).
Example 34d
4-Fluoro-3-methoxyphenylamine hydrochloric acid salt
(tert-Butoxy)-N-(4-fluoro-3-methoxyphenyl)carboxamide (0.98 g, 4.06 mmol) (from Example 34c supra) was treated with 4 Ν hydrochloric acid in dioxane (20 mL) (Aldrich) overnight at room temperature. The resulting precipitate was coUected by filtration and washed with dry ether to give 4-fluoro-3-methoxyphenylamine hydrochloric acid salt as a white, crystalline, solid. (Yield 512 mg, 71%).
Example 34e
l-[cz5-3,5-Bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7-(4- fluoro-3-methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000094_0001
A solution of 1- [d5-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl] -7-chloro-
3-(4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.20 g, 0.23 mmol) (from Example 33a supra) and 4-fluoro-3-methoxy-phenylamine hydrochloride salt (51 mg, 0.29 mmol) (from Example 34d supra) in 2-propanol (4 mL) was placed in a microwave reactor (SmithSynthesizer™). The reaction mixture was heated at 160 °C for 10 minutes. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (3:7 then 2:3) to give l-[d5-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7- (4-fluoro-3-methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 0.08 g, 35 %). Example 34f
1 - (ds-3,5-Dihydroxy-cyclohexyl) -3 - (4-methoxy-phenyl) -7- (4-fluoro-3-methoxy- phenylamino)-3)4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000095_0001
A solution of 1- [ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl] -3-(4- methoxy-phenyl)-7-(4-fluoro-3-methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one (0.08 g, 0.08 mmol) (from Example 34e supra) and tetrabutylammonium fluoride (0.24 mL, 1.0 M solution in tetrahydrofuran, 0.24 mmol) (Aldrich) in tetrahydrofuran (5 mL) was heated at reflux for 3 hours. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - dichloromethane (5:95) to give l-(d5-3,5- dihydroxy-cyclohexyl)-3-(4-mefhoxy-phenyl)-7-(4-fluoro-3-methoxy-phenylamino)- 3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 18.0 mg, 78 %).
Example 35a
l-[ds-3,5-Bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000095_0002
A mixture of l-[ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-7-chloro- 3-(4-methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.20 g, 0.23 mmol) (from Example 33a supra) and anUine (0.03 mL, 0.29 mmol) (Aldrich) in 2- propanol (4 mL) was placed in a microwave reactor (SmithSynthesizer™). The reaction mixture was heated at 160 °C for 10 minutes. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (3:7 then 2:3) to give l-[d5-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)- cyclohexyl]-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one. (Yield 0.14 g, 64%).
Example 35b
l-(d5-3,5-Dihydroxy-cyclohexyl)-3-(4-mefhoxy-phenyl)-7-phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000096_0001
A solution of l-[ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(4- methoxy-phenyl) -7-phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (0.14 g, 0.15 mmol) (from Example 35a supra) and tetrabutylammonium fluoride (0.44 mL, 1.0 M solution in tetrahydrofuran, 0.44 mmol) (Aldrich) in tetrahydrofuran (5 mL) was heated at reflux for 3 hours. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - dichloromethane (5:95) to give l-(d5-3,5-dihydroxy-cyclohexyl)-3-(4-methoxy-phenyl)- 7-phenylamino-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 42.0 mg, 61 %).
ICso (KDR) = 0.075 μM, IC50 (FGFR) = 0.263 μM.
Example 36a
l-[ds-3,5-Bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(2-fluoro-4-methoxy- phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000096_0002
A mixture of l-[ds-3,5-bis-(tert-butyl-diphenyl-silanyloxy)-cyclohexyl]-7-chloro- 3-(2-fluoro-4-methoxy-ρhenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.21 g, 0.23 mmol) (from Example 32d supra) and anUine (0.03 mL, 0.30 mmol) (Aldrich) in 2-propanol (4 mL) was placed in a microwave reactor (SmithSynthesizer™). The reaction mixture was heated at 160 °C for 10 minutes. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - dichloromethane (5:95) to give l-[ds-3,5-bis-(tert-butyl-diphenyl- silanyloxy)-cyclohexyl]-3-(2-fluoro-4-methoxy-phenyl)-7-phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 0.21 g, 35 %).
Example 36b
l-(d5-3,5-Dihydroxy-cyclohexyl)-3-(2-fluoro-4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000097_0001
A solution of l-[ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(2-fluoro-4- methoxy-phenyl) -7-phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (0.21 g, 0.22 mmol) (from Example 36a supra) and tetrabutylammonium fluoride (0.66 mL, 1.0 M solution in tetrahydrofuran, 0.66 mmol) (Aldrich) in tetrahydrofuran (5 mL) was heated at reflux for 3 hours. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - dichloromethane (5:95) to give l-(ds-3,5-dihydroxy-cyclohexyl)-3-(2-fluoro-4-methoxy- phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one. (Yield 82.0 mg, 78 %).
Example 37a
1 - [ds-3,5-Bis- (tert-butyl-diphenyl-sUanyloxy) -cyclohexyl] -3 - (2-fluoro-4-methoxy- ρhenyl)-7-(4-fluoro-3-methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5- d] pyrimidin-2-one
Figure imgf000098_0001
A mixture of 1- [ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl] -7-chloro- 3-(2-fluoro-4-methoxy-phenyl)-3J4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (0.22g, 0.24 mmol) (from Example 32d supra) and 4-fluoro-3-methoxy-phenylamine hydrochloric acid salt (56.3 mg, 0.32 mmol) (from Example 34d supra) in 2-propanol (4 mL) was placed in a microwave reactor (SmithSynthesizer™). The reaction mixture was heated at 160 °C for 10 minutes. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - hexanes (3:7 then 2:3) to give l-[d5-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]- 3-(2-fluoro-4-methoxy-phenyl)-7-(4-fluoro-3-methoxy-phenylamino)-3,4-dihydro-lH- pyrimido [4,5-d]pyrimidin-2-one. (Yield 0.15 g, 63 %).
Example 37b
l-(d5-3,5-Dihydroxy-cyclohexyI)-3-(2-fluoro-4-methoxy-phenyl)-7-(4-fluoro-3- methoxyphenylamino) -3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000098_0002
A solution of 1- [d5-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl] -3-(2- fluoro-4-methoxy-phenyl)-7-(4-fluoro-3-methoxy-phenylamino)-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one (0.15 g, 0.15 mmol) (from Example 37a supra) and tetrabutylammonium fluoride (0.45 mL, 1.0 M solution in tetrahydrofuran, 0.45 mmol) (Aldrich) in tetrahydrofuran (5 mL) was heated at reflux for 3 hours. After cooling, it was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate - dichloromethane (5:95) to give l-(ds-3,5- dihydroxy-cyclohexyl)-3-(2-fluoro-4-methoxy-phenyl)-7-(4-fluoro-3- methoxyphenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one. (Yield 35.0 mg, 44 %).
Example 38a
(R) -2- (tert-Butyl-dimethyl-sUanyloxy) - 1 -methyl-ethylamine
Figure imgf000099_0001
D-Alaninol hydrochloride (500 mg, 6.66 mmol) (Aldrich) was dissolved in anhydrous dimethylformamide (10 mL) (Aldrich). Imidazole (544 mg, 8 mmol) (Aldrich) and tert-butyldimethylsUyl chloride (1.05 g, 7 mmol) (Aldrich) were successively added at room temperature. This mixture was stirred at room temperature for 2 hours, quenched with a solution of water - saturated aqueous sodium bicarbonate solution (5:1, 15 mL) and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over sodium sulfate, and concentrated under reduce pressure to yield (R)-2-(tert-butyl-dimethyl-silanyloxy)-l-methyl-ethylamine as a colorless oil. (Yield 852 mg, 68%).
Example 38b
(R)-[2-(tert-Butyl-dimethyl-sUanyloxy)-l-methyl-ethyl] -carbamic acid 4-nitro-phenyl ester
Figure imgf000099_0002
A mixture of (R)-2-(tert-butyl-dimethyl-sUanyloxy)-l-methyl-ethylamine (693 mg, 3,66 mmol) (from Example 38a supra) and triethylamine (0.77 mL, 5.5 mmol) (AUied Signal) in dichloromethane was treated with 4-nitrophenyl chloroformate (885 mg, 4.39 mmol) (Aldrich) at room temperature for 30 minutes. The reaction was quenched with 1 N aqueous hydrochloric acid and then extracted with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium bicarbonate solution foUowed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography (15% ethyl acetate in hexanes) to give (R)-[2-(tert-butyl-dimethyl-sUanyloxy)-l-methyl-ethyl]- . carbamic acid 4-nitro-phenyl ester as a colorless oU that solidified upon standing. (Yield i 0.49 g, 38%).
Example 38c
(2,4-Dichloro-pyrimidin-5-ylmethyl)-(4-ethyl-phenyl)-amme
Figure imgf000100_0001
A heterogeneous mixture of 2,4-dichloro-5-(iodomethyl)pyrimidine (31.07 g, 107.3 mmol) (from Example lc supra) and potassium carbonate (74 g, 536.5 mmol) in acetone (535 mL) was treated with 4-ethylanUine (13.3 mL, 107.3 mmol) (Aldrich). The mixture was stirred at room temperature overnight, then dUuted with water (500 mL) and extracted with ethyl acetate. The combined organic layers were successively washed with 1 N aqueous hydrochloric acid, saturated aqueous sodium bicarbonate solution and brine, then dried over anhydrous sodium sulfate, filtered and concentrated under reduce pressure. The crude mixture was purified by flash chromatography (20% ethyl acetate in hexanes) to give (2,4-dicWoro-pyrimidin-5-yl-methyl)-(4-ethyl-phenyl)-amine as a beige solid. (Yield 21.4 g, 70%).
Example 38d
(R)-3-[2-(tert-Butyl-dimethyl-sUanyloxy)-l-methyl-etiiyl]-l-(2,4-dichloro-pyrimidin-5- ylmethyl) - 1 - (4-ethyl-phenyl) -urea
Figure imgf000100_0002
A solution of (2,4-dichloro-pyrimidin-5-yl-methyl)-(4-ethyl-phenyl)amine (620 mg, 2.19 mmol) (from Example 38c supra), (R)-[2-(tert-butyl-dimethyl-sUanyloxy)-l- methyl-ethyl] -carbamic acid 4-nitro-phenyl ester (778 mg, 2.19 mmol) (from Example 38b supra) and triethylamine (0.93 mL, 6.6 mmol) (Allied Signal) in toluene (20 mL) was heated at reflux for 48 hours. The reaction mixture was quenched at room temperature with 1 N aqueous hydrochloric acid then extracted with ethyl acetate. The combined organic layers were successively washed with 1 N aqueous sodium hydroxide solution and brine, then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (30% ethyl acetate in hexanes) to give (R)-3-[2-(te^butyl-dimethyl-sUanyloxy)-l-methyl-ethyl]-l-(2,4- dichloro-pyrimidin-5-yl-methyl)-l-(4-ethyl-phenyl)-urea. (Yield 383 mg, 36%).
Example 38e
(R)-l-[2-(tert-Butyl-dimethyl-sUanyloxy)-l-methyl-ethyl]-7-chloro-3-(4-ethyl-ρhenyl)- 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000101_0001
A solution of (R)-3-[2-(tert-butyl-dimethyl-sUanyloxy)-l-methyl-ethyl]-l-(2,4- dichloro-pyrimidin-5-yl-methyl)-l-(4-ethyl-phenyl)-urea (380 mg, 0.76 mmol) (from Example 38d supra) in tetrahydrofuran (10 mL) was treated at room temperature with potassium tert-butoxide (160 mg, 1.14 mmol) (Aldrich). The mixture was stirred at room temperature for 1.5 hours. The reaction mixture was quenched with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue (395 mg, yeUow oil) was purified by flash chromatography to give (R)-l-[2-(tert-butyl-dimethyl-sUanyloxy)-l-methyl-ethyl]- 7-c oro-3-(4-ell yl-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one as a colorless oil. (Yield 102 mg, 30%).
Example 38f
(R)-l-[2-(tert-Butyl-dimethyl-sUanyloxy)-l-mellιyl-ethyl]-3-(4-ethyl-ρhenyl)-7-(4- fluoro-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000102_0001
(R) - 1 - [2- ( tert-Butyl-dimethyl-sUanyloxy) - 1 -methyl- ethyl] -7-chloro-3- (4-ethyl- phenyl) -3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (100 mg, 0.21 mmol) (from Example 3.8e supra) was suspended in 2-propanol (2 mL) (Fisher). 4-Fluoroaniline (0.03 mL, 0.32 mmol) (Aldrich) was added and the mixture was heated to 160 °C in a microwave synthesizer (SmithSynthesizer™) for 30 minutes. After cooling to room temperature, the heterogeneous reaction mixture was diluted with dichloromethane. The resulting solution was washed with 1 N aqueous hydrochloric acid. The layers were separated and the organic phase was dried over anhydrous sodium sulfate, filtered and then concentrated under reduce pressure to give (R)-l-[2-(tert-butyl-dimethyl- sUanyloxy)-l-methyl-ethyl]-3-(4-ethyl-phenyl)-7-(4-fluoro-phenylamino)-3,4-dihydro- lH-pyrimido[4,5-d]pyrimidin-2-one as a pale yeUow solid. (Yield 107 mg, 91%).
Example 38g
(R)-3-(4-Ethyl-phenyl)-7-(4-fluoro-phenylamino)-l-(2-hydroxy-l-methyl-ethyl)-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000102_0002
(R)-l-[2-(tert-Butyl-dimethyl-sUanyloxy)-l-methyl-ethyl]-3-(4-ethyl-phenyl)-7-
(4rfluoro-phenylamino)-3,4-dihydro-lH-pyrimido [4,5-d]pyrimidin-2-one ( 100 mg, 0.18 mmol) (from Example 38f supra) in pyridine (1.5 mL) (Fisher) was treated at room temperature with- hydrogen fluoride - pyridine (0.6 mL) (Aldrich) for 15 minutes. The reaction mixture was quenched with 1 N aqueous hydrochloric acid at 0 °C, then extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (50% ethyl acetate in hexanes) to give (R)-3-(4-ethyl-phenyl)-7-(4- fluoro-phenylamino) - 1 - (2-hydroxy- 1-methyl-ethyl) -3,4-dihydro- lH-pyrimido [4,5- d]pyrimidin-2-one as a colorless viscous oU. (Yield 45 mg, 61%).
IC50 (KDR) = 0.208 μM, IC50 (FGFR) = 0.329 μM.
Example 39a
(±)-[trflns-3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentyl]-{2-chloro-5-[(4-efhyl- phenylamino)-methyl]-pyrimidin-4-yl}-amine
Figure imgf000103_0001
(2,4-Dichloro-pyrimidin-5-yl-methyl)-(4-ethyl-phenyl)-amine (200 mg, 0.71 mmol) (from Example 38c supra) was dissolved in hot rz-butanol (2 mL) (Aldrich). After cooling to room temperature, triethylamine (0.20 mL, 0.92 mmol) (AUied Signal) and (+)-tr rt5-3-(tert-butyl-dimethyl-silanyloxy)-cyclopentylamine (198 mg, 0.91 mmol) (from Example 9c supra) were successively added and the mixture was stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and purified by flash chromatography (20% ethyl acetate in hexanes) to give (±)-[trαπ5-3- (tert-butyl-dimethyl-silanyloxy)-cyclopentyl]-{2-chloro-5-[(4-ethyl-phenylamino)- methyl] -pyrimidin-4-yl}-amine as a viscous oU. (Yield 272 mg, 84%).
Example 39b
(±) - 1 - [ trans-3 - (tert-Butyl-dimethyl-silanyloxy)-cyclopentyl] -7-chloro-3- (4-ethyl- phenyl)-3,4-dihydro- lH-pyrimido [4,5-d]pyrimidin-2-one
Figure imgf000103_0002
A mixture of (±)-[tr ns-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-{2-chloro- 5-[(4-ethyl-phenylamino)-methyl]-pyrimidin-4-yl}-amine (270 mg, 0.58 mmol) (from Example 39a supra) and triethylamine (0.25 mL, 1.76 mmol) (AUied Signal) in dichloromethane (6 mL) was cooled to 0 °C. A 20% phosgene in toluene solution (0.32 mL, 0.61 mmol) (Fluka) was added dropwise and the mixture was stirred at 0 °C for 1 hour. The mixture was aUowed to warm up to room temperature and 4- (dimethylamino)pyridine (15 mg, 0.12 mmol) (Aldrich) was added. The reaction was stirred at room temperature overnight, heated at reflux for 4 hours, and then concentrated to dryness. The yeUow residue was purified by flash chromatography (20% ethyl acetate in hexanes) to give (±)- 1- [tr πs-3-(tert-butyl-dimethyl-sUanyloxy)- cyclopentyl]-7-cMoro-3-(4-ethyl-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2- one. (Yield 213 mg, 75%).
Example 39c
(+)-l-[tr rts-3-(tert-Butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-ethyl-phenyl)-7-(4- fluoro-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one
Figure imgf000104_0001
(+)-l-[trα«5-3-(tert-Butyl-dimetlιyl-sUanyloxy)-cyclopen1yl]-7-cMoro-3-(4-ethyl- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (125 mg, 0.25 mmol) (from Example 39b supra) was suspended in 2-propanol (3 mL) (Fisher). 4-FluoroanUine (0.036 L, 0.38 mmol) (Aldrich) and p-toluenesulfonic acid mono-hydrate (12.5 mg, 0.05 mmol) (Aldrich) were added and the mixture was heated to 160 °C in a microwave synthesizer (SmithSynthesizer™) for 30 minutes. After cooling to room temperature, the heterogeneous reaction mixture was dUuted with dichloromethane. The resulting solution was washed with 1 N aqueous hydrochloric acid. The layers were separated and the organic phase was dried over anhydrous sodium sulfate, filtered and then concentrated under reduce pressure to give (±)-l-[tr ns-3-(tert-butyl-dimethyl- sUanyloxy)-cyclopentyl]-3-(4-ethyl-phenyl)-7-(4-fluoro-phenylamino)-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one as a pale green solid. (Yield 123 mg, 85%). Example 39d
(±)-3-(4-Ethyl-phenyl)-7-(4-fluoro-phenylamino)-l-(trfln5-3-hydroxy-cyclopentyl)-3,4- dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one
Figure imgf000105_0001
A solution of (±)-l-[trαns-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4- ethyl-phenyl)-7-(4-fluoro-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2- one (47 mg, 0.08 mmol) in pyridine (1 mL) (Fisher) was treated at room temperature with hydrogen fluoride - pyridine (0.6 mL) (Aldrich) for 20 minutes. The reaction mixture was quenched with 1 N aqueous hydrochloric acid at 0 °C, then extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (50% ethyl acetate in hexanes) to give (±)-3-(4-ethyl-phenyl)-7-(4-fluoro-phenylamino)- l-(tr ns-3-hydroxy-cyclopentyl)-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one as a white solid. (Yield 32 mg, 87%).
Example 40
l-Cyclopropylmethyl-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidine-2-one
Figure imgf000105_0002
To a solution of [(2,4-dichloropyrimidin-5-yl)methyl](4-methoxy-phenyl)amine (198 mg, 0.7 mmol) (from Example Id supra) in π-butanol (5 mL) was added cyclopropanemethylamine (0.12 mL, 1.4 mmol) (Aldrich) and N,N-diisopropyl- ethylamine (10.13 mL) (Aldrich). The reaction mixture was stirred at room temperature overnight, and then quenched with water and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were successively washed with water (10 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude mono chloride as a colorless oU (Yield 220 mg) which was used in the next step without further purification.
To a solution of crude mono chloride (220 mg) in dichloromethane (20 mL) at 0 °C was added triethylamine (0.3 mL, 2.1 mmol) (Aldrich) foUowed by addition of 20% solution of phosgene in toluene (0.5 mL, 0.98 mmol) (Fluka) dropwise. This mixture was stirred at room temperature for 15 minutes. The reaction mixture was then poured into ice - cold water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were successively washed with water (10 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude intermediate which was dissolved again in dichloromethane (5 mL) and heated under reflux in the presence of 4-(dimethylamino)pyridine (20 mg) (Aldrich) overnight. The reaction mixture was quenched with water and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were successively washed with water (10 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude products which was then separated by preparative thin layer chromatography to give 7-chloro-l-cyclopropylmethyl-3-(4-methoxy-phenyl)-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidine-2-one. (Yield 259 mg, 74.8 %, 3 steps).
The mixture of 7-chloro-l-cyclopropylmethyl-3-(4-methoxy-phenyl)-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidine-2-one (129 mg, 0.37 mmol) in aniline (1.0 mL) (Aldrich) was heated to 120 °C for 5.5 hours. After cooling, the reaction mixture was washed with hexanes (4 x 100 mL) and the crude product was purified by preparative thin layer chromatography to give l-cyclopropylmethyl-3-(4-methoxy-phenyl)-7-phenylamino- 3,4-dihydro-lH-pyrimido [4,5-d] pyrimidine-2-one as an off-white solid. (Yield 20.6 mg, 13.7 %).
Antiproliferative Activity
The antiproliferative activity of the compounds of the invention is demonstrated below in Examples 41 and 42. These activities indicate that the compounds of the present invention are useful in treating cancer, in particular solid tumors such as breast, lung, prostate and colon tumors, more particularly breast and colon tumors.
Example 41
Kinase Assays
To determine inhibition of KDR, FGFR, EGFR, and PDGFR activity, kinase assays were conducted using an HTRF (Homogeneous Time Resolved Fluorescence) assay. This assav is described in A. J. Kolb et. al., Drug Discovery Today, 1998, 3(7), p 333. Prior to kinase reaction, recombinant EEE-tagged KDR was activated in the presence of activation buffer (50 mM HEPES, pH 7.4, 1 mM DTT, 10% glycerol, 150 mM NaCl, 0.1 mM EDTA, 26 mM MgCl2, and 4 mM ATP). The enzyme was incubated at 4 °C for 1 hour.
Kinase activity assays were performed in 96-weU polypropylene plates (Falcon) with a total volume of 90 μL in each weU. Each weU contained 1 μM KDR substrate (Biotin-EEEEYFELVAKKKK), 1 nM activated KDR, and a test compound with one of 8 assay concentrations ranging from 100 μM to 128 pM (1:5 serial dilution). The kinase activity assay was done in the presence of 100 mM HEPES, pH 7.4, 1 mM DTT, 0.1 mM Na2VO4, 25 mM MgCl2, 50 mM NaCl (from KDR stock solution), 1% DMSO (from compound), 0.3 mM ATP (at Km concentration) and 0.02% BSA. The reaction was incubated at 37 °C for 30 minutes. To stop the KDR reaction, 72 μL of reaction mixture was transferred into a STOP plate containing 18 μL of revelation buffer (20 mM EDTA, 50 mM HEPES, pH 7.4, 0.02% BSA, 10 nM Eu-labeUed anti-pY antibody (final cone. 2 nM), and 100 nM streptavidin (final cone. 20 nM)). After mixing, 35 μL of solution was transferred into duplicate weUs of a 384-weU black plate (Costar), and read at 615/665 nm on a WaUac Victor 5 reader.
FGFR, EGFR, and PDGFR activity assays were carried out as described above for the KDR activity assay with the following differences. GST-tagged FGFR enzyme was activated at room temperature for 1 hour in the foUowing activation buffer: 100 mM HEPES, pH 7.4, 50 mM NaCl, 20 mM MgCl2, and 4 mM ATP. The kinase activity assay was performed with 1 μM substrate (Biotin-EEEEYFELV), 1.5 nM activated FGFR, and test compound in the presence of 100 mM HEPES, 1 mM DTT, 0.4 mM MgCl2, 0.4 mM MnCl2, 50 mM NaCl, 1% DMSO, 10 μM ATP (Km= 8.5 μM for FGFR), 0.1 mM Na2VO4, and 0.02% BSA, in a total volume of 90 μL. The rest of the assay was performed in the same manner as KDR assay.
The EGFR kinase activity assay was performed with 1 μM substrate (Biotin- EEEEYFELV), 1.5 nM EGFR, test compounds, 100 mM HEPES, pH 7.4, 1 mM DTT, 5 mM MgCl2, 2 mM MnCl2, 1% DMSO, 0.5 μM ATP (Kmfor EGFR), 0.1 mM Na2VO4, and 0.02% BSA. The rest of the assay was performed in the same manner as the KDR assay.
The PDGFR kinase activity assay was performed with 1 μM substrate (Biotin- EEEEYFELV), 1.0 nM PDGFR, test compounds, 100 mM HEPES, pH 7.4, 1 mM DTT, 5 mM MgCl2, 2 mM MnCl2, 1% DMSO, 2.3 μM ATP (Km for PDGFR), 0.1 mM Na2VO4, and 0.02% BSA. The rest of the assay was performed in the same manner as the KDR assay. Compound IC50 values were determined from duplicate sets of data, and calculated by using Excel and fitting data to equation Y=[(a-b)/{l+(X/c)d]+b, where a and b are enzyme activity in the presence of no test inhibitor compound and an infinite amount of inhibitor test compound, respectively, c is the IC50 and d is the hill constant of the compound response. The IC50 value is the concentration of test compound that reduces by 50% the enzyme activity under the test conditions described.
The IC50 values in the above-described enzyme inhibition assays for the compounds of the invention are as foUows: KDR less than 0.50 μM; FGFR less than 2 μM.
Example 42
VEGF and FGF-Stimulated HUVEC Proliferation Assays
The antiproliferative activity of test compounds of this invention in ceU-based assays was evaluated by BrdU assay using the BrdU kit (Roche Biochemicals 1-647-229). Human umbUical vein endothelial ceUs (Clonetics CC-2519) were cultured in EGM-2 (Clonetics CC-3162) medium and seeded at 10000 ceUs per weU in a volume of 200 μL of EGM-2 (Clonetics CC-3162) media in a 96-weU flat bottom plates (Costar 3595) overnight. After 24 hours of growth at 37 °C with 5% CO2, the incubation media was removed slowly by aspiration and the content of each weU was washed with 300 μL pre- warmed EBM-2 (Clonetics CC-3156) containing 50 μg per mL of gentamycin and 50 ng per mL of amphotericin-B (Clonetics CC-4083). Subsequently, the remaining media was again aspirated and replaced with 160 μL per weU of serum starvation media (EBM-2 supplemented with 1% heat inactivated FBS (Clonetics CC-4102), 50 μg per mL gentamycin and 50 ng per mL of amphotericin-B (Clonetics CC-4083), 10 units per mL ofWyefh-Ayerstheparin (NDC0641-0391-25), and 2 mM L-glutamine (GIBCO 25030- 081). After serum starving the cells for 24 hours, 20 μL of test compound at 10X test concentration in serum starvation medium with 2.5% DMSO was added to the appropriate wells. The control wells contained 20 μL of serum starvation medium with 2.5% DMSO. Plates were returned to the incubator for 2 hours. After pre-incubating the ceUs with the test compounds for 2 hours, 20 μL of growth factors at 10X assay concentration diluted in serum starvation media, FGF at 50 ng per mL, or VEGF (R8?D systems 293-VE) at 200 ng per mL were added. The final concentration of FGF in the assay was 5 ng per L, and the final concentration of VEGF in the assays was 20 ng per mL. The growth factor free control weUs had 20 μL per weU of serum starvation media with the same amount of BSA as the wells with growth factors. The plates were returned to the incubator for an additional 22 hours. BrdU ELISA
After 24 hour exposure to the test compounds, the ceUs were labeled with BrdU (Roche Biochemicals 1-647-229), by adding 20 μL per weU of BrdU labeling reagent that has been dUuted (1:100) in serum starvation medium. The plates were then returned to the incubator for 4 hours. The labeling medium was removed by draining the medium onto paper towels. The ceUs were fixed and DNA denatured by adding 200 μL of fixation / denaturation solution to each weU and incubating at room temperature for 45 minutes. The fixation / denaturation solution was drained onto paper towels and to each weU was added 100 μL of anti-BrdU-POD and the weUs were incubated for 2 hours at room temperature. The antibody solution was removed and the weUs were each washed 3 - 4 times with 300 μL PBS. 100 μL of the TMB substrate solution was added to each well and the weUs were incubated at room temperature for 5 - 8 minutes. The reaction was then stopped by adding 100 μL per weU of 1 M phosphoric acid. The plates were read at 450 nm with reference wavelength of 650. nm. The percent inhibition for each test compound was calculated by subtracting the absorbency of the blank (no ceUs) weUs from all weUs, then subtracting the division of the average absorbency of each test duplicate by the average of the controls from 1. The final product was then multiplied by 100 (% of inhibition = (1-average absorbency of test duplicate/average of control) 100). The IC5o value is the concentration of test compound that inhibits by 50% BrdU labeling, and is a measure of inhibition of ceU proliferation. The IC50 is determined from the linear regression of a plot of the logarithm of the concentration versus percent inhibition.
The IC50 values of VEGF and FGF-stimulated HUVEC proliferation assays for the compounds of the invention measured as described herein are as follows: HUVEC/VEFG less than 1.00 μM; HUVEC/bFGF less than 1.00 μM.
Example 43
Tablet Formulation
Figure imgf000110_0001
"•"Compound A represents a compound of the invention.
Manufacturing Procedure:
Mix Items 1, 2 and 3 in a suitable mixer for 15 minutes.
Granulate the powder mix from Step 1 with 20% Povidone K30 Solution (Item 4).
Dry the granulation from Step 2 at 50 °C.
Pass the granulation from Step 3 through a suitable miUing equipment.
Add the Item 5 to the miUed granulation Step 4 and mix for 3 minutes.
Compress the granulation from Step 5 on a suitable press.
Example 44
Capsule Formulation
Figure imgf000111_0001
""Compound A represents a compound of the invention.
Manufacturing Procedure:
Mix Items 1, 2 and 3 in a suitable mixer for 15 minutes.
Add Items 4 & 5 and mix for 3 minutes.
Fill into a suitable capsule.
Example 45
Injection Solution/Emulsion Preparation
Figure imgf000112_0001
^Compound A represents a compound of the invention.
Manufacturing Procedure:
Dissolve item 1 in item 2.
Add items 3, 4 and 5 to item 6 and mix untU dispersed, then homogenize.
Add the solution from step 1 to the mixture from step 2 and homogenize untU the dispersion is translucent.
SterUe filter through a 0.2 μm filter and fiU into vials.
Example 46
Injection Solution/Emulsion Preparation
Figure imgf000113_0001
""Compound A represents a compound of the invention.
Manufacturing Procedure:
Dissolve item 1 in item 2.
Add items 3, 4 and 5 to item 6 and mix untU dispersed, then homogenize.
Add the solution from step 1 to the mixture from step 2 and homogenize until the dispersion is translucent.
Sterile filter through a 0.2 μm filter and fill into vials.
While the invention has been iUustrated by reference to specific and preferred embodiments, those skiUed in the art wiU understand that variations and modifications may be made through routine experimentation and practice of the invention. Thus, the invention is intended not to be limited by the foregoing description, but to be defined by the appended claims and their equivalents.

Claims

Claims
1. Compounds of formula
Figure imgf000114_0001
wherein
R1 is selected from the group consisting of -H,
- ( CH2) n-heter ocycle, alkyl, cycloalkyl, alkenyl, and alkynyl,
where n is 0, 1, 2, or 3, and the heterocycle, alkyl, cycloalkyl, alkenyl, and alkynyl groups are each independently, optionally substituted by up to 3 groups selected
-OR9, -COR10, -CO2R10, -CONR10Rn, -SO2NR10RU, -SO2R10, and -CN;
R2 and R3 are independently selected from the group consisting of -H, -OR9,
-halogen,
-COR10,
-CO2R10,
-(CH2)π-heterocycle,
-alkyl,
-cycloalkyl, -alkenyl, and -alkynyl,
where n is 0, 1, 2, or 3, and the heterocycle, alkyl, cycloalkyl, alkenyl, and alkynyl groups are each independently, optionaUy substituted by up to 3 groups selected
-OR9, -halogen, -COR10, and -CO2R10;
R4, R5, R6, R7 and R8 are each independently selected from the group consisting of -H,
-lower alkyl that optionally may be substituted by hydroxy or alkoxy, -OR12,
-halogen, -COR13, and -CO2R13;
R9 is selected from the group consisting of -H,
-COR10, lower alkyl that optionaUy maybe substituted by hydroxy or alkoxy, cycloalkyl that optionally maybe substituted by hydroxy, alkoxy, and lower alkyl, and heterocycle that optionally may be substituted by hydroxy, alkoxy or lower alkyl;
R10 and R11 are each independently selected from the group consisting of . -H, lower alkyl that optionally may be substituted by hydroxy or alkoxy, cycloalkyl that optionaUy may be substituted by hydroxy, alkoxy or lower alkyl, and heterocycle that optionally may be substituted by hydroxy, alkoxy or lower alkyl;
R12 is selected from the group consisting of -H, lower alkyl and -COR13; and
R13 is selected from the group consisting of -H and lower alkyl;
or the pharmaceuticaUy acceptable salts thereof.
2 Compounds of formula I of clairi 1 wherein R1 is selected from cycloalkyl; cycloalkyl substituted by -OH; heterocycle; lower alkyl; and lower alkyl substituted by -OH.
3. Compounds of formula I of claim 1 wherein R2 is -H or -OCH3.
4. Compounds of formula I of claim 1 wherein R3 is -H, F, or -OCH3.
5. Compounds of formula I of claim 1 wherein R2 and R3 are both -H.
6. Compounds of formula I of claim 1 wherein R4, R5 and R7 are -H.
7. Compounds of formula I of claim 1 wherein R6 is halogen or -OR12.
8. Compounds of formula I of claim 7 wherein R6 is -OCH3.
9. Compounds of formula I of claim 1 wherein R8 is -H or -F.
10. Compounds of formula I of claim 1 wherein R9is -H, lower alkyl, or lower alkyl substituted by hydroxy.
11. Compounds of formula I of claim 10 wherein R9 is -H.
12. Compounds of formula I of claim 1 wherein R10 is -H, lower alkyl, or lower alkyl substituted by hydroxy.
13. Compounds of formula I of claim 12 wherein R10 is -H.
14. Compounds of formula I of claim 1 wherein R11 is -H, lower alkyl, or lower alkyl substituted by hydroxy.
15. Compounds of formula I of claim 14 wherein R11 is -H.
16. Compounds of formula I of claim 1 wherein R12 is -H or lower alkyl.
17. Compounds of formula I of claim 16 wherein R12 is -H.
18. Compounds of formula I of claim 1 wherein R13 is -H or lower alkyl.
190 Compounds of formula I of claim 18 wherein R13 is -H.
20. Compounds of formula I of claim 1, selected from the group consisting of
l-cyclohexyl-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one (Example le),
3-(4-methoxy-phenyl)-7-phenylamino-l-piperidin-4-yl-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one (Example 2b),
1 -(trflπs-4-hydroxy-cyclohexyl) -3 - (4-methoxy-phenyl) -7-phenylamino-3,4-dihydro- 1H- nvrimidor4.5-dlDvrimidin-2-one (Example 3c), 3-(4-methoxy-phenyl)-7-phenylamino-l-piperidin-3-yl-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one (Example 4b),
l-cyclopentyl-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dmydro-lH-pyrimido[4,5- d]pyrimidin-2-one (Example 5),
l-( 1,1-dioxo-tetrahydro-ll 6-thiophen-3-yl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (Example 6),
3-[3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5- d] pyrimidin- 1-yl] -piperidine- 1 -carbaldehyde (Example 7),
3-(4-metlιoxy-phenyl)-7-phenylamino-l-(tetrahydro-pyran-4-yl)-3,4-dihydro-lH- pyrimido [4,5-d] pyrimidin-2-one (Example 8),
(±) - 1 -(t ns-3-hydroxy-cyclopentyl) -3 - (4-methoxy-phenyl) -7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 9d), and
(±)-ds-l-(3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example lOe).
21. Compounds of formula I of claim 1, selected from the group consisting of
(R)-3-(4-methoxy-phenyl)-7-phenylamino-l-(tetrahydro-furan-3-yl)-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one (Example lib) (R)-3-(4-Mefhoxy-phenyl)-7- phenylamino-l-pyrrolidin-3-yl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 12),
(±)-7-(4-fluoro-phenylamino)-l-(trfl?25-3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)- 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 13c),
(±)-3-(2-fluoro-4-methoxy-phenyl)-l-(t r25-3-hydroxy-cyclopentyl)-7-phenylamino- 3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (Example 14d),
(S)-(+)-l-(2-hydroxy-l-methyl-ethyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 15d),
(S)-(+)-7-(4-fluoro-phenylamino)-l-(2-hydroxy-l-methyl-ethyl)-3-(4-methoxy- phenyl)-3,4-dihydro- lH-pyrimido [4,5-d]pyrimidin-2-one (Example 16),
3 -(2-fluoro-4-methoxy-phenyl) i- 1 - (trαns-4-hydr oxy- cyclohexyl) -7- (4-methoxy- phenylamino)-3,4-dihydro- lH-pyrimido [4,5-d]pyrimidin-2-one (Example 17d), 3-(2-fluoro-4-methoxy-phenyl)-l-(trflπ5-4-hydroxy-cyclohexyl)-7-(3,4-dimethoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 18),
3 - (4-methoxy-phenyl) - 1 - ( tr n5-4-hydroxy-cyclohexyl) -7- ( 3 ,4-dimethoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 19c),
3-(4-methoxy-phenyl)-l-(trøns-4-hydroxy-cyclohexyl)-7-(4-methoxy-phenylamino)- 3,4-dihydro-lH-ρyrimido [4,5-d] pyrimidin-2-one (Example 20b), and
(S)-(+)-3-(2-Fluoro-4-methoxy-phenyl)-7-(4-fluoro-phenylamino)-l-(2-hydroxy-l- methyl-ethyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 21b).
22. Compounds of formula I of claim 1, selected from the group consisting of
(S)-(-l-)-3-(2-fluoro-4-methoxy-phenyl)-l-(2-hydroxy-l-methyl-ethyl)-7-(4-methoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 22),
(R) - (-)- 1 - (2-hydroxy- 1 -methyl-ethyl) -3- (4-methoxy-phenyl) -7-phenylamino-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (Example 23d),
3-(4-methoxy-ρhenyl)-l-methyl -7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidine-2-one (Example 24b),
l-(2-metlιoxy-ethoxymetl yl)-3-(4-metlιoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-one (Example 25),
3-[-3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d] pyrimidin- l-yl]-propionitrile (Example 26),
(-l-)-(lR,3R)-l-(3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (Example 27f),
(R) - 1 - (2-hydroxy-propyl) -3- (4-methoxy-phenyl) -7-phenylamino-3,4-dihydro- 1H- pyrimido[4,5-d]pyrimidin-2-one (Example 28d),
(-)-(lS,3S)-l-(3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (Example 29h),
3-[-3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5- d] pyrimidin- l-yl]-propionamide (Example 30), and
(S)-(+)-l-(2-hydroxy-propyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-lH- pyrimido[4,5-d]pyrimidin-2-orie (Example 31d).
23. Compounds of formula I of claim 1, selected from the group consisting of
l-(ds-3,5-dihydroxy-cyclohexyl)-3-(2-fluoro-4-methoxy-phenyl)-7-(4- methoxyphenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 32f),
l-(ds-3,5-dihydroxy-cyclohexyl)-3-(4-methoxy-phenyl)-7-(4-methoxy-phenylamino)- 3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example 33c),
l-(ds-3,5-dihydroxy-cyclohexyl)-3-(4-mefhoxy-phenyl)-7-(4-fluoro-3-methoxy- phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 34f),
l-(ds-3,5-dihydroxy-cyclohexyl)-3-(4-methoxy-ρhenyl)-7-phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example 35b),
l-(ds-3,5-dihydroxy-cyclohexyl)-3-(2-fluoro-4-methoxy-phenyl)-7-phenylamino-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (Example 36b),
l-(ds-3,5-dihydroxy-cyclohexyl)-3-(2-fluoro-4-methoxy-phenyl)-7-(4-fluoro-3- methoxyphenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 37b),
(R)-3-(4-ethyl-phenyl)-7-(4-fluoro-phenylamino)-l-(2-hydroxy-l-methyl-ethyl)-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (Example 38g),
(±) -3- (4-ethyl-phenyl) -7- (4-fluoro-phenylamino) - 1 - (trans-3 -hydroxy-cyclopentyl) -3,4- dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example 39d), and
l-cyclopropylmefhyl-3-(4-methoxy-phenyl)- 7-phenylamino-3,4-dihydro-lH- pyrimido [4,5-d]pyrimidine-2-one (Example 40).
24. Compounds of formula I of claim 1 having the formula
Figure imgf000119_0001
wherein
R1 is selected from -H, lower alkyl substituted by -OH, COR10, -CN or -CONH2, -(CH2)n-heterocycle,
-(CH2)n-heterocycle substituted by -COR10, or -CO2R10, cycloalkyl, cycloalkyl substituted by -OH;
R2 is H or -OCH3;
R3 is H, F or -OCH3;
R4 , R5 and R7 are H;
R6 is -OCH3 or lower alkyl;
R8 is H or F;
R10 is lower aUcyl substituted by alkoxy; and
n is O or l.
25. A pharmaceutical composition comprising a therapeuticaUy effective amount of a compound of formula I of any one of claims 1 to 24 and a pharmaceuticaUy acceptable carrier or excipient.
26. The pharmaceutical composition of claim 25, wherein the compounds is suitable for administration to a patient having cancer.
27. Compounds of formula I of any one of claims 1 to 24 for use as medicaments.
28. Use of compounds of formula I of any one of claims 1 to 24 for the preparation of medicaments for the treatment and control of cancer.
29. The use of claim 28 for the treatment and control of breast, lung, colon or prostate cancer.
30. The use of claim 28 wherein the cancer is breast or colon cancer.
31. A process for the preparation of a compound of formula I of claim 1, which process comprises reacting a compound of the formula
Figure imgf000121_0001
wherein X is Cl or SO2CH3, and R1, R , R5, R6, R7 and R8 are as defined in claim 1, with an anUine derivative of the formula
Figure imgf000121_0002
wherein R2 and R3 are as defined in claim 1, to obtain a compound of the formula
Figure imgf000121_0003
and if desired, converting the compound of formula I into a pharmaceuticaUy acceptable salt.
32. A compound of formula I of any one of claims 1 to 24 prepared by a process according to claim 31.
33. An intermediate compound selected from the group consisting of
4-[3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5- d] pyrimidin- 1-yl] -piperidine- 1 -carboxylic acid tert-butyl ester (Example 2a), 1 - [trans-4- (tert-butyl-dimethyl-sUanyloxy) -cyclohexyl] -3 - (4-methoxy-phenyl) -7- phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 3b),
3-[3-(4-methoxy-phenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5-. d]pyrimidin-l-yl]-piperidine-l-carboxylic acid tert-butyl ester (Example 4a),
(±) -3-ds- (tert-butyl-dimethyl-sUanyloxy) -cyclopentyl] -3- (4-methoxy-phenyl) - 7- phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example lOd),
(R)-2-methylsulfanyl-4-(tetrahydro-furan-3-ylamino)-pyrimidine-5-carboxylic cid ethyl ester (Example 11a),
(±)-4-[trαns-3-(tert-butyl-dimemyl-sUanyloxy)-cyclopentylamino]-2-methylsulfanyl- pyrimidine-5-carbaldehyde (Example 13a),
(+) - 1 - [ trans-3 - (tert-butyl-dimethyl-silanyloxy) -cyclopentyl] -3- (4-methoxy-phenyl) -7- methylsulfanyl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 13b),
(±)-[3-trαns-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-{5-[(2-fluoro-4-methoxy- phenylamino) -methyl] -2-methylsulfanyl-pyrimidin-4-yl}-amine (Example 14b),
(±) - 1 - [ trans-3- (tert-butyl-dimethyl-sUanyloxy) -cyclopentyl] -3- (4-mefhoxy-phenyl)-7- methylsulfanyl-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 14c),
(S)-l-[2-(tert-butyl-diphenyl-silanyloxy)-l-methyl-ethyl]-7-chloro-3-(4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 15c),
l-[tr ns-4-(tert-butyl-dimethyl-sUanyloxy)-cyclohexyl]-7-chloro-3-(2-fluoro-4- methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 17c),
l-[traπ5-4-(tert-butyl-dimethyl-sUanyloxy)-cyclohexyl]-7-chloro-3-(4-methoxy-phenyl)- 3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 19a),
l-[trflns-4-(tert-butyl-dimethyl-sUanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7-(3,4- dimethoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 19b),
1 - [ trans-4- ( tert-butyl-dimethyl-sUanyloxy) -cyclohexyl] -3 - (4-methoxy-phenyl) -7- (4- methoxy-phenylamino)-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example 20a),
(S)-l-[2-(tert-butyl-diphenyl-silanyloxy)-l-methyl-ethyl]-7-chloro-3-(2-fluoro-4- methoxv-ϋhenvl -3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 21a), (R) - 1 - [2- (tert-butyl-diphenyl-sUanyloxy) - 1 -methyl-ethyl] -7-chloro-3- (4-methoxy- phenyl)-3,4-dihydro-lH-pyrimidp[4,5-d]pyrimidin-2-one (Example 23c),
3-(4-methoxy-phenyl)-7-phenylamino-3,4-dmydro-lH-pyrimido[4,5-d]pyrimidine-2- one (Example 24a),
(+)-(lR,3R)-4-[3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentylamino]-2-methylsulfanyl- pyrimidine-5-carboxylic acid ethyl ester (Example 27d),
(-)-(lR,3R)-l-[3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example 27e),
(R)-l-[2-(tert-butyl-diphenyl-sUanyloxy)-propyl]-7-chloro-3-(4-methoxy-phenyl)-3,4- dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (Example 28c),
(-)-(lS,3S)-4-[3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentylamino]-2-methylsulfanyl- pyrimidine-5-carboxylic acid ethyl ester (Example 29d),
(-)-(lS,3S)-4-[3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentylamino]-2-methylsulfanyl- pyrimidine-5-carbaldehyde (Example 29e),
(-)-(lS,3S)-l-[3-(tert-butyl-dimethyl-silanyloxy)-cyclopentyl]-3-(4-methoxy-phenyl)-7- methylsulfanyl-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (Example 29f),
(-)-(lS,3S)-l-[3-( tert-butyl-dimethyl-sUanyloxy) -cyclopentyl] -3- (4-mefhoxy-phenyl) -7- phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 29g),
(S)-l-[2-(tert-butyl-diphenyl-sUanyloxy)-propyl]-7-chloro-3-(4-methoxy-phenyl)-3,4- dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 31c),
l-[ds-3,5-bis-(tert-butyl-diphenyl-silanyloxy)-cyclohexyl]-7-chloro-3-(2-fluoro-4- methoxy-phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 32d),
l-[ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(2-fluoro-4-methoxy- phenyl)-7-(4-methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 32e),
l-[ds-3,5-bis-(tert-butyl-diphenyl-silanyloxy)-cyclohexyl]-7-chloro-3-(4-methoxy- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 33a),
l-[ds-3,5-bis-(tert-butyl-diphenyl-silanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7-(4- methoxy-phenylamino)-3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example 33b), l-[ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7-(4- fluoro-3-methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 34e),
l-[ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(4-methoxy-phenyl)-7- phenylamino-3,4-dihydro-lH-pyrimido [4,5-d] pyrimidin-2-one (Example 35a),
l-[d5-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(2-fluoro-4-methoxy- phenyl)-7-phenylamino-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 36a),
l-[ds-3,5-bis-(tert-butyl-diphenyl-sUanyloxy)-cyclohexyl]-3-(2-fluoro-4-mefhoxy- phenyl)-7-(4-fluoro-3-methoxy-phenylamino)-3,4-dihydro-lH-pyrimido[4,5- d]pyrimidin-2-one (Example 37a),
(2,4-dicMoro-pyrimidin-5-ylmethyl)-(4-ethyl-phenyl)-amine (Example 38c),
(R)-3-[2-(tert-butyl-dimethyl-sUanyloxy)-l-methyl-ethyl]-l-(2,4-dichloro-pyrimidin-5- ylmethyl)-l-(4-ethyl-phenyl)-urea (Example 38d),
(R)-l-[2-(tert-butyl-dimetlιyl-silanyloxy)-l-methyl-ethyl]-7-chloro-3-(4-ethyl-phenyl)- 3,4-dihydro- lH-pyrimido [4,5-d] pyrimidin-2-one (Example 38e),
(R)- 1- [2-(tert-butyl-dimethyl-sUanyloxy)-l-methyl-ethyl] -3-(4-ethyl-phenyl)-7-(4- fluoro-ρhenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 38f),
(±)-[t ns-3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-{2-chloro-5-[(4-ethyl- phenylamino)-methyl]-pyrimidin-4-yl}-amine (Example 39a),
(±)-l-[trflns-3-(te^butyl-dimethyl-sUanyloxy)-cyclopentyl]-7-chloro-3-(4-ethyl- phenyl)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 39b), and
(±)-l-[tr -3-(tert-butyl-dimethyl-sUanyloxy)-cyclopentyl]-3-(4-ethyl-phenyl)-7-(4- fluoro-phenylamino)-3,4-dihydro-lH-pyrimido[4,5-d]pyrimidin-2-one (Example 39c).
34. The novel compounds, pharmaceutical compositions, processes, and uses as described herein before.
PCT/EP2004/003447 2003-04-10 2004-04-01 Pyrimido compounds WO2004089955A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2004228155A AU2004228155A1 (en) 2003-04-10 2004-04-01 Pyrimido compounds
CA002521124A CA2521124A1 (en) 2003-04-10 2004-04-01 Pyrimido compounds
MXPA05010765A MXPA05010765A (en) 2003-04-10 2004-04-01 Pyrimido compounds.
JP2006504944A JP2006522756A (en) 2003-04-10 2004-04-01 Pyrimido compounds
BRPI0409366-6A BRPI0409366A (en) 2003-04-10 2004-04-01 pyrimidine compounds
EP04725039A EP1615928A1 (en) 2003-04-10 2004-04-01 Pyrimido compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46169403P 2003-04-10 2003-04-10
US60/461,694 2003-04-10

Publications (1)

Publication Number Publication Date
WO2004089955A1 true WO2004089955A1 (en) 2004-10-21

Family

ID=33159829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/003447 WO2004089955A1 (en) 2003-04-10 2004-04-01 Pyrimido compounds

Country Status (11)

Country Link
US (1) US7115740B2 (en)
EP (1) EP1615928A1 (en)
JP (1) JP2006522756A (en)
KR (2) KR100864393B1 (en)
CN (1) CN100497339C (en)
AU (1) AU2004228155A1 (en)
BR (1) BRPI0409366A (en)
CA (1) CA2521124A1 (en)
MX (1) MXPA05010765A (en)
RU (1) RU2350617C2 (en)
WO (1) WO2004089955A1 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
WO2010067886A1 (en) 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivative
US8058283B2 (en) 2006-01-31 2011-11-15 Hoffmann-La Roche Inc. 7H-pyrido[3,4-D]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9663524B2 (en) 2013-03-15 2017-05-30 Celgene Car Llc Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10065966B2 (en) 2013-03-15 2018-09-04 Celgene Car Llc Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases
CN110225914A (en) * 2016-07-05 2019-09-10 布罗德研究所股份有限公司 Bicyclic urea kinase inhibitor and application thereof
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11285158B2 (en) 2017-02-28 2022-03-29 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US12012409B2 (en) 2021-01-14 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
CN101048384A (en) * 2004-10-28 2007-10-03 默克公司 Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
KR20080063865A (en) * 2005-11-28 2008-07-07 에프. 호프만-라 로슈 아게 Inhibitors of diacylglycerol acyltransferase (dgat)
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519282A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
PL2699553T3 (en) * 2011-04-22 2024-03-25 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EP2727920B1 (en) 2011-07-29 2016-11-02 FUJIFILM Corporation 1,5-naphthyridine derivative or salt thereof
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AR094812A1 (en) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR
DK3172213T3 (en) 2014-07-21 2021-12-13 Dana Farber Cancer Inst Inc MACROCYCLIC CHINESE INHIBITORS AND USES THEREOF
CA2954186A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
AU2015300782B2 (en) 2014-08-08 2020-04-16 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (SIK) inhibitors
BR112017002268B1 (en) 2014-08-18 2022-11-08 Eisai R&D Management Co., Ltd MONOCYCLIC PYRIDINE DERIVATIVE SALT AND ITS CRYSTAL
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
JP7226804B2 (en) * 2017-03-03 2023-02-21 オークランド ユニサービシズ リミテッド FGFR kinase inhibitor and pharmaceutical use
WO2019029541A1 (en) * 2017-08-08 2019-02-14 南京药捷安康生物科技有限公司 Fibroblast growth factor receptor inhibitor and use thereof
CN109836427B (en) * 2017-11-29 2022-04-15 暨南大学 Pyrimidopyrimidinone compounds and application thereof
KR20200135945A (en) 2018-03-28 2020-12-04 에자이 알앤드디 매니지먼트 가부시키가이샤 Hepatocellular carcinoma treatment
PE20212303A1 (en) * 2018-12-27 2021-12-10 Les Laboratoires Servier Sas AZA-HETEROBYCYCLIC MAT2A INHIBITORS AND METHODS OF USE IN THE TREATMENT OF CANCER
GB201908511D0 (en) 2019-06-13 2019-07-31 Adorx Therapeutics Ltd Hydroxamate compounds
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061444A2 (en) * 1998-05-26 1999-12-02 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US6150373A (en) * 1998-10-23 2000-11-21 Hoffmann-La Roche Inc. Bicyclic nitrogen heterocycles
WO2001029042A1 (en) * 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
WO2001029041A1 (en) * 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) * 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
NL6704601A (en) * 1966-04-06 1967-10-09
US4425346A (en) * 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (en) * 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd Novel pyrimidopyrimidine derivative
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
MY141144A (en) 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CA2420286A1 (en) 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
DK1470124T3 (en) 2002-01-22 2006-04-18 Warner Lambert Co 2- (Pyridin-2-yl amino) pyrido [2,3] pyrimidin-7-one
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
JP2006512313A (en) * 2002-10-31 2006-04-13 アムジェン インコーポレイテッド Anti-inflammatory agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061444A2 (en) * 1998-05-26 1999-12-02 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US6150373A (en) * 1998-10-23 2000-11-21 Hoffmann-La Roche Inc. Bicyclic nitrogen heterocycles
WO2001029042A1 (en) * 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
WO2001029041A1 (en) * 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058283B2 (en) 2006-01-31 2011-11-15 Hoffmann-La Roche Inc. 7H-pyrido[3,4-D]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
WO2010067886A1 (en) 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivative
US8507505B2 (en) 2008-12-12 2013-08-13 Msd K.K. Dihydropyrazolopyrimidinone derivative
US8575179B2 (en) 2008-12-12 2013-11-05 Msd K.K. Dihydropyrazolopyrimidinone derivatives
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
US10813930B2 (en) 2010-12-22 2020-10-27 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10131667B2 (en) 2012-06-13 2018-11-20 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9695132B2 (en) 2013-03-15 2017-07-04 Celgene Car Llc Heteroaryl compounds and uses thereof
US9663524B2 (en) 2013-03-15 2017-05-30 Celgene Car Llc Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors
US10189794B2 (en) 2013-03-15 2019-01-29 Celgene Car Llc Heteroaryl compounds and uses thereof
US10774052B2 (en) 2013-03-15 2020-09-15 Celgene Car Llc Heteroaryl compounds and uses thereof
US10618902B2 (en) 2013-03-15 2020-04-14 Celgene Car Llc Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10065966B2 (en) 2013-03-15 2018-09-04 Celgene Car Llc Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases
US10450313B2 (en) 2013-04-19 2019-10-22 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10040790B2 (en) 2013-04-19 2018-08-07 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10947230B2 (en) 2013-04-19 2021-03-16 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10632126B2 (en) 2015-02-20 2020-04-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10738048B2 (en) 2015-02-20 2020-08-11 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9801889B2 (en) 2015-02-20 2017-10-31 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10251892B2 (en) 2015-02-20 2019-04-09 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10016438B2 (en) 2015-02-20 2018-07-10 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10214528B2 (en) 2015-02-20 2019-02-26 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN110225914A (en) * 2016-07-05 2019-09-10 布罗德研究所股份有限公司 Bicyclic urea kinase inhibitor and application thereof
US11725011B2 (en) 2016-07-05 2023-08-15 The General Hospital Corporation Bicyclic urea kinase inhibitors and uses thereof
US11285158B2 (en) 2017-02-28 2022-03-29 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
US11878019B2 (en) 2017-02-28 2024-01-23 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US12012409B2 (en) 2021-01-14 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Also Published As

Publication number Publication date
MXPA05010765A (en) 2005-12-12
US20040204427A1 (en) 2004-10-14
KR20070087053A (en) 2007-08-27
CN1809569A (en) 2006-07-26
KR20050111636A (en) 2005-11-25
CN100497339C (en) 2009-06-10
RU2350617C2 (en) 2009-03-27
JP2006522756A (en) 2006-10-05
EP1615928A1 (en) 2006-01-18
CA2521124A1 (en) 2004-10-21
US7115740B2 (en) 2006-10-03
AU2004228155A1 (en) 2004-10-21
KR100864393B1 (en) 2008-10-20
RU2005134686A (en) 2006-07-27
BRPI0409366A (en) 2006-04-25

Similar Documents

Publication Publication Date Title
EP1615928A1 (en) Pyrimido compounds
EP1560832B1 (en) Pyrimido 4,5-d pyrimidine derivatives with anticancer activity
US7098332B2 (en) 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
EP1556384B1 (en) Pyrimido compounds having antiproliferative activity
TWI458730B (en) Novel 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one derivatives, preparation thereof and pharmaceutical use thereof
EP2448940B1 (en) 6,7,8,9-tetrahydro-pyrimido{1,2-a} pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof
EP3294742A1 (en) New 5,8-dimethyl-9-phenyl-5,8-dihydro-6h
KR20180028521A (en) Condensed ring pyrimidine-based compounds, intermediates, methods for their preparation, compositions and applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004725039

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2521124

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/010765

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006504944

Country of ref document: JP

Ref document number: 1020057019109

Country of ref document: KR

Ref document number: 2572/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20048095133

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004228155

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004228155

Country of ref document: AU

Date of ref document: 20040401

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004228155

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005134686

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020057019109

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004725039

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0409366

Country of ref document: BR